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Protease-activated receptors (PARs) are class A G protein-coupled receptors 
(GPCRs) with 4 subtypes (PAR 1 – 4) and with a unique mode of action. PARs are 
cleaved by extracellular proteases at the N-terminus, creating a new tethered ligand that 
activates the receptor and transduces biological signals into the cell. PARs have been 
implicated in various productive and pathological signals, including those related to 
thrombosis, inflammation, reperfusion injury, and cancer cell metastasis. Despite the fact 
that PARs are attractive as drug targets, their intramolecular mode of activation makes it 
challenging to modulate them with drugs in a selective manner, and only one PAR-
targeting therapy, the PAR1 antagonist and antiplatelet drug vorapaxar, is currently 
approved by the FDA. Previously in the Dockendorff lab, compounds with a 1,3-
diaminobenzene scaffold, called parmodulins, were identified as biased ligands of PAR1 
that selectively inhibit Gαq-mediated signaling of PAR1 without significantly inhibiting 
Gα12/13-mediated signaling leading to platelet shape change. More recently, 
cytoprotective and anti-inflammatory effects of parmodulins in endothelial cells were 
identified that could be fruitful for the treatment of sepsis and myocardial infarction. We 




) assay in endothelial 
cells to perform medium-throughput screening and characterization of parmodulins, and 
we demonstrated that they are reversible, negative allosteric modulators of PAR1, unlike 
ligands such as vorapaxar. We also extended structure-activity relationship (SAR) studies 
of parmodulins to identify analogues with potentially improved properties using 
medicinal chemistry, and these parmodulins are promising leads for safer antithrombotic 
and sepsis drugs. Additionally, we commenced investigations into the role of heteromeric 
PAR complexes in proliferative disorders such as restenosis and cancer cell metastasis. 
We synthesized a novel class of bivalent ligands targeting putative PAR1/2 heteromers 
and characterized them using our iCa
2+ 
assay with endothelial cells (EA.hy926) and the 
breast cancer cell line MDA-MB-231. Such bivalent PAR ligands hold promise for the 
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Introduction of GPCRs and PARs 
 
 
1.1. Overview of GPCRs 
 
Figure 1.1. Heterotrimeric G-protein associated intracellularly with GPCR. 
G-protein coupled receptors (GPCRs) are the largest and most diverse family of 
membrane proteins in eukaryotes (Figure 1.1). Structurally, GPCRs are the single 
polypeptides with seven folds located at cell membrane. The polypeptide possesses N-
terminus at extracellular site and C-terminus at intracellular site along with heterotrimeric 
G-protein. They act like messengers to communicate with peptides, hormones, small 
molecules, etc. to mediate most cellular responses. They are responsible for the vast array 





normal heart function to neuronal activity and widely present in every organ of the body. 
Hence, mutation to GPCRs have been reported to triggering many diseases like cancer, 
cardiovascular dysfunction, neuronal disorders, diabetes, inflammation and pain, and 
have been identified as potential drug targets for a majority of the best selling drugs and 
overall of 40% of prescribed pharmaceuticals till this date.
1
  
 GPCRs, based on sequence homology and structural similarities, are commonly 
classified in 6 different families. Family A, rhodopsin receptor family is by far the largest 
family, which accounts for approximately 85% of GPCR genes and over 50% of these are 
involved with the olfaction.
2
 Rhodopsin family is further subdivided to three classes 
based on their mode of activation. Class 1 (A1) includes small ligands activated 
rhodopsin and β-adrenergic receptors. Class 2 (A2) includes the receptors activated by N-
terminal peptides and class 3 (A3) includes GPCRs for glycoprotein ligands. Family B, 
secretin receptor family shares similar morphology to A3 family but has different 
sequence homology. Hormones like growth hormones, calcitonin, secretin, glucagon, 
etc., also activate this family of GPCRs. Family C, metabotropic glutamate receptor 
family mainly includes mGluR, olfactory, taste, Ca
2+
 sensing and GABA receptors.
3
 This 
family by so far is the most potential target for CNS disorders due to involvement of 
excitatory glutamate hormone binding to mGluR and inhibitory GABA binding to GABA 
receptors. Both Family D and E, fungus pheromone receptor family and cAMP receptor 
family, don’t found in vertebrates. Family F, frizzled/Smoothened receptor family: This 
family recruits 10 frizzled (FZD) and smoothened (SMO) receptors. Theses receptors are 
involved in the embryonic development.  The FZDs are activated by lipoglycoproteins, 
















Figure 1.2: Selected examples of GPCR crystal structure in ribbon cartoon. A) human beta2 adrenergic 




 GPCRs, also known as seven transmembrane receptors (7TMRs), are structurally 
a single polypeptide arranged in 7 folds that compose a cylindrical/barrel shape in the cell 





TM7), connected by intracellular loops (IL 1-3) and extracellular loops (EL 1-3), with an 
extracellular N-terminus and an intracellular C-terminus and a heterotrimeric G-protein at 
the intracellular side (Figure 1.1). X-ray characterization of few GPCRs has been 
reported in literature (Figure 1.2). Due to their cylindrical/barrel shape, GPCRs make a 
cavity within the cell membrane that is open on the extracellular side, which is known as 
ligand binding pocket/active site, from where GPCRs serve as the essential nodes of  
  
Figure 1.3. Activation of β2AR receptor by adrenaline: After binding with adrenaline, receptor changes its 
conformation to activate heterotrimeric G-protein complex by exchanging GTP from cytosol to GDP. 
Heterotrimeric complex dissociates and GTP-Gα activates adenylate cyclase to activate cAMP from ATP 
and therefore activates protein kinase A. Activation of receptor also leads to phosphorylation by G-protein-
coupled receptor kinase (GRK) and thus coupling with β-arrestin. Arrestin is signaling regulatory protein 








communications between extracellular and intracellular cell environment. First a ligand 
binds to the GPCRs at the active site, changes the receptor conformation in a way to 
stimulate the associated heterotrimeric G proteins, which in turn leads to the modulation 
of downstream effector proteins. The conformational change in the heterotrimeric G-
protein releases guanosine diphosphate (GDP) from the Gα subunit in exchange for 
guanosine triphosphate (GTP). The GTP bound Gα subunit then dissociates from the Gβγ 
dimer subunit, and both GTP-Gα, and Gβγ can trigger several cellular signaling pathways. 
For example, β2-adrenergic receptor (β2AR) is a subtype of adrenergic GPCRs and 
belongs to family A (Subfamily A17, cAMP receptors) of GPCRs.
9
 Binding of the 
hormone adrenaline to β2AR leads to the activation of Gαs subunit, which activates 
downstream signaling pathways. In this case, activated Gαs activates cAMP-dependent 
phosphorylation of protein kinase A (PKA) via stimulation of adenylate cyclase, and 





Figure 1.4: A ternary complex model (D- Agonist. R- Receptor, G- G protein, E-Enzyme, K, K`, L, M- 
Rate constants)10 
 
D +    R + G
D +      RG














Over past 40 years, extensive efforts have been undertaken to investigate the 
mode of action of GPCRs and their involvement in normal and pathological processes. 
For instance, Lefkowitz and co-workers proposed a ternary complex model
10
 to 
understand the allosteric mode of activation of G-protein mediated signal transduction 
pathway. The ternary complex model (Figure 1.4) involves an agonist (D, e.g., hormone, 
neurotransmitters), 7-TMR (R) and G-protein (G) as activated signaling unit. The agonist 
binds to an extracellular region (the binding pocket) of the 7-TMR to form a low affinity 
binary [DR] complex which further leads to a conformational change of the receptor and 
associates with guanine nucleotide G at the intracellular region to form DRG, a high 
affinity ternary complex. For example, adrenaline binds to β2AR and G-protein forming a 
high affinity ternary complex, which in turn exchanges GDP for GTP. The resultant 
GTP-Gɑ complex activates adenylate cyclase. In other words, after ligand binding, 
GPCRs lead to the conformational change, transduce the signal via heterotrimeric G 
proteins to various downstream effectors via G-protein dependent and independent 
pathways and each pathway can stimulate a variety of intracellular signaling cascades to 
mediate physiological responses.  
 
1.2.1. GPCR-mediated signaling 
1.2.1.1. G-protein dependent signaling 
G-proteins exist in complex heterotrimeric forms. They are comprised of a Gα 
subunit and Gβγ dimer. After agonist binding to GPCR, the conformational change in the 





in the Gα subunit (Figure 1.2).
11-13
 The active GTP-bound Gα subunit then dissociates 
from the receptor and Gβγ dimer and activates/inhibits downstream effector proteins, and 
regulators of G-protein-signaling (RGS) proteins. For example, RGS proteins, containing 
GTPase-activating protein, attenuate GTPase activity of Gα subunits and thereby decrease 
its signal amplitude and duration.
11
 RGS proteins, containing guanine nucleotide 
dissociation protein, inhibit dissociation of Gα subunits and thereby inhibit Gα mediated 
signaling.  
 
Gα subunit: Structurally, Gα subunits are 39-45 kDa proteins, modified at the N-terminus 
by the covalent attachment of myristate/palmitate fatty acids. The lipophilic portion is 
mainly responsible for the specific signal transduction of Gα subunits. Palmitolyation is 
responsible for the stable attachment of Gα with the receptor, whereas myristolyation is 
responsible for membrane localization of Gα. Based on sequence similarity, Gα proteins 
are divided into four major class: Gα(s/olf), Gα(i1/i2/i3/o/z/gust/t-cone/t-rod/), Gα(q/11/14/16) and Gα(12/13). 
Functionally, Gα subunits are responsible for targeting from the specific membrane region 
of the receptor and interactions with other effector proteins like stimulate or inhibit 




Gβγ subunit: The Gβγ subunit is a heterodimer of Gβ and Gγ polypeptides. There are 5 
known genes encoding Gβ and 12 known genes encoding Gγ, leading to potential 
combinations of Gβγ polypeptide dimers. Gβ contains seven WD40 units (tryptophan – 
aspartic acid repeats for 40 times), and these seven units are arranged anti-parallel in β-





of the Gγ subunit is prenylated either with 15-carbon farnesyl or 20-carbon 
geranylgeranyl moiety. Similar to Gα, this lipophilic portion of Gγ is responsible for the 
membrane localization of the Gβγ heterodimer. As of now, there are more reported in vitro 
assays measuring Gα function, but Gβγ-mediated signal transduction has gained attention 
to better understand the roles of Gβγ heterodimer in downstream effector activation. In 
addition, Gβγ doesn’t change conformation like Gα when it dissociates from heterogenic 




1.2.1.2. G-protein independent / β-arrestin-mediated signaling 
 
Figure 1.5. GPCR activation after ligand binding activates the heterotrimeric G-protein and β-arrestin. 
Activated β-arrestin desensitizes or internalizes the dissociated GTP bound receptor and shuts down G-
protein mediated signaling. Alternatively, β-arrestin transduces its own signal.  
 
β-arrestins are ubiquitously expressed in mammalian tissues. They play a key role 
in the termination of GPCR signals by desensitization and internalization (Figure 1.5).
15
 





protein-coupled receptor kinases (GRKs), β-arrestin can form a complex with the 
receptor, and prevent further activation of G-proteins, effectively turning off G-protein-
mediated signaling (also termed GPCR desensitization).  β-arrestin desensitizes GPCRs 
either by blocking GPCR – G-protein interactions or by the recruitment of enzymes to 
degrade secondary messenger molecules.
16
  
 β-arrestin also plays an important role in receptor internalization, the process of 
transporting GPCRs into intracellular compartments. β-arrestin-mediated internalization 
is a first crucial step in the recycling of desensitized receptors. Internalized receptors are 
then involved in the receptor trafficking where they either recycled to plasma membranes 
or degraded by enzymes.
16, 17
  
 In recent studies, β-arrestin has also shown to transduce signal through G-protein 
independent pathway in the regulation of cardiovascular function
15
 and could be an 
important tool for the treatment for heart failure. More rigorous investigations are 
underway to understand β-arrestin signaling mechanism, and its ultimate significance in 
finding novel drug targets.  
 
1.2.2. Interaction of ligands with GPCRs 
 GPCRs are one of the best targets to develop medications and have maintained 
popularity amongst medicinal chemists because of their broad spectrum of interactions 
with ligands. In a traditional way, a ligand that activates the receptor is called agonist, 
and a ligand that blocks the activation of the receptor is known as antagonist. However, 





also dependent on the binding site and kinetics of binding (Figure 1.6). A ligand can 
interact with the receptor either binding to an orthosteric site (natural ligand binding- 
 
Figure 1.6. Categorizations of ligand-receptor interactions 
 
pocket) or to an alternative (allosteric) site. Orthosteric antagonists bind to the agonist 
active site typically in a competitive or non-competitive fashion and shut down all 
signaling, whereas allosteric antagonists bind to an alternative site of the receptor relative 
to the agonist, altering the receptor conformation in a way that can shut down some or all 
of the defined signaling through the receptor.  
 
Receptor - Ligand interactions 
Based on signaling pattern 
Agonism (ligand that 
activates the receptor) 
Antagonism (ligand that 
block the activation of the 
receptor) 
Based on interaction site 
Orthosteric site (active site) 
Allosteric site 










Figure 1.7. Differences between full/partial agonist, antagonist, and inverse agonist signaling 
 
Traditionally, apart from full agonists and antagonists, a ligand can stimulate the 
receptor with a lower efficacy compared to a full agonist. Such ligands are termed partial 
agonists. GPCRs may also have basal activity even in the absence of a ligand. In such 
cases, if a ligand binds to the receptor as an agonist but produces an opposite 
pharmacological response, i.e. the response is less than the basal level, it is termed an 
inverse agonist (Figure 1.7). The agonist activity is measured in terms of EC50 (the 
concentration of agonist at which the response is half its maximal value), and antagonist 
activity is measured in terms of IC50 (the concentration of antagonist which inhibits the 











A) Orthosteric ligands of GPCRs.  
 
 
Figure 1.8: Schematic representation of orthosteric binding of agonist and antagonist at ligand binding 
pocket  
 
As discussed in earlier sections, 7-TMRs can transduce the signal via either G-
protein or β-arrestin pathways. Therefore, ligands are categorized by their interactions 
with GPCRs and the resulting signals. The ligand-binding pocket, exposed to the 
extracellular site, is termed active sit. In general, antagonists, full agonists, partial 
agonists and inverse agonists interact with GPCR at active site, resulting in the complete 
activation of all G-protein mediated signals. Such ligands are termed as orthosteric 
agonists. In contrast, ligands that shut down all G-protein signaling are termed as 











B) Allosteric modulators and biased ligands of GPCRs. 
 
Figure 1.9: Schematic representation of biased signaling of GPCRS: A) Balanced/non-biased signaling; B) 
Biased agonist favors only one G-protein mediated signaling; C) β-arrestin biased agonist potentiated only 
β-arrestin signaling; D) PAM in presence of an orthosteric agonist prefers only one G-protein mediated 
signaling; E) NAM in presence of an orthosteric agonist inhibits only one G-protein mediated signaling. 
 
 Allosterism of GPCRs has gained popularity amongst the researchers due to the 
diverse signaling pattern. Allosteric modulators possess different binding site than 
orthosteric ligands and can alter the selectivity, affinity, efficacy and potency of 
orthosteric ligands via modulating conformational changes. In literature, allosteric 
modulators are identified as negative allosteric modulators (NAM) and positive allosteric 
modulators (PAM). NAMs decrease the efficacy or affinity to the orthosteric binding site 
of the agonists. Conversely, PAMs increase the efficacy or affinity of the agonists at the 





necessary to exhibit effects of PAMs.
18, 19
 In some cases, ligands bind at the active site of 
the receptor, but exerts biased signaling pattern like NAMs and PAMs. These ligands 
favors either only one G-protein mediate signaling or β-arrestin mediated signaling or 
such ligands are called as biased ligands (figure 1.9).  These ligands stabilize receptor 
conformation in a way to affect only one signaling over others but the exact reason for 
such biased behavior is unknown. Investigations in studying ligand-receptor interaction 
will provide vital information about how we can modify such type of interactions in 
designing of drugs.  
Focusing on allosteric nature and biased signaling pathways of GPCRs, this 
project work mainly enlightens structural and functional insights of PARs to understand 
ligand interaction and selectivity with the receptor in a biased way to modify GPCR 
signal and to utilize this application in drug discovery. 
 
1.3 Protease Activated Receptors (PARs): A novel family of GPCR as potential 
therapeutic targets  
 
Protease Activated Receptors (PARs), are a novel family of GPCRs with a unique 
mode of action. Instead of being stimulated with ligands (endogenous ligands like 
hormone, neurotransmitters, small molecules, etc,) binding at the active site, this family 
of receptors is activated by the cleavage of the extracellular N-terminus by serine 
proteases, generating a new tethered ligand that interacts with the extracellular loop of the 
receptor and activates the downstream signaling pathways.
20
 












 can be activated by the serine protease thrombin and activated 




 as well as by coagulation 
factors VIIa and Xa,
28
 but not by thrombin.
29
 PAR1 is the main “thrombin receptor” in 
human platelets. PAR1 is also expressed in endothelial cells, fibroblasts, monocytes, and 
smooth muscle cells. PAR2 and PAR3 are expressed in endothelial cells, but notably not 
in human platelets. Similar to PAR1, PAR4 is also expressed in human platelets but 
possesses lower affinity for thrombin.
30
 In platelets, thrombin cleaves the extracellular N- 
terminus of PAR1 and PAR4 receptors at low and high concentration respectively, which 
activates Gαi mediated granule secretion and G12/13 mediated platelet aggregation.  
 
1.3.1. Platelets as therapeutic targets for antithrombotic agents 
Platelets are disc-shaped cells found in the blood and plasma that can become 
activated upon vascular injury and help to form clots to prevent blood loss from 
hemorrhage. The activation of platelets is an essential function during haemostasis. 
Haemostasis is the physiological response of the blood vessels to maintain blood fluidity 
and to limit the damage from hemorrhage by forming blood clots. After an injury, 
thrombin activates platelet aggregation at the site of an injury to prevent blood loss. The 
adhered platelets recruit more platelets, which aggregate to form an armored plug 
covering the injury. Although blood clotting is an essential function to prevent blood loss 
upon tissue injury, excess or undesired thrombus formation must be avoided. For 
example, upon vascular damage, such as rupture of an arteriosclerotic plaque, platelet-





and thrombosis of a cerebral artery can results in acute ischemic stroke. These thrombotic 
events are the leading cause of morbidity and mortality in the industrialized world
31
 and  
platelet aggregation inhibitors play a vital role in the prevention of such adverse 
cardiovascular events. 
 
1.3.2. PAR1 as a therapeutic target  
Thrombus formation occurs via activation of platelets, and coagulation cascade. 
At the end of coagulation cascade, thrombin activates fibrin and thus activates platelets. 
There are numerous anti-thrombotic agents in clinical use to prevent thrombus formation 
or dissolve existing one. These drugs either target coagulation cascade to prevent 
thrombin formation or target platelets aggregation. Hence, current anti-thrombotics bear 
the risk of excess bleeding. In addition, the application of current anti-platelet therapy has 
significant limitations like inadequate platelet response, delayed onset of action and 
increased bleeding risks.
32, 33
 Moreover, poor oral bioavailability of this class of drugs has 
limited their use. These limitations have provided the motivation to fulfill an unmet 
clinical demand of antiplatelet therapy with better pharmacokinetic and pharmacological 
profile. Now, as described earlier, thrombin also activates PAR1 and hence, acts as a dual 
activator of platelets. Therefore, PAR1 could be better therapeutic target to selectively 
block only one pathway of platelet aggregation that could be beneficial in providing the 
treatment with less bleeding risk and maintain hemostatic balance. Furthermore, recently 
FDA approved, orally active, orthosteric antagonist of PAR1 (vorapaxar) has opened the 






1.3.3. Mode of action  
 
Figure 1.10. Activation of PAR1 by cleavage of its N-terminal tethered ligand by thrombin. Upon 
activation by thrombin, PAR1 signals through Gαq and Gα12/13, causing granule secretion and platelet shape 
change, both of which are important for clot formation. PAR1 can also activate β-arrestin in endothelial 
cells, which may have cytoprotective effects. 
 
PAR1 is activated by an unusual proteolytic mechanism. Thrombin recognizes the N-
terminal exodomain of PAR1 and cleaves the peptide bond between Arg41 and Ser42 
residues. The resultant SFLLRN sequence functions as a tethered ligand and binds to the 
receptor intramolecularly to transduce signaling. Thus PAR1 is a peptide receptor that 




1.4 Orthosteric antagonism of PAR1  
 PAR1 inhibitors could serve as important antiplatelet drug candidates by 
inhibiting thrombin-induced platelet activation but not thrombin-induced cleavage of 





between a reduced risk of thrombosis and an increased risk of bleeding. Therefore, many 
investigations are underway to target PAR1-mediated platelet aggregation with the 
promise of providing anti-platelet agents with better pharmacodynamic and 
pharmacokinetic profiles. However, PAR1 carries its own agonist for activation, which 
makes it difficult to develop small molecules as PAR1 antagonists since they need to 
compete with the high effective concentration of the tethered ligand at the PAR1 binding 
site. However, several efforts were attempted to develop orthosteric antagonists of PAR1. 
Amongst them, 3 distinct approaches have been reported to develop orthosteric 
antagonists of PAR1: peptidomimetic antagonist and non-peptide antagonist.  
 
1.4.1 Peptidomimetic antagonists 
 
Figure 1.11. Peptidomimetic antagonist: 1- RWJ-56110 and 2- RWJ-58259, reported IC50 in TRAP 
induced  (SFLLRN-NH2, 2 µM) receptor binding assay. 
 Thrombin cleaves the N-terminus of PAR1 at Arg41-Ser42 and exposes 
SFLLRN, which acts as an agonist of PAR1.
35
 Therefore, the design of peptidomimetics 
can be based on the structure of SFLLRN. The structure-function requirements for these 
peptides are a terminal free amine, adjacent to an aromatic ring (such as phenylalanine), 





template was designed computationally by researchers at R.W. Johnson 
Pharmaceuticals.
36
 The 6-aminoindole template meets the required spatial arrangement of 
the pharmacophore and hence, it was selected as a scaffold for the development of 
orthosteric antagonists of PAR1. The first potent molecule based on the 6-aminoindole 
template was RWJ-56110 (1, Figure 1.10), which showed an IC50 of 0.16 µM in a 
SFLLRN-NH2-induced platelet aggregation assay.
37
 However, RWJ56110 showed 
hypotensive effects in guinea pig models, which led to the development of RWJ-58259 
(2, Figure 1.11),
38
 using the related 6-aminoindazole scaffold. RWJ-58259 was the most 
potent analogue in this series with 0.11 µM IC50 in the SFLLRN-NH2-induced platelet 
aggregation assay, however, RWJ-58259 was not advanced to the clinical trials because 




1.4.2  Non-peptide based antagonist 
Anh and coworkers at Schering-Plough discovered a series of pyrroloquinazoline 
PAR1 antagonists (Figure 1.12). They introduced SCH-79797 (3) and its N-methylated 
derivative SCH-203099 (4) as the first high-affinity PAR1 ligands with nanomolar 
potencies (IC50 70 and 45 nM respectively in TRAP – thrombine receptor activated 
peptide induced binding assay). Both ligands were the new embankment to achieve non-
peptide based PAR1 antagonists where entropic restrictions of PAR1 tethered peptide 
didn’t hamper binding with PAR1. Unfortunately due to the lack of sustained inhibition, 









Figure 1.12. Non-peptide based antagonist: reported IC50 in TRAP (SFLLRN-NH2) assay. 
 





 and phenyl-isoxazole 7
42
 were also reported by Merck with 
sub-micromolar potencies. Schering-Plough and Eisai reported cyclic guanidine and 
amidine
30
 based molecules 8 and 9 with nanomolar potencies. Both antagonists were 
advanced to clinical trials for the treatment of acute coronary syndrome (ACS,) the latter 








3 (SCH-79797), R = H; IC50 = 70 nM




















































Figure 1.13. Development of vorapaxar from the natural product himbacine. All IC50 were measured in the 
haTRAP induced binding assay.   
 
 Himbacine (10, Figure 1.12) is a tetracyclic piperidine alkaloid isolated from the 
bark of the Australian pine tree of the Galbulimima species. It was discovered to be a 
potent inhibitor of the M2 muscarinic receptor.
44
 The original therapeutic interest for 
himbacine was to treat cognitive defects from Alzheimer’s disease, and it had no activity 
against PAR1. During the SAR studies of himbacine, the more basic piperdine ring was 
replaced with the less basic pyridine, resulting in analogue 11 (Figure 1.13). Decreasing 
the basicity resulted in a loss of muscarinic activity in 11, but an unrelated, later screen 
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binding assay, and that was the first breakthrough in the development of the first orally 
available PAR1 antagonist.
45
 The resolution of racemic 11 to 11a (Figure 1.13) showed 
the activity against PAR1 was greater for the ent-himbacine analogue with an IC50 of 150 
nm. Further SAR investigations led to development of 12 (SCH-205831) with the biaryl 
group attached to the tricyclic core. 12 was highly potent, with an IC50 of 11 nM in the 
TRAP assay, and Ki of 2.7 nM. However, 12 was subjected to enzyme induced 
metabolism in monkeys and the tricyclic core of 12 was oxidized in vivo to 13 (SCH-
219122). 13 was less potent than 12 but has considerable potency with an IC50 of 17 nM 
in TRAP assay and Ki was 11 nM. Unfortunately, 13 had a poor clearance profile in 
monkeys (80% clearance observed after 30 days with IV dose 1 mg/kg) and needed 
further SAR investigations.
46
 SAR studies on the tricyclic core led to the development of 
14 (SCH-530348, also known as vorapaxar and Zontivity®, Figure 1.13). It is the 
carbamate analogue of 13 with the best pharamacokinetic and pharmacodynamics profile 
of this series. 14 (vorapaxar) inhibited SFLLRN-NH2-induced platelet aggregation with 
an IC50 of 15 nM and Ki of 8.5 nM in a competitive binding assay. 14 showed prolonged 
inhibition of platelets (100% inhibition for 24 h), and was orally active with 86% 
bioavailability.
47
 Later, 14 was approved by FDA as the first PAR1 antagonist, for use as 





1.5 Allosteric antagonism of PAR1 and project aim   
 As discussed in earlier section, several orthosteric antagonists were synthesized 





approved by FDA in 2014.
48
 9 is in phase II clinical trail for treatment of ACS, however, 
9 showed a higher rate of TIMI (thrombolysis in myocardial infarction) bleeding in high 
doses.
49
 In addition, 9 showed dose-dependent increase in liver transaminases and QTcF 
prolongation.
49, 50
 On the other hand, 14 showed increased risk of intracranial bleeding 
and it cannot be used in patients with history of stroke.
50-53
 Therefore, safe and effective 
treatments for patients with coronary artery diseases (CAD) are still needed. 
 
 
Figure 1.14: High resolution (2.2 Å) crystal structure of modified PAR1 with vorapaxar 14 (in green).54  
 
 Coughlin and co-workers reported a crystal structure of 14 bound to PAR1 
(Figure 1.14).
54
 14 binds to PAR1 at the orthosteric site near the extracellular surface, in 
contrast to other GPCR ligands that usually penetrate more deeply into the 
transmembrane core. PAR1 carries its own agonist as a tethered ligand. When 14 binds to 
PAR1, it can be covered with excess tethered ligand of PAR1, to prevent 14 from leaving 
the receptor easily. Indeed, evidence supports binding of 14 to PAR1 in a virtually 










Figure 1.15: Concentration-response curves of SFLLRN-NH2 in the presence of different concentrations of 
vorapaxar (14, VOR).  Insurmountable response dependent on dose of 14 indicates irreversible binding of 
14 to PAR1.54 
 
In summary, the high risk of irreversible binding and complete shutdown of G-
protein mediated signaling by orthosteric antagonists to PAR1 could explain possible 
excess bleeding risks and undesired side effects associated with the use of these anti-
thrombotic agents. Selective inhibition of G-protein downstream signaling could be 
beneficial, and it could be achieved by binding a ligand at an allosteric site, which could 












Figure 1.16: Comparison of 14 (as orthosteric antagonist, A) and parmodulin (as allosteric modulator, B) 
on downstream singling of PAR1 and its ultimate pharmacological effect. 
 
 This project emphasizes the design and development of allosteric modulators of 
PAR1, termed “parmodulins”. Parmodulins are functionally biased ligands of PAR1 and 
could be beneficial to provide a safer and more effective ways of inhibiting platelet 
activation. Preliminary studies suggested that parmodulins ligands antagonizes Gαi and 
Gαq mediated downstream signaling, but have no effect against Gα12/13 or β-arrestin 
mediated signaling
50
 and could be superior anti-thrombotics compared to orthosteric 








Chapter 2:  
 
 
Background information on 1,3-diaminobenezen scaffold as biased antagonists / 
negative allosteric modulators of PAR1 
 
 
 As discussed in the earlier sections, PAR1 plays an important role in activation of 
platelets and has been studied as an anti-platelet drug target for the prevention of adverse 
cardiovascular events. Several efforts have been made to develop orthosteric PAR1 
antagonists. Amongst them, vorapaxar (1, an orthosteric PAR1 antagonist) has been 
approved by the FDA for the secondary prevention of myocardial infarction (MI) and 
percutaneous coronary intervention (PCI). Although 1 showed a decreased risk of adverse 
cardiac events in patients with acute coronary disease during phase III clinical trials, it 
showed an increased risk of bleeding events including intracranial hemorrhage (ICH) and 
fatal bleeding. For this reason, allosteric modulation of PAR1 could be a promising 
venture to selectively inhibit PAR1 and to overcome the liabilities associated with current 









2.1. Discovery of 1,3-diaminobenzene scaffold 
 
 
Figure 2.1: PAR1 inhibition by A) vorapaxar (1), an FDA approved orthosteric PAR1 antagonist, and B) 
ML161 (2), an allosteric, biased antagonist of PAR1, and the lead compound for our studies. IC50 was 
measured using a haTRAP (SFLLRN-NH2, 2 μM) binding assay for 1 and in a platelet P-selectin assay (P-
selection expression on human platelets induced by 5 μM SFLLRN-NH2) for 2
50. 
 
Platelets undergo phenotypic changes like dense granule secretion and shape 
change in response to injury. After a vascular injury, diverse array of agonists (e.g., 
thrombin, thromboxane-A2, ADP, etc.) trigger phenotypic changes via interaction with 
platelet surface receptors. To identify a novel, small molecule inhibitor of platelet 
activation, a high throughput screening (HTS) of 302,457 molecules with 7.5 µM 
concentration was performed at Broad Institute.
55
 The primary screening assay measured 
platelet activation via dense granule secretion. In this assay, SFLLRN-NH2 (thrombin 
activating peptide) was used to activate platelets, which undergo phenotypic changes that 
include dense granule secretion. Activated platelets were quantified via amount of ATP 
(stored in dense granules) released after dense granule secretion using a 
luciferin/luciferase detection system.
 





considered as hits based on > 50% inhibition of ATP generation. A secondary screen was 
performed using the primary assay on a selection of 1584 compounds of the original set 
that included 661 hit molecules and their structural analogs. From this set, 651 molecules 
tested as active, with measured IC50 < 10 µM. To rule out potential false positives, 
inhibitors of the luciferin/luciferase detection system were determined and excluded from 
the set of hits. From the results of these assays, 28 candidates were selected for additional 
characterization, by measuring the inhibition of P-selectin surface expression, a 
transmembrane cell adhesion molecule that is stored at the inner wall of α-granules in un-
activated platelets. Upon platelet activation, P-selectin is released onto the surface of 
platelets and can be measured by flow cytometry.
56
 After additional studies, 3 probe 
molecules were nominated. Of these probes, ML161 (2, also known as parmodulin 2 or 
PM2) inhibited PAR1-mediated platelet aggregation. Therefore, compound 2 with the 
1,3-diaminobenzene pharmacophore was considered for further pharmacological 














2.2. Pharmacology of 1,3-diaminobenzene scaffold 
 
Figure 2.2: ML161 selectively inhibited PAR1 receptor. A) P-selectin assay: 3 µM ML161 to inhibit 
platelet activation in response to 5 µM SFLLRN-NH2, 0.2 µM PMA, 100 µM AYPGKF, 1 µM U46619, or 
10 µg/ml collagen. Inhibition was observed only with PAR1 agonist SFLLRN-NH2; B) PM2 selectively 
inhibited PAR1 mediated secretion of VWF in endothelial cells; C) GPCR profiling: PM2 (10 µM) was 
tested in HEK cells with reference compounds for agonist and antagonist activity; agonist activity was 
compared with SFLLRN-NH2 in iCa
2+ flux and with isoproterenol in cAMP assay; antagonist activity was 
measured with control inhibitors of represented receptors.57 
 
 
P-selectin surface expression assay was considered as a functional assay to 
characterize 1,3-diminobenezene scaffold. ML161 (2) was moderately potent with IC50 of 
0.26 µM in the SFLLRN-NH2 mediated P-selectin assay. Inhibition of platelets by 





ML161. Assays were performed on washed human platelets, separately treated with the 
peptide AYPGKF (a PAR4 agonist), PMA (a protein kinase C activator), U46619 (a 
thromboxane receptor agonist), and collagen (an agonist of collagen receptors), and 
ML161 showed little or no inhibition of platelet activation via the receptors other than 
PAR1 (Figure 2.2A). In endothelial cells, ML161 selectively blocked only PAR1-
mediated VWF (Von Willebrand Factor, glycoprotein involved in haemostasis) secretion 
when tested against other receptor agonists (Figure 2.2B). Additional assays were 
performed for GPCR profiling of ML161 where it selectively inhibited some, but not all, 




Figure 2.3: ML161 inhibited Gαq mediated signaling but not Gα12/13 mediate signaling. A) Gαq mediated 
signaling of PAR1: N/A is vehicle; PM1-4 represents different parmodulins where PM2 is ML161; V = 
vorapaxar, A = atopaxar, S = SCH-79797, B = BMS-200261; V,A,S,B are orthosteric antagonists; Conc. 
were used – 10 µM PM1, 3 µM PM2, 10µM PM3, 10 µM PM4, 0.3 µM V, 0.3 µM A, 1 µM S, 3 µM B and 
5 µM SFLLRN-NH2; Platelets were incubated with parmodulins and orthosteric antagonists and iCa
2+ flux 
was measured after incubation with SFLLRN-NH2. B) Gα12/13 mediate signaling of PAR1:  Conc. of PM2, 
V and A were similar to A; Platelet shape change is not affected by ML161; black trace is vehicle, red trace 
is SFLLRN-NH2 agonist before wash and blue trace is SFLLRN-NH2 agonist after wash.
57  
 
Although ML161 was moderately active relative to orthosteric antagonists such as 





activation of PAR1 by thrombin leads to multiple downstream effects like β-arrestin 
activation and G-protein activation, leading to phenotypic changes (Gαq stimulation for 
granule release and Gα12/13  stimulation for shape change). A traditional orthosteric 
antagonist, vorapaxar (1), blocks all phenotypic changes. But ML161 showed inhibition 
of Gαq-mediated granule secretion but no effect on Gα12/13-mediated platelet shape change 
(Figure 2.3). These preliminary results were suggestive of ML161 as a biased ligand for 
PAR1. Additionally, the insurmountable antagonism by ML161 of SFLLRN-NH2-driven 
P-selectin expression suggested ML161 (2) could be either a negative allosteric 
modulator or an irreversible biased antagonist of PAR1 (Figure 2.4). 
 
 
Figure 2.4: SFLLRN-NH2 Induced P-selectin expression in presence of varying concentrations of ML161. 
Instead of a rightward shift of the dose− response curve (as expected of an orthosteric inhibitor) ML161 
demonstrated insurmountable antagonism at higher doses, consistent with allosteric inhibitory 
mechanism.50 
 
 Moderate potency, selectivity for PAR1, biased signaling, and the possibility of 
an allosteric mode of action were promising criteria to consider ML161 as a “lead” 
molecule to develop anti-thrombotics with improved safety profiles. Therefore, the 1,3-





2.3       Identify the binding site of parmodulins on PAR1  
  
Figure 2.5: Identification of binding site of ML161. The effect of vehicle (N/A), 10 µM parmodulin 1 
(PM1), 3 µM parmodulin 2 (PM2), and 1 µM SCH79797 (S) on agonist-induced iCa2+ flux was evaluated 
in COS-7 cells transfected with (B) wild-type (WT) PAR1, (C) WT PAR4, (D) the ΔH8 PAR1 mutant, (E) 
a chimeric PAR1 in which il2 was replaced with il2 of PAR4, and (F) a chimeric PAR1 in which il3 was 
replaced with il3 of PAR4. iCa2+ flux was evaluated after stimulation with either 5 µM SFLLRN-NH2 
(B,D-F) or 300 mM AYPGKF (C).57 
  
The preliminary studies showed biased mode of action by ML161 but didn’t 
specify the binding site of ML161 on PAR1 and the reason for its signaling bias. Our 
collaborators, Robert Flaumenhaft and co-workers, attempted to determine the putative 
binding site of ML161. Their work with chimeric PAR1 receptors suggests that ML161 is 
binding on the cytosolic face near intracellular loop 3 (Figure 3.10).
57
 They demonstrated 
that replacement of the 3
rd
 intracellular loop of PAR1 with that of PAR4 (Figure 3.10E) 
leads to a drastic decrease in PM2 activity in a iCa
2+ flux assay with COS-7 cells with 
SFLLRN-NH2 as agonist There are very rare examples available in the literature where 





workers developed a modified peptide series, termed as pepducins, as PAR modulators.
58
 
Pepducins modeled after 1
st
 intracellular loop of PAR1 and they act as either agonists or 
antagonists, in a manner which is not fully understood yet. It may be possible for 
parmodulins to share a similar site and can modulate the signal in a way act as either 
agonist or antagonist. In such cases, it’s very important to learn about mode of action of 
parmodulins.  
 Kobilka and co-workers presented x-ray structure of PAR1 embedded with 
Vorapaxar, unfortunately they heavily modified intracellular loop 3 and disordered the C-
terminus to facilitate crystallization, making it difficult for us to identify putative binding 
site via computational studies.  
 
2.4       Parmodulins as cytoprotective agents 
Initially, PAR1 was focused as the anti-platelet target for the treatment of 
cardiovascular diseases but recent studies suggest that PAR1-mediated cytoprotective 
and/or anti-inflammatory signaling could be beneficial for the treatment of conditions 
such as sepsis and reperfusion injury. The activation of PARs is unique among GPCRs as 
they not only carry their own ligands for activation, but also trigger different signaling 
cascades based on cell type and proteases by which they are cleaved. For example, in 
platelets PAR1 is cleaved at the Arg41 residue on the N-terminus by thrombin, leading to 
platelet activation. In endothelial cells, PAR1 triggers pro-inflammatory and barrier 
disruption in presence of thrombin.
59
 In contrast, APC (activated protein C)-mediated 
PAR1 activation triggers the opposite anti-inflammatory and barrier stabilizing effects.
60
 





separate efforts of Mosnier and Trejo. Mosnier and co-workers demonstrated that APC 
cleaves PAR1 at Arg46 instead of Arg41.
61
 Trejo and co-workers demonstrated that APC 
binds to EPCR (endothelial protein C receptor) to form APC-EPCR complex, which can 
cleave the N-terminus of PAR1 at Arg46 and activate biased PAR1 signaling via β-
arrestin, which exerts cytoprotective effects.
62
 These contrasting observations make 
PAR1 an interesting target anti-inflammatory target in endothelial cells, in addition to 
being an anti-thrombotic target in platelets. This functionally biased phenomenon of 
PAR1 adds to the difficulty of developing orthosteric antagonists for PARs. It was found 
that parmodulins blocked thrombin generation mediated by inflammatory mediators LPS 
(lipopolysaccharide, an endotoxin) and TNF-α (tumor necrosis factor alpha, a cytokine 
involved in inflammation) in endothelial cells. The anti-inflammatory effects of 
parmodulins are exerted via PAR1 and are independent of anti-platelet activity. In other 
words, parmodulins blocked pro-inflammatory responses and exhibited APC-like 
cytoprotective effects, thus emerging as a new class of cytoprotective agents for the 
treatment of sepsis. 
 
2.4.1 Biased mode of action of parmodulin 2 in endothelial cells and their 
evaluation as cytoprotective agents. 
 
 Previously, the advantage of parmodulins as functionally biased PAR1 ligands 
was discussed. During the course of our studies, our collaborator Flaumenhaft and co-
workers studied the cytoprotective effects of parmodulins in endothelial cells. In 





PAR1-mediated pro-thrombotic responses by inhibiting Gαq but not significantly 
inhibiting G12/13.
57
More recently, they demonstrated that ML161 (aka PM2) selectively 
inhibited Gαq mediated signaling over G12/13 in endothelial cells (Figure 2.6). 
 
 
Figure 2.6: Parmodulins demonstrated biased signaling in endothelial cells. A) Parmodulins blocked Gaq 
mediated iCa2+ flux; B) Orthosteric antagonists blocked Gaq mediated iCa2+ flux; C) vorapaxar but not PM2 
blocked G12/13 mediated RhoA-GTP activation.
57  
 
 To further evaluate the effects of vorapaxar and PM2 in endothelial cells, they 
incubated human umbilical vein endothelial cells (HUVECs) with vorapaxar and PM2 
and observed apoptosis in a dose-dependent manner. Increasing the length of exposure of 
vorapaxar from 24 h to 48 h leads to increasing rates of apoptosis even at lower 
concentrations. The similar effect was observed with other orthosteric antagonists like 









Figure 2.7: Effect of orthosteric antagonists and parmodulins on apoptosis in endothelial cells. 
  
 A previous study showed that APC (a vitamin K‐dependent plasma protein) can 
reduce the rate of mortality associated with sepsis.
63
 APC was studied in clinical trial for 
the treatment of severe sepsis; however, it was retracted owing to increased rate of 
mortality.
64
 Later exhaustive efforts were made in understanding the mode of activation 
of APC that suggested that the distinct anti-thrombotic effects of APC are due to 
inactivation of factors (F) Va and VIIIa,
65
 and cytoprotective effects are due to 









Figure 2.8: Vorapaxar blocks APC mediated cytoprotection in endothelial cells. A) Mock and PAR1 
siRNA transfected HUVECs were incubated with buffer (NA) or APC before the treatment with TNF-α; B) 
HUVECs were incubated with PM2 (10 µM) or vorapaxar (0.3 µM) for 30 min, followed by treatment with 




 Because vorapaxar and PM2 inhibited PAR1, and APC mediates its 
cytoprotective effects with PAR1 agonism, our collaborators investigated vorapaxar and 
PM2 effects on APC mediated cytoprotection. They demonstrated that application of 
APC before TNF-α exposure significantly reduces apoptosis (Figure 2.8A). Next, they 
treated HUVECs with PM2 or vorapaxar prior to APC and observed inhibition of APC-
mediated cytoprotection by vorapaxar but not PM2 (figure 2.8B). These results indicated 
parmodulins can interfere thrombin formation without blocking APC-mediated 
cytoprotective effects, and possibly could show anti-inflammatory activity through β-







2.4.2 Profiling of parmodulin as cytoprotective agents 
 
 
Figure 2.9: Inhibition of thrombin generation by A) ML161 (3 µM) and B) APC (10 nM) in endothelial 
cells. Thrombin generation was detected by fluorogenic thrombin substrate in HUVECs incubated with 
LPS mixture (100 ng/mL LPS, 10 ng/mL LBP, 100 ng/mL sCD14) or TNF-α (10 ng/mL) with or without 
ML161 and APC.66 
 
Parmodulins inhibited thrombin formation mediated by inflammatory factors like 
LPS and TNF-α in endothelial cells and demonstrated APC-like cytoprotective effects. 
LPS and TNF-α are inflammatory mediators to induce thrombin formation in endothelial 
cells. ML161 was incubated with LPS or TNF-α in HUVECs for 4 h and inhibited 70% 
of LPS induced thrombin activation and 54% of TNF-α induced thrombin activation 
(Figure 2.9A). In a similar assay, APC also exerted inhibition of thrombin activation via 
LPS and TNF-α (Figure 2.9B).  
Next, factor Va (FVa) and factor Xa (FXa) assays were performed investigate the 
mode of cytoprotective effects of PM2 and APC. In the factor V assay, parmodulins 
showed no effect on FVa generation whereas APC significantly inhibited it (Figure 
2.10A). In contrast, parmodulin 2 inhibited LPS- and TNF-α-induced FXa generation 





the possibility to cleave tissue factor pathways inhibitor by APC,
67
 and thereby 
preventing tissue factor inhibition. 
 
Figure 2.10: Effect of PM2 and APC in FVa and FX generation in endothelial cells: A) FVa generation: 
HUVECs were incubated with APC (10 nM) for 15 min and PM2 (10 µM) for 4 h, followed by 
measurement of FVa generation as a function of time.66  
 
  To demonstrate anti-thrombotic effect of parmodulins 2 via cytoprotective 
pathways, they exposed endothelial cells with TNF-α before the whole blood and let 
platelets accumulate on endothelial cells. After that they treated these endothelial cells 
with parmodulin 2 and observed no effect on platelet accumulation on endothelial cells. 
In contrast, after incubating parmodulin 2 with endothelial cell for 4 h followed by TNF-
α exposure lead to inhibition of TNF-α induced platelet accumulation (Figure 2.11). 
These evidences suggested the anti-thrombotic activity of parmodulin 2 mediated through 
inflammatory factors, demonstrating that parmodulins stimulate cytoprotective signaling 









Figure 2.11: Parmodulin 2 mediates anti-thrombotic activity via a cytoprotective pathway in endothelial 
cells: A) HUVECs cell surface micrographs; B) quantification of TNF-α induced platelet aggregation.66  
 
 Additionally, they exposed HUVECs to TNF-α and staurosporine after incubation 
with parmodulin 2 and APC, and measured the apoptosis rate (figure 2.12A-B), which 
confirmed the cytoprotective effects of parmodulin 2. To eliminate the possibility of any 
off target effect on apoptosis by parmodulins, they performed PAR1 knockdown studies. 
They inhibited PAR1 expression by siRNA directed to F2R (coagulation factor II 
receptor, in human encoded as F2R gene). Abrogation PM2 activity demonstrates 
cytoprotective activity via PAR1 (figure 2.12C). They also performed time course of 
PM2 mediated cytoprotection in HUVECs (figure 2.12D)  that showed pre-incubation 








Figure 2.12: Parmodulin 2 induces cytoprotective effects in endothelial cells. A) HUVECs were exposed 
to vehicle, PM1 (10 µM), PM2 (3 µM) and APC (10 µg/mL) for 4 h followed by treatment with buffer 
(NA), TNF-α (10 ng/mL), staurosporine (10 µM) or thrombin (1 U/mL). Quantification of % apoptotic 
cells demonstrated APC like cytoprotective effects by PM2; B) HUVECs were exposed to vehicle, PM1 
(10 µM), PM2 (10 µM) and APC (5 µg/mL) for 4 h followed by treatment with buffer (NA), TNF-α (50 
ng/mL). Apoptosis was evaluated using cleaved caspase-3 antibody; C) PAR1 knockdown studies 
performed in similar fashion like (A); D) Time course of PM2 mediated cytoprotection from staurosporine 
induced apoptosis.66 
 
 We originally designed and developed a small library of functionally biased 
parmodulins as to find safer and more effective alternatives to current anti-thrombotic 
agents and tested them in the P-selectin assay, in collaboration with the Flaumenhaft lab. 
However, the cytoprotective properties of the parmodulins encouraged us to emphasize 
the development of cytoprotective agents. In the literature, PAR1 showed barrier 
protection through β-arrestin activation in endothelial cells. We hypothesize that the 





their allosteric site of interaction on PAR1 in endothelial cells. Similar to P-selectin assay 
in platelets, we needed to develop Gaq mediated signaling assay in endothelial cells, as a 
primary tool to study the biased mode of activation of PAR1 by parmodulins, and to 
study their SAR to find a potent anti-inflammatory agent to treat sepsis. Our progress was 
hindered due to the lack of a standard protocol for such an assay. In order to achieve an 
easy and reproducible measurement for functional bias, we planned to develop Gaq 
driven intracellular Ca
2+















Gɑq driven intracellular Ca
2+
 flux bioassay optimization in endothelial cells 
 
 
3.1   Introduction and mode of action of Gɑq driven intracellular Ca
2+
 flux 
In addition to maintaining bone structure and function, intracellular calcium ions 
(Ca
2+
) serve as secondary messengers to control numerous cellular processes like cell 
division and differentiation, transcription factor activation, apoptosis, vasodilation and 
vasoconstriction, hormonal secretion, nerve transmission, muscle function, etc.
68, 69
 
During resting conditions, concentration of Ca
2+
 ions is ~ 100 nM that can increase 
roughly to 1000 nM upon activation.
68
 This increase could be due to the i) transport of 
extracellular Ca
2+
 through voltage gated or receptor operated Ca
2+
 channels, or ii) release 
of stored Ca
2+
 ions from endoplasmic reticulum (ER) or lysosome related stores.
70
 Later, 
the elevated intracellular Ca
2+
 level is regulated by Ca
2+







 exchangers to restore the normal cytosolic concentrations.
71
 





 channel pumps or sequester the stored Ca
2+
 from the endoplasmic 
reticulum. In case of GPCRs, activated receptor stimulates heterotrimeric G-protein (Gɑ 
and Gβγ subunits). Based on sequence homology of GPCRs, there are 4 types of Gɑ 
protein Gα(s/olf), Gα(i1/i2/i3/o/z/gust/t-cone/t-rod/), Gα(q/11/14/16) and Gα(12/13). Upon activation with 





When GPCRs transduces signal through a series of Gɑq protein, GTP bound Gɑq activates 
phospholipase β (PLCβ). The later catalyzes the hydrolysis of phosphatidylinositol-4,5-
bisphosphate (PIP2) into 1,4,5–inositol triphosphate (IP3) and diacylglycerol (DAG). The 
released IP3 binds to IP3 sensitive Ca
2+
 channels on endoplasmic reticulum (ER) to 
release Ca
2+
 ions into the cytosol (Figure 3.1).
72
 Therefore, cell based functional assays to 
monitor the intracellular Ca
2+
 concentrations have provided the grate platform in high 
throughput screening and pharmacological characterization of ligands with GPCRs and 
have been widely used in academia and pharmaceutical industries.  
 
 
Figure 3.1: Gαq mediated intracellular Ca
2+ flux fluorescent assay mechanism: Upon interaction of agonist 
with GPCR (a), the activated receptor exchanges GDP for GTP and dissociates heterotrimeric Gɑ and Gβγ 
subunit (b). The released Gɑ protein activates PLCβ (c) that catalyses hydrolysis of PIP2 into IP3 and DAG 
(d). Diffused IP3 than binds with IP3 sensitive Ca2+ channel on ER (e) and releases free Ca2+ into cytosol 
(f). Upon the treatment of cells with a fluorescent dye (e.g. Fluo-4-AM), the released free Ca2+ then binds 
with anionic fluorescent dye (e.g., Fluo-4) and the fluorescence of the resultant complex can measured by 





3.2    Fluorescent indicators for the measurement of intracellular Ca
2+
 concentration 
The very first approach to measure intracellular Ca
2+
 level was performed by 
Ridgway and Ashley who used a photoprotein aequorin, isolated from the jellyfish 
Aequorea Victoria. Aequorin is a 21 kDa polypeptide with 3 potential Ca
2+ 
binding sites 
that upon binding with free Ca
2+
 emits photons at 470 nm.
73
 However, due to the 
complicated application of photoproteins, a range of Ca
2+
 sensitive fluorescence synthetic 
indicators were developed including Rhod-2, Indo-1, Fura-2 and Fura-3.
74-76
 These 
indicators are based on the structures of Ca
2+
 chelators like EGTA, incorporated with a 
fluorescent moiety and lipophilic acetoxymethyl (AM) ester. AM ester facilitates 
transportation into the cells, where it gets hydrolysed to free carboxylic acid to retain the 





Based on biochemical properties, synthetic indicators have been classified as 
ratiometric (e.g. Fura-2, Indo-1, etc) and non-ratiometric indicators (e.g. Fluo-3, Fluo-4, 
etc). Ratiometric indicators like Fura-2 exhibit dual excitation wavelength in Ca
2+ 
bound 
and free forms. For example, Fura-2 has excitation wavelength 340 nm in Ca
2+ 
bound 
form and 380 nm in Ca
2+ 
free form. Upon binding with Ca
2+
, excitation at 340 nm 










 The most widely used non-ratiometric Ca
2+
 indicators for biological 
purposes are Fluo-3 developed by Tsien and co-workers,
76
 and Fluo-4 developed by 
Johnson and co-workers.
78
 In vivo, fluo-4 exhibits high rate of cell permeation, high 








3.3      Optimization of Calcium mobilization assay 
 
Figure 3.2: iCa2+ flux assay protocol: A) EA.hy926 cells were seeded to costar 96-well plate for ~40 h and 
imaged under EVOS microscope, followed by media removal with HBSS-HEPES buffer; B) Fluo-4 dye 
incubation for 1 h and imaged under EVOS microscope, followed by dye replacement with HBSS-HEPES 
buffer; C) fluorescent trace with antagonist, followed by agonist addition. A spike in fluorescence is 
observed after agonist addition indication PAR1 activation leading to increased iCa2+ from endoplasmic 
reticulum.79 
 
 All assay work was carried out at the Blood Research Institute, Milwaukee in our 
collaborator Dr. Hartmut Weiler’s lab. During the initial phase of our study, EA.hy926 
cells were cultured by Irene Hernandez, however, afterwards we cultured our own batch 
of EA.hy926 cells. The assay development described here represent my combined efforts 
with my colleagues Dr. Mark Majewski and my advisor Dr. Chris Dockendorff. 
 To initiate our study, the transformed endothelial cell line (EA.hy926)
80
 was our 
primary choice for measuring calcium mobilization in adherent endothelial cells. 
EA.hy926 cell line is widely used in PAR-related studies and could be cultured to 
extended number of passages and grown reliably in tissue culture-treated 96 well plates. 
Frozen vial of EA.hy926 cells was purchased from ATCC and cultured up to 14 passages 







chose Corning Costar (#3603) with black wall, flat and clear bottom. Black wall plates 
are recommended for fluorescent assays, flat bottom aids in even distribution of cells and 
clear bottom permits direct microscopic analysis. These plates are available as tissue 
culture treated to adhere cell line to the plate. The cell seeding density was set to 25000 
cells per well followed by incubation period of 42-48 h to reach maximum confluency 
(figure 3.2A). We chose Fluo-4 dye to quantify iCa
2+ flux. Fluo-4 offers a brighter 
fluorescence emission due to its greater absorption at 488 nm and also offers a high rate 
of cell permeation than other dyes. It has been highly recommended for fluorometric 
analysis in high throughput screening assays.
78
 Fluo-4 was dosed as its acetoxymethyl 
ester (Fluo-4/AM) and generated emission signals at 525 nm in our assay. Pluronic F-127 
was used to dissolve Fluo-4 dye. Both of Pluronic F-127 and probenecid (Fluo-4 anion 
efflux inhibitor) were purchased directly from vendor. The cells were incubated with dye 
for 60 – 75 min during our initial studies (figure 3.2B). PerkinElmer EnSpire plate reader 
was used to take fluorescent measurements. The major limitation of EnSpire plate reader 
is to imagine one well at a time instead all wells concurrently like with FLIPR 
instrument.
82
 A representative trace of response versus time is shown in figure 3.2C. For 
initial studies, we used normalized response of each well with difference between 
maximal response and average of baseline.  PAR1 agonist TFLLRN-NH2, PAR2 agonist 
SLIGKV-NH2, PAR1/2 agonist SFLLRN-NH2, PAR1 orthosteric antagonist vorapaxar 
and PAR1 allosteric antagonist ML161 were chosen to optimize the assay conditions.  
 During our initial attempts, we observed acceptable signal/noise measured 
concentration response curves with PAR1 and PAR2 agonists. However, the results were 





with 100% DMSO (1% final concentration of DMSO in assay) but adverse effects of 
DMSO on endothelial cells (retraction) was observed. DMSO concentration was 
minimized from 1% to 0.1-0.2% but high deviations were observed. Considering the poor 
solubility of our molecules to be a root of high deviations, we tested several excipients to 
keep parmodulins in solution form. We tested different excipients like Tween-20, Tween-
80, Triton X-100, BSA, and Pluronic F-127 in final concentration range of 0.01 – 0.1%. 
These excipients were incorporated with antagonists in vehicle. Although the excipients 
had improved solubility, it didn’t help in improving inconsistent results. In case of Tween 
20, Tween 80 and Triton X-100, dye was leaked extracellularly after 5 -10 minute of 
incubation period whereas in case of BSA and Pluronic F-127, dye leaking was observed 
over 45 – 60 min incubation period. Therefore, we eliminated poor solubility of 
parmodulins as a cause for inconsistent results and fixed to use DMSO concentration 0.01 
– 0.02% for the rest assay development.  
 
 
Figure 3.3: Micrograph of EA.hy926 cells. A)  Under transmission light without any dye; B) After dye 






 We next examined volume of antagonist addition, dye and antagonist incubation 
period, dye loading amount with any profound effects form probenecid and pipetting 
technique. When we eliminated the probenecid from experiments, we observed the no 
retention of dye inside the cells (figure 3.3C), which confers the necessity of probenecid. 
Our antagonist loading volume was 2 µL. We reasoned that lower volume may be the 
cause for high deviation due to inadequate pipetting. We tried different volume of 
injection ranging from 2 µL to 50 µL keeping antagonists solution temperature 37°C. We 
tried different pipetting techniques like forward/reverse pipetting to avoid air-bubble 
formation. Unfortunately, these efforts were not successful. We gained access to single 
channel automated liquid handler for addition but the process to add 1 well at a time in a 
96-well plate for inadequate timewise and Fluo-4 dye was significantly leaked outside 
causing lower calcium maxima signals. We next analyzed incubation period of dye and 
antagonists and decreased Fluo-4 dye concentration. But dye was leaking slowly over 
prolonged period of time and that cannot be fruitful in longer experiments. We serum 
starved our cells, yet observed similar results.   
 
 
Figure 3.4: ML16 concentration response curves: A) With PAR1 agonist TFLLRN-NH2 (3.16 µM) using 







 During the course of assay optimization, we observed inconsistency of cells in 
some of the wells. When tracked the results with inconsistent wells, we observed high 
variability associated with them. To reason with the source of inconsistency, we imagined 
confluency of cells before first media wash (figure 3.4A), and observed fully confluent 
cells. However, when we imagined cells after replacing the media with dye and the later 
with the fresh HBSS-HEPES buffer, we observed inconsistency in few of the wells 
(figure 3.3D-E).  It turned out that we used “flicking” for our liquid exchanges and that 
dislodged the cells from the plate causing high variability in assay results (figure 3.4A). 
When we performed liquid exchanges using 8-channel automated liquid handler 
(Beckman Coulter), our inconsistent results disappeared. Agonists and antagonists 
concentration response curves were reproducibly obtained with low deviations with use 
of Beckman Coulter (figure 3.4B).  
 
3.4     Results and discussion of bioassay results  
3.4.1 Z-factor calculation for assay reliability 
 
Figure 3.5: Z- Calcium mobilization responses- with PAR1 agonist 5 μM TFLLRN-NH2 and plus with 
































 Z-factor is a statistical effect size measurement and widely used for high 
throughput screening. As this assay was developed to screen parmodulins, we determined 



















EC50 = 4.77 μM 
B. SLIGKV-NH2 
 
EC50 = 5.79 μM 
C. SFLLRN-NH2 
  
EC50 = 2.38 μM 
Figure 3.6: PAR agonist concentration-response with EA.hy926 cells: A) TFLLRN-NH2 (PAR1)-mediated 
iCa2+ mobilization; B) SLIGKV-NH2 (PAR2)-mediated iCa
2+  mobilization; C) SFLLRN-NH2 (PAR1/2)-
mediated iCa2+  mobilization.79 
  
 With a reliable assay in our hand, we started pharmacological profiling of our 
molecules. We first determined concentration response curve of 3 agonists: PAR1 agonist 
(TFLLRN-NH2; EC50 = 4.77 μM; figure 3.6A); PAR2 agonist (SLIGKV-NH2; EC50 = 










IC50 = 0.032 μM 
B. Atopaxar 
 
IC50 =0.033 μM 
C. RWJ-58259 
 
IC50 = 0.020 μM 
Figure 3.7. Concentration-response for PAR1 antagonists in the TFLLRN-NH2-mediated iCa
2+ 
mobilization assay (5 µM) with EA.hy926 cells: A) vorapaxar, B) atopaxar, (C) RWJ-58259.79  
 
 Using EC50 of agonists, we obtained concentration response curve for PAR1 
orthosteric antagonists vorapaxar (IC50 = 0.032 μM; figure 3.7A), atopaxar (IC50 = 0.033 








IC50 = 0.847 μM 
B. RR-90 
 
IC50 = 0.978 μM 
C. DG-5 
 
IC50 = 94 μM 
D. EMG-21 
 
IC50 = 3.31 μM 
Figure 3.8: Concentration-response for ML161 analogs (parmodulins) in the TFLLRN-NH2-mediated (5 
µM) iCa2+ mobilization assay with EA.hy926 cells: A) ML161; B) RR90; C) DG5; D) EMG21.79 
  
 We obtained concentration response curve for several parmodulins ML161 (IC50 
= 0.847 μM; figure 3.8A), RR90 (IC50 = 0.978 μM; figure 3.8B), DG5 (IC50 = 94 μM; 







Figure 3.9. Concentration-response for the PAR2 antagonist TJF5 (Fairlie’s PAR2 antagonist; IC50 = 1.66 
μM) in the SLIGKV-NH2-mediated (5 μM) iCa
2+ mobilization assay.79 
 
 Fairlie reported TJF5 as PAR2 antagonist,
84
 which was synthesized in solution 
phase in our lab as a standard for PAR2 antagonist. We obtained concentration-response 
curve for TJF5 with IC50 of 1.66 μM in presence of PAR2 agonist SLIGKV-NH2 (5 μM), 
indicates versatility of our assay for other PARs (figure 3.9).   
 
3.5 Conclusion 
  A protocol to measure Gaq mediated intracellular Ca
2+
 was successfully 
developed in adherent endothelial cells. This assay can be used to measure concentration-
responses for a variety of PAR1 and PAR2 ligands in a reproducible manner. This assay 
is suitable for both orthosteric and allosteric PAR1 and PAR2 ligands and provides a 
good platform to small academic labs to perform preliminary pharmacological evaluation 
in the absence of automated high throughput screening instruments. We also developed a 





pharmacological behavior with PAR1 using this assay. In addition, it has provided a good 






Chapter 4:  
 
 
Design and development of negative allosteric modulators of PAR1 
 
 
4.1. Early SAR studies 
 
            Figure 4.1: SAR summary of the 1,3-diaminobenzene scaffold50 
 
A brief summary of SAR study on 1,3-diaminobenzene pharmacophore was 
published in 2012
50
 (Figure 4.1). To track SAR trends, the structure of ML161 was 
divided into 3 sections:  west region, central ring system and eastern region. All 






Figure 4.2: SAR of selected eastern modified analogues 
 
Preliminary SAR studies suggested that the maximal activity was observed with 
eastern arenes with ortho substituents; meta and para substituents had neutral or negative 
effects on potency. Some compounds with di-substitution on the eastern benzene retained 
activity but did not improve potency. Small electron withdrawing or neutral groups at the 
ortho position were the most potent, with the ortho bromide (e.g. as in ML161, IC50 = 
0.26 µM in P-selectin assay) so far being the most potent compound of the series. 
Increasing bulkiness at the ortho position (e.g. phenyl) or replacing the eastern arene with 
heterocycles (e.g, furan, pyridine, quinoline) led to poorly active or inactive compounds. 
The arrangement of amide was also necessary to retain the activity. When the position of 
the amide was reversed, the analogue lost activity. When at the east side, amide nitrogen 
was methylated, indicating the possibility of this functional group acting as a hydrogen 







Figure 4.3: SAR of selected western modified analogues 
 
Keeping the east side fixed, the alkyl group at the west side was explored (Figure 
4.3). Optimal potency was observed with a 3-carbon chain (ML161). Some potency was 
observed with 2-carbon chain but 4-carbon chain analogue was inactive. Poor plasma 
stability issue of ML161 was answered with replacing normal alkyl chain to branched 
alkyl chain with similar potency like ML161. The overall modifications at west side of 
1,3-diaminobenzene pharmacophore offered some flexibility, which were utilized in this 
thesis. During early SAR studies, modifications at central ring system was not fully 
explored however, replacement of 1,3-disubstituion to 1,4-disubstituion caused loss in 
activity.   
Previous SAR study highlighted possible sites for modification but additional 
investigations are needed to understand mode of action of this pharmacophore and where 
it is binding to PAR1. In addition, ML161 has dianilide groups, which can have potential 
to undergo enzymatic hydrolysis to yield toxic aniline derivatives. It has moderate 
solubility (40 µM in PBS) and it suffers from poor mouse plasma stability (2% left after 5 
h).
 





other liabilities associated with ML161 need an equal attention to develop a drug 
candidate. A part of this thesis work has been dedicated to explore SAR study to answer 
all liabilities associated with ML161. 
 
4.2. Extended SAR studies of 1,3-diminobenezene scaffold 
 
Figure 4.4: 1,3-diaminobenzene core. 
 
 This section highlights how the 1,3-diaminobenzene based scaffold was utilized 
to explore SAR studies. The first part will discuss the design, synthesis and biological 
evaluation of western parmodulins. The second part will discuss the design, synthesis and 
biological evaluation of central parmodulin analogues. The third part will discuss the 
design, synthesis and biological evaluation of eastern parmodulins. The fourth part will 
discuss the attempts made to investigate binding site to PAR1. At last, the fifth part will 
discuss results of iCa
2+
 assay in endothelial cells. 
 To track SAR, 1,3-diminobenzene based scaffold was divided into 3 parts: west 
side, central ring, and east side (Figure 4.4). Designing of these molecules were done by 





advisor Dr. Chris Dockendorff. I optimized reaction conditions of intermediate, 
synthesized few west side analogues and mainly focused on synthesis of complex central 
heterocycles. The rest of the library was prepared by other graduate students Ricardo 
Rosas Jr. and Eric Greve, and undergraduates (specifically, Meredith Kuhn, Teresa 
Yeung, Andrew Kreatsoulas, Allison Stephan, Kaitlin Kentala, Ben Plehaus, Alaa Shana, 
Khia Kurtenbach, Trevor Foster, Vlada Kot and N’Gussen Diby) under my, Ricardo and 
Eric’s direct supervision.  
 Screening of parmodulins using P-selectin assay of platelets was performed at 
Beth Israel Deaconess Medical Center (Harvard Medical School, Boston, Massachusetts) 
institute in our collaborator Dr. Robert Flaumenhaft’s laboratory.  Analogues were tested 
by Dr. Omoz Aisiku in P-selectin expression assay at 10 µM concentration. Table 3.1 – 
3.3 represents P-selectin assay data. For initial screening, only %inhibition was measured 




 flux assay of endothelial cells, we discussed and demonstrated the 
reliability of assay to measure concentration-response curve of PARs agonists and 
antagonists in previous chapter 3. We screened our parmodulins library in this Gaq 
mediated iCa
2+
 flux assay to identify ‘potent” parmodulins and further characterize as 
PAR1 biased ligands in endothelial cells for their cytoprotective effects.  
 Medium throughput screening was carried out at Blood Research Institute, 
Milwaukee in our collaborator Dr. Hartmut Weiler’s lab. Screening protocol was 
designed by me. Screening of all parmodulins in this thesis was performed by myself and 





of me and graduate student Ricardo Rosas Jr. under the guidance of my advisor Dr. Chris 
Dockendorff.  
 In 96-well plate, screening was mapped out for 18 parmodulins (n=4) at a time, 
along with Vorapaxar as positive control. Concentration parmodulins were set to 10 µM 
final concentration with 0.03% final concentration of DMSO for initial screening. 
TFLLRN-NH2 was selected as PAR1 selective agonist and concentration was set to 5 
µM. All liquid exchanges and antagonists’ addition were performed using automated 
liquid handler. Final agonist addition was done via multichannel pipette to minimize 
variations at the best.  Z-factor was measured for each plate using agonist response as 
negative control and Vorapaxar response as positive control to verify validity of 
screening.  
 
4.3      Design, synthesis and biological evaluation of western ML161 analogues 
 
Figure 4.5: Planned SAR studies on west side of 1,3-diaminobenzene core 
  
 Figure 4.5 illustrates key points of structure where modifications can be done. 
From previous results, we knew that 3-carbon chain to amide is optimal for activity. 





Heteroatoms can boost solubility and can make addition H-bods with the target that can 
improve potency. Therefore, keeping the east side fixed, we designed ether, carbamate 
and malonate derivatives at the west side chain. Additionally, we inserted amine to this 
chain to make molecule more basic and it is expected to be protonated at physiological 
pH which can improve solubility of ML161. Branched alkyl chain was reported with 
improved plasma stability, but the resultant molecule has poor solubility. We designed to 
insert alcohol on branched chain to improve solubility and we reversed the position of 
amide to observe tolerance in activity. Insertion of F-atom is widely popular among 
medicinal chemists due to similar size of F compared to H-atom and fluorinated 
molecules are tend to be more metabolically stable. Due to limited availability, cost and 
efforts to synthesize fluorinated starting materials, we have designed only one molecule 
and this area needs further investigations. 
 
4.3.1 Synthesis of west side analogues 
 





 To build a library of western analogues, commercially available nitro aniline 4.1 
was acylated with commercially available 2-bromo benzoyl chloride under anhydrous 
conditions to give nitro-anilide 4.2 in >90% yield.  Previously, reduction of nitro-anilide 
4.2 to aniline 4.3 was reported using sodium dithionite as reducing agent in 60% yield 
with 16 h of reaction time. However, the major drawback for this step was formation of 
N-sulfate by product that required additional treatment to hydrolyze N-sulfate to aniline 
4.3. We optimized this step with 80% yield and 2 h of reaction time using Sn(II)Cl2 as 
reducing agent. Aniline 4.3 was prepared in 5-10 of quantity and stored as HCl salt to 
prevent carbamate formation. Aniline 4.3 was then peptide coupled with carboxylic acid, 
or acylated with acid chloride or acid chlorofomate to synthesize the western analogues 
(Scheme 4.1). 
  
4.3.2 Representative reductive amination to synthesize amine analogues  
 
 
Scheme 4.2: Synthesis of amine / aniline analogues.  
 
 To prepare amine analogues, aniline 4.3 was condensed with aldehyde or ketone 
to imine. Imine then reduced to secondary or tertiary amine using sodium triacetoxy 





















Log IC50 ± SEM 




82%  ± 1.7%;  
-6.1 ± 0.10 
CJD125 
 




54% ± 2.7%; 





 ± 5.1% 
EMG22 
 





85% ± 1.6%; 
-6.0 ± 0.19 
KMK22 
 




























 ± 5.7% 
DG75 
 
3% 17% ± 5.9% 
VAK11 
 
N.D. 3.0% ± 2.9% 
Branched alkyl, fluorinated and reverse amide analogues 
DG119 
 
27% 21% ± 1.7% 
DG121 
 
65% 48% ± 13% 
DG120 
 















 63% ± 4.0% 
Ether, malonate and carbamate analogues 
NDRD27 
 


















Log IC50 ± SEM 
RR72 
 
Inactive 58% ± 7.2% 
TY13 
 
88%, 2.7 57% ± 3.6% 
VAK12 
 
N.D. 38% ± 4.9% 
DG14 
 
12% 11% ± 12% 
DG17 
 
5% 37% ± 11% 
DG37 
 
14% 36% ± 13% 
VAK9 
 
N.D. 42% ± 12% 
VAK10 
 
N.D. 60% ± 3.7% 

































Log IC50 ± SEM 
NDRD22 
 
N.D. 58% ± 4.4% 
AS2 
 
100%, 0.99 42% ± 2.9% 
AS4 
 
11% 44% ± 1.9% 
KMK15B 
 
Inactive 4% ± 5.7% 
KMK14B 
 
Inactive 63% ± 3.9% 
KMK15A 
 
Inactive -8% ± 5.7% 
KMK14A 
 
Inactive 65% ± 4.4% 
KMK17 
 
Inactive -60% ± 8.1% 
Notes: a. %Inhibition and IC50 was measured at 10 μM concentration in P-selectin expression on 
human platelets induced by 5 μM SFLLRN-NH2; b. %Inhibition was measured at 10 μM 
concentration in iCa
2+
 assay in EA.hy926 cells induced by 5 μM TFLLRN-NH2 and n=4, unless 
otherwise noted; c. IC50 measurements are pending; d. n=3; e. %Inhibition and IC50 was measured at 
1 μM concentration in P-selectin expression on human platelets induced by 5 μM SFLLRN-NH2; 









4.4      Design of central ML161 analogues 
 
Figure 4.6: Planned SAR studies on central region of 1,3-diaminobenzene core 
 
 From previously published SAR data, we didn’t have evidences for the 
importance of central aromatic ring as pharmacophore. Therefore we expanded our 
efforts in modifying central pharmacophore by addition of heteroatoms and replacing 
central ring with urea derivatives or heterocycles (Figure 4.6). First, we replaced central 
aromatic ring with urea and saturated piperidine ring. We investigated the tolerance of 
additional substitutions at central aromatic ring and here we are reporting 3 analogues. 
We have planned to add heteroatoms on central aromatic ring (e.g., pyridine, pyrimidine, 
pyrazine, etc.). However, unavailability, high cost and limited literature precedence on 
aromatic heterocyclic starting materials have limited our efforts at this time. 
 Majority of marketed drugs and natural products contain heterocycles. Many 





ADMET profile of a ligand. With similar concept in mind, we designed basic and 
electron-rich -N containing heterocycles like indole, indazole and benzimidazole.  
 
4.4.1 Representative synthesis of urea analogues 
 
 
Scheme 4.3: Synthesis of urea analogues.  
 
 East side intermediate 4.4 was reacted with CDI to yield intermediate urea 4.5. In 
some cases, intermediate urea 4.5 was isolated and reacted with amine to final urea 
analogues. Depends on stability of intermediate urea 4.5, was carried forward into the 














4.4.2 Synthesis of piperidine  based central analogues 
 
 
Scheme 4.4: Synthesis of piperidine based central analogues.  
 
 Commercially available N-boc-3-amino piperidine 4.6 was acylated with benzoyl 
chloride to N-boc piperidine amide 4.7 in >95% yield. Boc group was deprotected to give 
piperidine – HCl salt 4.8 (70% yield) using 4M HCl in dioxane. Piperidine – HCl salt 4.8 
was acylated with commercially available butyryl chloride to give piperidine analogue 
4.9 (71% yield). All piperidine based central analogues were synthesized in a similar 












4.4.3 Synthesis of Benzimidazoles 
 
 
Scheme 4.5: Synthesis of benzimidazole central analogues (unoptimized reaction conditions).  
 
 We attempted condensation of 4-nitro-O-phenylenediamine 4.10 and butanal to 
imine, followed by nucleophilic attack of aniline to imine to ring closure nitro 
benzimidazole 4.11. However, the attempt was unsuccessful. We than followed a 
literature procedure to form benzimidazole from diamine 4.10 and butyric acid in 
presence of 4 N HCl and refluxed the reaction.
85
 Unfortunately, the reaction didn’t 
proceed and we recovered the starting material. Another literature search lead us to 
acylation of diamine 4.10 with butyryl chloride and then to condense in presence of conc. 
HCl and ethanol as solvent.
86
 This attempt yielded 12% of benzimidazole 4.10 along with 
some by products. Later, we found a paper
 
to synthesize nitro benzimidazole 4.11 from 
phenylenediamine 4.10 and butyric acid using POCl3 as solvent.
87
 This reaction was gave 
nitro bnenzimidazole 4.11 in 23% yield (unoptimized). Nitro-Benzimidazole 4.11 was 





Pd/C. Amine 4.12 was acylated with 2-bromobenzoyl chloride to give benzimidazole 
analogue 4.13 in 45% yield (unoptimized, Scheme 4.5). 
 
4.4.4 Synthesis of Indazoles 
 
 
Scheme 4.6: Synthesis of indazole central analogues. 
 
 Synthesis of nitro-indazole 4.15 was first attempted by conversion of nitro aniline 
4.14 to diazonium intermediate followed by ring closure in aqueous acidic condition 
using 1M HCl. In this reaction starting material was recovered back. Later we followed a 
literature procedure to make diazosalt in glacial acetic acid followed by cyclisation at 
room temperature.
88
 Reaction worked well to give analytically pure crude nitro-indazole 
4.15 in 82% yield. Nitro-indazole 4.15 was then alkylated with 1-bromobutane to give 
alkylated nitro-indazole isomers 4.16 and 4.17, which were separated easily by normal 
phase flash chromatography and characterized by 2D NMR to assign the structure. 
Alkylated nitro- indazole 4.17 was reduced to aniline 4.18 using 10 mol% Pd/C under the 





2-bromobenzoyl chloride to final indazole analogues 4.19 in 81% yield. The rest of 
indazole based analogues were synthesized in similar fashion (Scheme 4.6).  
 
4.4.5  Synthesis of Indoles 
 
Scheme 4.7: Synthesis of indole central analogues (unoptimized reaction conditions).. 
 
 A literature procedure of similar analogue to nitro-indole 4.24 was followed.
89
 
First acylation of commercially available nitro-aniline 4.20 was performed to make amide 
4.21 with 68% yield. The Phenol group in amide 4.21 was converted to triflate 4.22 with 
47% yield. Triflate 4.22 was subjected to Sonogashira cross coupling with 1-pentyne to 
give alkyne 4.23 and flowed by heteroannulation to nitro-indole 4.24 under basic 
conditions. Nitro-indole 4.24 was reduced using 10 mol% Pd/C under the complete 





bromobenzoyl chloride to final indole analogue 4.26 with 18% yield (unoptimized, 
Scheme 4.7). 
 















Log IC50 ± SEM 
Piperidine based analogues at central region  
DG81 
 
25% 5% ± 3.7% 
DG82 
 
Inactive 76% ± 3.0% 
RR3 
 
Inactive -5% ± 15% 
RR5 
 
N.D. -2% ± 4.5% 
Replacement of central aromatic ring with urea 
TY7 
 
11% 48% ± 2.7% 
TY10 
 



















Log IC50 ± SEM 
Heterocycleic analogues at central region 
DG26 
 
47% 3% ± 4.7% 
RR2 
 
Inactive 1% ± 6.8% 
DG45 
 
30% 14% ± 3.1% 
DG9 
 
Inactive 6% ± 5.7% 
DG51 
 
42% 31% ± 12% 
Additional substitutions on central aromatic ring 
MK7 
 
13% 8% ± 2.9% 
TY9 
 
10% 70% ± 2.2% 
a-b







4.5      Design of eastern  ML161 analogues 
 
 
Figure 4.7: Planned SAR studies on east side of 1,3-diaminobenzene core 
  
 SAR at east side was extensively explored previously. Therefore, to fill in the gap, 
we designed few mono- and di-substituted analogues (Figure 4.7). In addition, loss of 
potency was observed when phenyl ring was replaced with pyridine. We hypothesized 
that perhaps loss of activity was associated with the protonation of pyridine at the 
physiological pH. Therefore, keeping the west side fixed, we added –F atoms to the east 
ring to decrease pH of the molecule. Further, the order of amide at east side was 
necessary to retain the activity. However, other functional group tolerance was not tested 
yet. Therefore, keeping the sequence of “–N and –CO” of amide, we replaced amide 








Figure 4.8: Promising ML161 analogues. 
 
 We had two promising analogues (Figure 4.8) from the combined SAR study 
before and after published results. CJD125 offered improved plasma stability whereas 
AS2 was unique heterocycle with a fixed position of oxygen atom responsible for the 
activity. Many times, changing one part of molecule can affect the activity of entire 
pharmacophore. Keeping in mind, we decided to reinvestigate the east side with fixed 
west branched chain of CJD125 and tetrahydrofuran of AS2.  
 
4.5.1 Synthesis of east side analogues 
 





 Strategically similar to western analogues, commercially available nitro aniline 
4.1 was acylated with commercially available butyryl chloride to nitro-anilide 4.27 in 
90% yield. Nitro-anilide 4.27 was reduced under complete hydrogen gas environment 
using 10 mol% Pd/C catalyst to aniline 4.28.  Aniline 4.28 was stored as HCl salt to avoid 
carbamate formation. Aniline 4.28 was then peptide coupled with carboxylic acid, or 
acylated with acid chloride or acid chlorofomate to synthesize the eastern analogues 
(Scheme 4.8).  
 
















Log IC50 ± SEM 
Replacing amide to urea and sulfonamide 
BWP27 
 
Inactive 38% ± 4.4% 
BWP13 
 
Inactive 8% ± 5.5% 
BWP14 
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 40% ± 8.9% 
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 15% ± 4.7% 
BWP25 
 
7% 42% ± 6.5% 
BWP24 
 
Inactive 38% ± 5.6% 
BWP20 
 



















Log IC50 ± SEM 
BWP23 
 
Inactive 13% ± 6.4% 
BWP18 
 
16% 22% ± 4.8% 
BWP21 
 
12% 17% ± 4.9% 










 9.0% ± 8.6% 
AFS5 
 
N.D. 70% ± 2.5% 
DG64 
 
22% 46% ± 2.9% 
DG67 
 
Inactive 12% ± 5.8% 
ACK42 
 


































 21% ± 21% 
AFS15 
 
N.D. -11% ± 5.7% 
AFS16 
 
N.D. 37% ± 3.3% 
RR31 
 








47% ± 3.3% 
Fixed branched chain analogues 
BWP48 
 



















Log IC50 ± SEM 
BWP49 
 
N.D. 21% ± 7.9% 
BWP54 
 
N.D. 56% ± 3.7% 
BWP55 
 
N.D. 61% ± 2.0% 
BWP57 
 
N.D. 37% ± 5.7% 
a,b.e
See table 4.1 foot notes.  
 
















Log IC50 ± SEM 
KEK1 
 
N.D. 45% ± 6.2% 
KEK2 
 



















Log IC50 ± SEM 
KEK3 
 
N.D. 58% ± 3.4% 
KEK4 
 
N.D. 47% ± 6.5% 
KEK6 
 
N.D. 54% ± 3.3% 
KEK7 
 
N.D. 61% ± 3.6% 
KEK9 
 
N.D. 60% ± 5.1% 
KEK10 
 
N.D. 41% ± 7.5% 
KEK11 
 
N.D. 56% ± 3.9% 
KEK8 
 
N.D. 62% ± 4.2% 
a-b

























Log IC50 ± SEM 
BWP45 
 
N.D. 54% ± 3.0% 
BWP48 
 
N.D. 77% ± 4.4% 
BWP49 
 
N.D. 21% ± 7.9% 
BWP54 
 
N.D. 56% ± 3.7% 
BWP55 
 
N.D. 61% ± 2.0% 
BWP57 
 
N.D. 37% ± 5.7% 
a-b









4.6      Design of photoaffinity probes 
 
Figure 4.9: Design of photoaffinity probes for PAR1 
 
 In previous chapter 3, we discussed about the experiments in Flaumenhaft’s lab 
with chimeric PARs.
57




 intracellular loop of PAR1 with PAR4 
and mutant helix 8 of PAR1 lead to a considerable decrease in inhibition of SFLLRN-
NH2 induced Ca
2+
 flux by ML161. These results suggested that ML161 acts 
intracellularly at the cytosolic face of PAR1. Kobilka and co-workers reported x-ray 




 intracellular loop was highly 
modified and C-terminus was disordered to facilitate crystallization, and that made 
difficulty in determining putative binding site. To identify the precise binding site of 
parmodulins and mode of action of PAR1, we designed azide and alkyne based 
parmodulins (Figure 4.9).  We planned to adopt Nakanishi, Ernst and co-workers 
protocol of photo affinity studies of rhodopsin, where azide moieties  possess photo labile 









 For photo affinity studies, we planned to incubate aryl azide with the isolated 
human platelets membranes containing PAR1, followed by irradiation at >300 nm using 
UV lamp. Next, the membranes will be solubilized and the proteins will be separated 
from the membrane phospholipids.
91
 The collected proteins will be treated with trypsin, 
and filtered off to collect the complex peptide mixture. The peptide mixture will be next 
treated with azido – biotin conjugate and copper catalyst according to Ernst’s protocol.
90, 
92
 The result mixture will be flushed with buffer over avidin-agarose column to remove 
unlabeled peptides. Labeled peptides will be separated by HPLC, quantitated and 
sequenced by mass spectrometry to identify putative binding site.   
  
4.6.1 Synthesis photoaffinity ligands of 1,3-diminobenezene scaffold 
 
Scheme 4.9: Synthesis of photoaffinity ligands. 
 
 The amine of anthranilic acid 4.29 was transformed to azido acid 4.30 using 
Sandmeyer reaction conditions. Azido acid 4.30 was acylated with aniline 4.28 to give 




















 ± SEM; 
Log IC50 ± SEM 
DG5 
 










See table 4.1 foot notes.  
 
 We expect that the designed analogues will bind to intracellularly at cytosolic face 
of PAR1. Unfortunately, the azide and alkyne analogues we screened were not active 
enough to perform this photo affinity experiment. The most likely complication in our 
study could be rearrangement of photoaffinity probes upon photoactivation before 
binding to PAR1. More potent and selective for PAR1 analogue may facilitate these 










4.7      Summary of P-selectin assay results 
 
Figure 4.10: Extended SAR of parmodulins in P-selectin assay.  
  
 From the assay data, we concluded that the east side of 1,3-diamino benzene 
scaffold must be present to retain the activity (Figure 4.10). Severe modifications at the 
east side have adverse effect on activity. We have not fully explored central region, 
however, moderate activity of indazole and indole ring suggests a promising site with 
functional group tolerance. Replacing the central aromatic region with urea could be 
indicative of sensitivity of this scaffold over the marginal distance between two aniline 
nitrogen atoms.  
 We put extensive efforts in developing the west side analogues.  From the 
previous data the length of alkyl chain was necessary to retain the activity. We put 
additional branch and heteroatoms to alkyl side to improve solubility and plasma 
stability. But the assay data suggests that protonation at physiological pH (specifically 
amines) could hamper the activity. Among this set of the molecules, we found 2-





inhibition. Changing the position of “O” or replacing “O’ with “N” didn’t retain any 
activity. This could be indicative of specific H-bonding with the receptor and 
physiological property may be influencing the activity to a great extent. Unfortunately, 
these analogues were less potent than ML161 but still show reasonable activity.  
 
4.8     Summary of iCa
2+
 flux assay 
 
Figure 4.11: SAR of parmodulins in iCa2+ assay.  
 
 We didn’t screen the complete set of previously published parmodulins, however, 
SAR profile of current set of parmodulins was similar to P-selectin assay with few 
exceptions (Figure 4.11). Such as, at the west side, 4-carbon chain was necessary. 3- and 
5- carbon chain analogues were poorly active. Another striking difference between both 
assay data was activity of 2- and 3- tetrahydrofuran analogues (AS2 and AS4) in both 
assays. In P-selecting assay, AS2 and AS4 showed 100% and 11% inhibition, 





retain the activity. However, in iCa
2+
 flux assay, both AS2 and AS4 showed similar 
activity with moderate 42% and 44% inhibition, respectively.  
 
 
Figure 4.12: “Hit molecules” from PAR1 mediated iCa2+ screening at 10 µM concentration of parmodulins 
in the presence of 5 µM TFLLRN-NH2 agonist  
 
 An interesting note to the observation was, unlike P-selectin assay, addition of 
heteroatoms was well tolerated at the west side. From this screening, we found 4 “hit 
molecules” along with ML161 and RR90, which will be further characterized using iCa
2+
 












4.9     Pharmacological profiling of parmodulins 
4.9.1 Selectivity of parmodulins 
A. PAR1 activity 
 
B. PAR2 activity 
 
Figure 4.13. Selectivity data of antagonists in A) PAR1 (TFLLRN-NH2) and B) PAR2 (SLIGKV-NH2)-
driven iCa2+  mobilization. ML161, RR90, Q94, TJF5 (Fairlie’s PAR2 antagonist) were used at 10 µM; 
Vorapaxar, Atopaxar, and RWJ-58259 were at 0.316 µM. TFLLRN-NH2 and SLIGKV-NH2 were used at 
3.16 µM; Vehicle (V) = 10% DMSO–HBSS/HEPES wash buffer.79 
 
 We demonstrated here that parmodulins are selective PAR1 receptor over PAR2 
receptor (Figure 4.13). To our knowledge, PAR1 orthosteric antagonists have not been 
tested against PAR2 because of the absence of PAR2 receptors in human platelets. We 
chose Ml161 and RR90 as parmodulins representatives because of their potency both in 
iCa
2+ 
mobilization and P-Selectin assay. TJF5 was chosen as PAR2 representative and 
Vorapaxar and RWJ-58259 were orthosteric antagonists. We additionally incorporated Q-
94 (a commercially available PAR1allosteric modulator). However, in our study it was 
found to be inactive. For rest of the compounds, we observed that parmodulins and 





selective for PAR2. We tested these compounds against PAR4 receptor; however, PAR4 
receptor agonist AYPGFK-NH2 didn’t show any activity even at 100 µM concentration. 
 













Figure 4.14. Concentration-response of the PAR1 agonist TFLLRN-NH2 in the presence of increasing 
concentrations of (A) vorapaxar, (B) RWJ 58259, (C) ML161, (D) RR90.79 
 
 We discussed earlier about possible binding site of parmodulins at intracellular 
loop may be the reason for their biased signaling. ML161 showed non-competitive 
binding in SFLLRN-NH2 mediated P-Selectin assay. In addition, it doesn’t affect binding 
of high affinity [
3
H]TRAP to platelet membranes.
57
 In contrast, Vorapaxar showed non-
competitive antagonism with very slow off rate to PAR1.
54





action of parmodulins, we measured concentration-response curve of TFLLRN-NH2 in 
varied concentration of parmodulins and orthosteric antagonists. We observed dose-
dependent decrease in TFLLRN-NH2 efficacy with Vorapaxar (Figure 4.14A), ML161 
(Figure 4.14C) and RR90 (Figure 4.14D). This observation could be suggestive of either 
irreversible interaction or negative allosteric modulation. In case of RWJ-58259 (Figure 
4.14B), we noted right forward shift indicating competitive antagonism, however, agonist 
concentration was not high enough to reach at maximum response.  
 
 
Figure 4.15: Reversibility studies of the PAR1 antagonists vorapaxar, RWJ-58259, ML161, CJD125, and 
RR-90. Cells containing antagonists were optionally washed with buffer prior to treatment with the PAR1 
agonist TFLLRN-NH2 (5 μM). Vorapaxar and RWJ-58259 were used at 0.316 µM. ML161, CJD125, RR90 
were used at 10 µM.79 
 
 To determine whether parmodulins are irreversible inhibitors or negative 
allosteric modulators, we performed “wash” studies. We treated antagonists with 
endothelial cells and measured the response before and after buffer wash (Figure 4.15). 
As indicated in literature, Vorapaxar binds to extracellular loop 2 of PAR1 and is 
virtually irreversible antagonist.
54





wash, Vorapaxar completely shuts down TFLLRN-NH2 mediated PAR1 signal. 
However, RWJ-58259, ML161, CJD125, and RR90 lost their activity for PAR1 
significantly. Hence, we concluded that at least ML161, CJD125 and RR90 are negative 
allosteric modulators of PAR1.  
 
4.10     Conclusion 
 A set of parmodulins, specifically concentrating at west side of ML161, was 
synthesized using optimized synthetic protocol. SAR was investigated using P-selectin 
assay to develop anti-thrombotic but the modifications at west side and central region did 
not improve potency of ML161. Next, we developed Gɑq mediated iCa
2+
 flux assay in 
EA.hy926 endothelial cell lines to characterize parmodulins in endothelial cells as PAR1 
selective ligands. This assay is suitable for medium throughput screening and obtaining 
concentration-responses for PAR1 and PAR2 ligands. We observed that ML161 and 
RR90 were highly selective for PAR1, decreasing the maximal signal of TFLLRN-NH2 
(PAR1 agonist) in concentration dependent manner in iCa
2+
 flux assay and binding to 
PAR1 with reversible interaction. This behavior characterized ML161 and RR90 as 
negative allosteric modulators of PAR1. Whereas FDA approved PAR1 inhibitor 
vorapaxar binds with PAR1 in irreversible manner and is non-competitive orthosteric 
antagonist. During the course of study, parmodulins were evaluated to exert APC like 
cytoprotective effects. Therefore, these results suggested that parmodulins could be 
potential towards the development of anti-inflammatory agents for the treatment of sepsis 
like disorders. With that aim, we screened ~100 molecules in iCa
2+
 flux assay and we 





future work is to characterize new hit molecules as negative allosteric modulators for 
PAR1 and to perform another screening in cytoprotection assay which is under 


























Introduction of GPCR oligomers and project aim 
 
 
5.1      GPCR oligomerization 
5.1.1. GPCR oligomers 
 
Figure 5.1: GPCRs as A: as monomers; B: as homomers; C: as heteromers. 
 
Traditionally, GPCRs were considered only as monomers, where ligand binds, 
resulting in conformational change to activate only G-protein, trigger secondary 







 In last two decades, several mechanisms to regulate GPCRs mediated 
signaling were published which highlighted the cross-talk with neighboring cell 
membrane receptors, suggesting multimeric GPCRs conformations.
96, 97
 GPCRs can exist 
as dimers (homomers or heteromers) or highly ordered oligomers (figure 5.1). In 
addition, the advancements in biochemical and biophysical tools provided indirect 
evidences of GPCR oligomerization. Initially, GPCRs were reported to be as homomers, 
but more intense investigations showed that some receptor subtypes can exist as 
heteromers as well, which may have different signal transduction pathways compared to 
homomers, and could have significant potential as novel drug targets.
98, 99
 
A very first example to demonstrate GPCR heteromerisation came from GABAB 
receptors. GABA (γ-amino butyric acid) is an inhibitory neurotransmitter and its 
inhibitory effects are mediated via GABAA-C receptors. GABAA and GABAC are ligand 







 in most 
heterologous cells with GABAB receptor ligands. However, co-expression of GABABR1 
and GABABR2 showed neuronal properties of GABAB receptors.
106
 This evidence was 
suggestive of the heteromerisation of GABAB. To support the theory, extensive research 
was done on both GABABR1 and GABABR2, and it was demonstrated that GABA binds 




Another example is sweet taste, which is believed to be due to the presence of 
GPCR T1R1 and T1R2 in taste buds.
109
 T1R3, another GPCR, extensively homologous 
with T1R1 and T1R2, was derived from Sac mice
110-114





toward sweet stimuli. When T1R1, T1R2 and T1R3 were expressed in heterologous cells, 
neither of them was responsive to sweet stimuli. However, T1R3 was activated by 
saccharin, when co-expressed with T1R2.
109, 110
 In same manner, co-expression of T1R3 
with T1R1 was responsive towards monosodium glutamate and amino acids,
115
 which 
gives a very distinctive “umami” taste.
109, 110, 116
 These findings were highly suggestive of 
the necessity of heteromerisation of T1R3 with T1R1 and T1R2 to develop sensitivity to 
giving the specific tastes. Although the concept of receptor-receptor interactions of 
GPCRs has been accepted, it’s unclear how these interactions result in dimer or oligomer 
formation, and what proportion of receptors exist as monomer, dimer (homomers or 
heteromers) or oligomer.  
 
5.1.2 Pharmacology of GPCR heteromers and their potential as novel drug targets  
 GPCRs can interact and associate with same family to form homomers or can 
interact with same family subtypes, or other GPCRs to form heteromers. Such 
interactions can result in completely different conformation of one or both receptor, 
leading to unique signaling pathway. For example, dopamine receptor heteromers D1R – 
D2R altered the Gɑi mediated signaling of D1R and Gɑs mediated signaling of D2R to 
Gɑq11 mediated pathway.
117
 Whereas the heteromerisation of δOR and µOR 
predominantly switches from G-protein mediated pathway to β-arrestin mediated 
pathway.
118
 The resulted change in conformation can alter the binding pocket for the 
receptor, and thus, affinity for ligands. For example, heteromers of δOR - µOR have 
decreased affinity for highly selective synthetic ligands of  δOR and µOR.
119
 In addition, 





For example, 5HT2A – mGluR2 receptor heteromers are specifically implicated in 
psychosis.
120
 Another example is that of the heteromers of prostaglandin EP1 and 
adrenaline receptor β2AR. The combination of EP1 – β2AR in airway smooth muscles 
results in reduced Gas coupling of β2AR followed by reduced bronchodilation by β2AR 
agonist isoproterenol and ultimately leading to asthma.
121
 
 These studies suggested that if heteromers are disease specific they could serve as 
novel therapeutic targets.. In such cases, ligands acting at heteromer complexes can 
modulate a specific physiological or pathophysiological process and this information 
could be utilized to develop drug candidates. For example, the adenosine A2A receptor, in 
brain, has an important role in the regulation of glutamate and dopamine release, and 
hence serves as a potential therapeutic target for the treatment of pain, insomnia, drug 
addiction, and Parkinson’s disease. SCH-442416, an A2A receptor antagonist, showed 
significantly less affinity when the A2A receptor was co-expressed with the dopamine D2 
receptor.
122
 From a pharmacological point of view, A2A-D2 receptors are located at 
postsynaptic neurons.
122, 123
 Blocking of the A2A receptor at postsynaptic neurons 
produces locomotor activation because of the interaction of A2A-D2 receptors. A2A 
antagonists increased the affinity of D2 receptor for dopamine and thus, A2A blockade at 
postsynaptic neurons can be effective for the treatment of Parkinson’s disease. 




Because of the improved understanding of GPCR heteromerisation and ongoing 
efforts to understand the pharmacology of heteromers, it has been possible to selectively 





nutshell, GPCR heteromers tend to have i) unique localization; ii) distinct allosteric 
properties which can offer ligand selectivity and functional selectivity (to study 
functional diversity) can be used as physiological tools and additionally but can be used 
as lead for development of highly selective drugs.    
 
5.1.3 Methods to determine the existence of GPCR oligomers 
Currently, a number of experimental techniques are available to detect the 
existence of GPCR oligomers including biochemical, biophysical, and molecular imaging 
techniques. Biochemical methods like co-immunoprecipitation (IP) and Western blotting 
(WB) are considered as a good starting point to show oligomers even though this 
technique requires cell lysis and specific antibodies for the receptors of interest. 
Biophysical methods like resonance energy transfer (FRET, BRET, etc.) provide 
evidence about the receptors proximity to each other.  Currently, no definitive method 
exists to determine GPCR oligomers because each method has its own advantages and 
disadvantages that are highly dependent on the receptor of interest. 
 
5.1.3.1 Biochemical methods 
Co-immunoprecipitation and Western blot were the first biochemical tools to 
detect monomers and oligomers. This technique provided the first direct evidence of 
homodimers of b2AR
125
  and dOR
126
. This method requires high affinity antibodies for 
the receptors of interest or incorporation of epitope tags like Flag, V5, His, Myc, etc. at 





receptors are solubilized and the lysate is incubated with the antibody of one of the 
receptors. The resultant receptor – antibody complex is treated with binding medium like 
sepharose beads and unbound proteins are washed away from the lysate. In the second 
stage of the process, the complex is subjected to SDS-PAGE and immunoblotted against 
the antibody or epitope tag of secondary receptor.
127, 128
 This method has been widely 
used to provide evidences of higher order of oligomersation such as interactions of 
A2AR, D2R, and mGlu5R and heteromer mediated effects on the progression of 
schizophrenia and drug addiction.
129
 However, there are two major limitations to this 
technique. First is cell lysis and solubilization step that may lead to oligomer formation or 
dissociation. And second is lack of availability of specific and high affinity antibody for 
the receptors of interest and specifically, when the receptors are heterogeneously 
expressed.  
 
5.1.3.2 Biophysical methods 
Biochemical methods are usually targeted for non-living cells. To determine the 
presence of oligomers in living cells, biophysical tools like resonance energy transfer are 
widely used. In this process, higher energy donor fluorophore transfers energy to the 
lower energy acceptor molecule, resulting in quenching of donor molecule and sensitized 
fluorescence of acceptor molecule. There are two types of resonance energy transfer 
techniques in use: Fluorescence resonance energy transfer (FRET) and Bioluminescence 
resonance energy transfer (BRET). The advantage of this method is to occur energy 








A) FRET (Fluorescence resonance energy transfer):  
 
Figure 5.2: Schematic representation of FRET method: Receptor R1 is tagged with donor CFP and R2 is 
tagged with acceptor YFP at C-terminus. CFP is excited at 433 nm that emits light at 475 nm. If R1 and R2 
are in close proximity <100 Å, then FRET occurs and YFP emits at 527 nm.  
 
 In this method, a high energy donor fluorescent protein is excited by 
monochromatic light, followed by resonance energy transfer to a lower energy acceptor 
protein if both proteins are in close proximity to each other and emission spectra of donor 
overlaps with excitation spectra of acceptor protein.  FRET is usually measured between 
two fluorophores in a cell suspension. In this method, two receptors of interests are 
usually tagged at C- terminus with the variants of green fluorescent protein (GFP), among 
which a donor protein is tagged as cyano fluorescent protein (CFP) and an acceptor 
protein is tagged as yellow fluorescent protein (YFP).  When the pair of CFP – YFP is in 
close proximity to each other (<100 Å), the energy transfer occurs after CFP excitation at 
433 nm and acceptor emission at 527 nm (Figure 5.2), and FRET can be quantitated by 











additional corrector factors are needed in this process due to the leaking of donor 
emission into the acceptor emission by the light used to excite the donor. For example, 
Cotecchia, et al., investigated higher order of oligomerization between A1a- and A1b-AR 
via FRET measurements.
131
 First, they excited CFP at 430 nm and measured the emission 
at 450 nm, followed by calculating the ratio of excitation at 450 nm in mock transferred 
and expressed cells, and used it as correction factor. Due to the difference in receptor 
expression in cells, they had to perform additional experiments to measure the fluorescent 
spectra of individually receptor expressed cells, adjusted by the correction factor to 
normalize cell density, and then FRET efficiency was measured.
131
 In addition, 
photobleaching of YFP to blue – cyan fluorescence can also affect FRET accuracy.
132, 133
 
Time resolved FRET (TR-FRET) and photobleaching FRET (Pb-FRET) are other 
reported indirect approaches to measure FRET. In TR-FRET, lanthanides like europium 
or terbium are incorporated to prolong the time frame between excitation and detection of 
FRET signal that allows decay of autofluoresence and provides improved signal to noise 
ratio. On the other hand, Pb-FRET measures the decay of fluorescent signal upon 
continued exposure to excitation by light. The donor fluorophore is photobleached by 
intense light and fluorescence is measure in the presence and absence of acceptor. If the 
acceptor is in proximity of the donor, FRET occurs resulting in decreased intensity of 
photobleaching.
128









B) BRET (Bioluminescence resonance energy transfer):  
 
Figure 5.3: Schematic representation of BRET method: Receptor R1 is tagged with Renilla luciferase 
(Rluc) and R2 is tagged with acceptor GFP at C-terminus. Rluc catalyses oxidation of DeepBlueC and in 
return emits light ta 410 nm. If R1 and R2 are in close proximity <100 Å, then BRET occurs and GFP emits 
at 515 nm.  
 
 In this method, energy transfer occurs from a luminescent donor to a fluorescent 
acceptor. Renilla luciferase (Rluc) from the marine sea pansy Renilla reniformis is 
commonly used as a luminescence donor and YFP or GFP are used as an acceptor 
protein. The Coelenterazine substrate DeepBlue C is oxidised to excite luciferase that 
emits light at 410 nm. Similar to FRET, when luciferase tagged donor protein is in close 
proximity to the acceptor protein YFP, the light from the donor excites the acceptor, 
followed by light emission from the acceptor at a unique wavelength (Figure 5.3). Then, 
calculating the ratio of acceptor to donor light emission, the interaction of the receptors 
interactions can be quantified.
127, 128
 This technique has played a major role in the 
characterization of GPCR heteromers. For example, Franco, et al., studied a direct 





AT1R could alter the cell signaling pathway of D2R, which could potentially be beneficial 
in the treatment of Parkinson’ disease. Second, they tagged AT1R with Rluc and D2R 
with YFP and measured BRET with and without ligand binding in HEK-293T cells. 
From the BRET results, they concluded that D2R and AT1R form heteromers in HEK-
293T cells and the heteromer structure is unaffected upon ligand binding.
134
 This could 
be an important tool to investigate ligand – heteromer interactions as well and ultimately, 
identifying drugs that can modify this signaling. The disadvantages of BRET are its 
limitation to detect only cell-surface receptors, and overexpression drastically affects the 
accuracy of BRET.  
Even though these methods have certain limitations, both biochemical and 
biophysical methods could be used together to predict GPCR heteromer or homomer 
formation. Other techniques are also in practice like computational based methods (e.g., 
protein – protein docking, sequence based methods), or modifications of current 
biophysical methods. In addition, x-ray crystallography of proteins has gained popularity 
as direct evidence. Although relatively few GPCR structures have been obtained from x-
ray crystallography, the method has not been successfully implied to support evidences 
for oligomers. In summary, these methods are a good starting point to investigate the 
existence of GPCR oligomers or form oligomers after ligand binding and exert unique 
signaling pattern compared to monomers. Then, this information could be utilized to 








5.1.4 Novel approaches to targeting GPCR heteromers 
5.1.4.1 Monovalent ligands specific for heteromers   
 As discussed before, heterodimersation of GPCRs can modulate receptor function 
by changing a receptor's conformation, but it may cause significant change in the ligand 
binding site as well. The altered binding site can then accommodate distinct ligands. For 
example, Waldhoer et al. reported that 6’-GNTI (6-guanidinonaltriindole)
 
was originally 
designed as a ƙOR agonist.
135, 136
 However, later it was discovered to act selectively 
through ƙOR – δOR heteromers, but not either of the homomers. 6’-GNTI showed the 
most potency and efficacy in ƙOR – δOR co-expressed cells in an agonist mediated iCa
2+
 
assay, while ƙOR selective agonists showed equivalent potency in both single and co-
expressed cells. Both ƙOR and δOR selective antagonists inhibited signaling of 6’-GNTI.  
Another proof of concept was revealed by selective targeting of SKF-83959
117
 for 
dopamine receptors. In animal models, SKF-83959 was found to induce a number of 
behavioral effects similar to dopamine D1 receptor agonists; however, in spite of high D1 
receptor affinity, SKF-83959 failed to induce cAMP production. Further investigations 
showed the selectivity of SKF-83959 for the D1-D2 heteromeric complex. SKF-83959 
caused an increase in intracellular calcium levels through activation of Gq/11 mediated by 
the D1-D2 heteromeric complex. This effect was abolished when D1 and D2 receptors 
were expressed alone. Moreover, radioligand binding studies of the D2 receptor 
antagonist raclopride showed a high affinity binding site of SKF-83959 on the D2 
receptor that was absent in D1 knockout models. In addition, pertussis toxin (PTX) 





showed minimal difference in the high affinity binding site for SKF-83959; 
demonstrating the involvement of Gq/11 mediated effects of SKF-83959. These findings 
suggest that heteromers specific ligands can promote or block specific signaling 
pathways that can be tuned into a specific pharmacological effect. 
 
5.1.4.2 Bitopic/Dualsteric ligands  
 GPCRs have been known to adopt multiple active sites via orthosteric ligands or 
allosteric modulators, giving rise to a specific cell signaling. Extension of this approach 
by linking orthosteric ligands and allosteric modulators yield a new class of ligands, 
known as bitopic hybrid ligands.  For example, Steinfeld et al, developed THR-
160209
137, 138
 (figure 5.4A), as a bitopic ligand for M2 receptor (muscarinic receptor 
subtype, located in heart and responsible for slowing heart rates). In compound THR-
160209, 4-ABP (4-aminobenzylpiperdine) motif showed allosteric behavior and 3-BHP 
(3-benzylhydrylpyrrolinyl) motif showed orthosteric behavior with M2 receptor. By 
linking both motifs by heptane chain, THR-160209 exhibited higher affinity and 
selectivity for M2 receptor compared to its individual components. 
Linking orthosteric and allosteric moieties together not only affects affinity but 
sometimes it develops bias signaling as well via unique confirmations.  For example, 
Christopoulos et al,
139, 140
 developed a biotopic ligand VCP-746 (Figure 5.4B by 
connecting an orthosteric adenosine motif to thienyl motif of VCP-171 (a positive 






Figure 5.4: Examples of bitopic ligands: A: THR-160209, M2 receptor bitopic ligand; B: VCP746, A1 
receptor bitopic ligand 
 
 As a result, VCP-746 showed a distinct biased profile compared to individual 
counterparts. VCP-171 was responsible for bradycardia and cytoprotection; however, 
connecting allosteric VCP-171 motif with orthosteric counterpart in VCP-746, in vitro 
studies of showed to protect cardiomyoblasts and cardiomyocytes against simulated 
ischemia, but showed no effect on rat atrial heart rate in vivo.
141
 These results suggested 
cytoproetction of VCP-746 without any significant effects on heart rate. 
 
5.1.4.3 Bivalent Ligands 
Portoghese and co-workers addressed the question of inter-receptor distance via 
developing bivalent ligands. The concept originally thrived from P.S. Portoghese, 
bivalent ligands are molecules which connect two pharmacophores with an appropriately 
designed spacer. Bivalent ligands can have two identical pharmacophores for binding at 
homomers or two different pharmacophore for binding at heteromers. These ligands can 





allosteric site of heteromers (Figure 5.5). These ligands may exhibit higher affinity with 
the receptor complex compared to monovalent ligands, which is excellent evidence for 
the presence of receptor complexes. When one pharmacophore binds with one of a 
receptor dimer, it increases the local concentration of second unbound tethered 
pharmacophore in the vicinity of neighboring receptor, and therefore lowers the entropy 





Figure 5.5: Schematic representation of bivalent ligand – receptor complex: A) bivalent ligand targeted to 
homomers at orthosteric site; B) bivalent ligand targeted to heteromers at orthosteric site; C) bivalent ligand 
targeted to heteromers at orthosteric site of R1 and allosteric site of R2. 
 
The first reported example of a bivalent GPCR ligand comprised two units of β-
naltrexamine (a μ-OR antagonist) linked by a polyethylene glycol spacer. This compound 
showed showed greatly enhanced selectivity for μ-OR.
143
 Numerous other bivalent 
ligands have been developed and characterized for a variety of putative GPCR dimers 






In summary, dimeric GPCRs exist naturally or under pathological conditions. The 
growing acceptance on GPCR heteromerisation and continual efforts in invaestigation of 
GPCR heteromers offer them as a potential drug targets. Further the extensive research 
on bivalent ligands showed access to unique pharmacological profiles than monovalent 
ligands, and therefore, employing bivalent ligand could be a feasible route to avoid 
undesired signaling of monovalent counter parts, and ultimately provide safer drug. In a 
similar way, PARs have been reported to form dimers under pathological conditions. This 
thesis work has focused on unique signaling of protease-activated receptors for the 
treatment of restenosis and breast cancer metastasis, which could be achieved by 
selectively targeting PARs heteromers with bivalent ligand.  
 
5.2       PAR oligomers and their pharmacological significance 
It is now evident that GPCRs can naturally exist as oligomers or can form 
oligomers via crosstalk with nearby GPCR monomers or other cell surface proteins upon 
receptor activation. As a result, these GPCR oligomers can possess different 
conformations and trigger a range of different signals as heteromers or dimers. There are 
four subtypes of Protease-Activated Receptors (PARs 1–4) which are expressed in 
numerous tissues, including platelets, smooth muscle cells, endothelial cells, astrocytes, 
immune cells and microglia of the central nervous system.
144-146
 PARs have been 
reported to exist as dimers and heteromers and their modified signaling has been studied 
in the context of different diseases states.
147, 148
  
Small molecules or natural molecules like hormones, peptides or ions can activate 





mimicking these ligands to target GPCRs. However, PARs have unique mode of action 
involving the irreversible site-specific receptor cleavage at the extracellular N-terminus, 
as the exposed tethered ligand, in the presence of different proteases. The tethered ligand 
does not diffuse away but the new N-terminus binds to the receptor resulting in the 
conformational change and ultimately, the activation of the variety of downstream 
signaling pathways like G-protein signaling, β-arrestin signaling or transactivation of 
other receptors. Depending on the activated signaling pathways, PARs can play critical 
role in the progression of thrombosis, hemostasis, and inflammatory and proliferative 
response.
147-149
 Recent studies have suggested the engagement of PARs in the progression 
of cancer metastasis
150
 and modulation of the immune response during viral infections.
151
 
Due to site-specific and tissue-specific signaling pattern, existence as oligomers, 
evidences of interactions with the neighboring receptors, and involvement in different 
disease progression, PARs have become the attractive candidates to develop bivalent 
ligands as novel therapeutics. 
 
5.2.1 Evidence of PAR crosstalk 
In the early 1990s, Coughlin and co-workers demonstrated the first evidence of 
self-association of the PAR1 receptor to form homodimers.
144
 The evidence showed that 
the exposed tethered ligand of PAR1 can intermolecularly transactivate an adjacent 
PAR1, but with less efficiency than intramolecular activation. Later, Brass and co-
workers observed that the complete blockade of thrombin-mediated cellular responses in 
HUVECs could only be achieved by blocking both PAR1 and PAR2 receptors. They 





200261) at previously studied inhibitory concentrations. The antibodies, which mimicked 
PAR tethered peptides, completely blocked thrombin mediated cellular responses, but the 
PAR1-selective antagonist was partially effective. They showed evidence of 
transactivation of PAR2 by a tethered PAR1 peptide, and therefore, such transactivation 
to form PAR1-PAR2 heteromers can limit the effectiveness of PAR1 monovalent 
ligands.
27
 McLaughlin and co-workers showed evidence via BRET studies that PAR3 can 
preferentially modulate Gα13 signaling of PAR1. Mosnier et al., and Madhusudan et al., 
showed that APC can cleave both PAR1 and PAR3 to promote cytoprotective signaling 
and can block either of the receptor attenuated the rate of apoptosis. Interestingly, PAR3 
signaling on its own is unknown until now,which therefore suggests the existence of 
PAR1-PAR3 heteromers. Similar results were observed where APC-mediated PAR3 
activation triggered PAR2-PAR3 heteromerization and ablation of PAR3, and completely 
blocked the cytoprotective effects of APC. Cunningham and co-workers demonstrated 
PAR2-PAR4 association when they observed increased trafficking of PAR4 on HEK293 
cell surface after co-expression of PAR2.  
 
Table 5.1: Selected examples of PAR oligomers and their effects on signaling 
PAR oligomers Function affected 
PAR1-PAR1 Ca
2+
 signaling  









PAR1-PAR3 Gα13 biased signaling  
PAR2-PAR3 Cytoprotective signaling 
 
Numerous studies have been done that show evidence of PAR dimerization and 
heteromerisation, and which reveal unique signaling patterns associated with them like 
biased G-protein signaling, β-arrestin mediated signaling or more efficient G-protein 
signaling (Table 5.1). However, the driving force to stimulate such co-precipitation of 
two PARs together is poorly understood at this time. X-ray structures of PAR1 and PAR2 
have been recently published but they do not reveal any dimer formation. It may be 
possible that PARs dimers are transient in nature and could be stabilized with interacting 
proteins or perhaps, small molecule ligands. This thesis work focuses specifically on 
putative PAR1-PAR2 heteromers and how antagonism of both receptors could block 
pathological signaling.  
 
5.2.2 Background on PAR1 – PAR2 heteromers and project aim 
 The connection between thrombosis and tumor cell metastasis has been studied 
from several decades. It has been reported that thrombin has significant effects in 
modifying the behavior of cancer cells via activation of thrombin receptors.
152
 There is 
strong evidence that PARs are implicated in cancer metastasis and the process is driven 
by the presence of both PAR1 AND PAR2. In 2004, Mueller and co-workers reported a 
study of metastasis in human melanoma cells to activate the coagulation cascade to 





simultaneously activates PAR2 and induces motility of metastatic tumor cells.
153, 154
 They 
reported that stimulation of PAR1 or PAR2 alone did not lead to migration of metastatic 
cells but in presence of both PAR1 AND PAR2 agonists there was 12-fold increase in 
tumor cell migration.
27, 155, 156
 These results are consistent with the greatly increased 
migration of cancer cells promoted by the PAR activator thrombin. In addition, there is 
complementary evidence from co-immunoprecipitation and fluorescent labeling 
(FRET/BRET) studies showing that PAR1 and PAR2 are present TOGETHER as 
complexes on different cell types, including breast cancer cells, and that RNA silencing 
of PAR2 significantly inhibits PAR1-driven invasion of MDA-MB-231 breast cancer 
cells.
157
 In 2011, Kuliopulos and co-workers reported the involvement of multimeric 
PAR complexes in restenosis (the narrowing of arteries after stent implantation and 
angioplasty). 158  
 
5.2.2.1 Role of PAR1 – PAR2 heteromers in cancer cell metastasis.  
PAR1 expression in human breast cancer cells correlates with tumor 
progression
152
 whereas it correlates with bone metastasis in prostate cancer.
153
 Mueller 
and co-workers showed correlation between thrombin generation and its effect on 
metastasis of melanoma cells.
159, 160
 They demonstrated that thrombin-mediated 
melanoma cell metastasis requires not only PAR1 activation but simultaneous PAR2 
activation is also necessary to induce the highest levels of metastasis. They observed 
stimulation of cell migration by thrombin and then observed abolition of cell migration in 







Figure 5.6: Cell migration enhanced in presence of both PAR1 and PAR2 agonists A) M24met melanoma 
cells and B) prostate cancer cells4 
  
They observed no cell migration in presence of thrombin and a PAR1 antibody, 
indicating that thrombin acts via PAR1. However, cell migration was not observed in the 
presence of PAR1 selective agonist TFLLRNPNDK, indicating that thrombin may act on 
other targets as well. To support the hypothesis, they expressed M24met cells with 
agonists where they observed thrombin-like cell migration only in the case of co-
administration of the PAR1 and PAR2 agonists (Figure 5.6).
154 
Additionally, 
desensitizing either the PAR1 or PAR2 receptor ablated cell migration.   
 
5.2.2.2 Role of PAR1 – PAR2 heteromers in restenosis 
Neointimal hyperplasia is the major cause of restenosis, the constriction of a 
blood vessel after stent implantation and/or angioplasty. A stent is a tube like structure 
kept after angioplasty to prevent narrowing of blood vessels or to support weak arteries to 
promote blood flow.
161
 However, many times blood vessels recognize stents as foreign 





vessels. Therefore, neointimal hyperplasia limits the effectiveness of vascular 
interventions and leads to poorer clinical outcomes, and therefore new solutions are 





Figure 5.7: Intimal hyperplasia effect of P1pal-13 in WT, PAR1 and PAR2 deficient mice. Intimal area 
was calculated from cross section of arteries; Veh = vehicle; WT = wild type mice; P1pal-13 = PAR1/2 
activating pepducin, PAR-/- = PAR1 deficient mice; PAR2-/- = PAR2 deficient mice. P1pal-13 significantly 




Kuliopulos and co-workers examined the role of PAR1 and PAR2 together in the 
rapidly changing microenvironment of damaged blood vessels. They accessed PAR1 and 
PAR2 functions in vivo after artery injury. After inducing arterial injuries, they harvested 
carotid arteries from WT mice and observed acute edema and cytoplasmic swelling, later 





in the presence of P1pal-13, and PAR1 and PAR2 deficient mice (Figure 5.7).  P1pal-13 
is a pepducin agonist based on intracellular loop 3 of PAR1, which activates PAR1 and 
putative PAR1 –PAR2 complexes but not PAR2.
58, 155, 163 
When they treated WT mice 
with P1pal-13 for 21 days, a 60% increase in medial area was observed compared to 
vehicle but the likewise effect was not observed in mice deficient in either PAR1 or 
PAR2.  
 According to FRET analysis, PAR 1 and PAR2 reside in close proximity to each 
other (≤100Å) on the cytoplasmic surface.
27, 155, 163 
They provided direct evidence through 
coimmunoprecipitation studies that PAR1 – PAR2 can form stable heteromers. They 
showed that PAR2 strongly associated with PAR1 when co-expressed, demonstrating the 
physical interaction, possibly in the form of heteromers.   
 
5.3     Design of Bivalent Ligands 
In last 40 years, many heterobivalent ligands showed improved potency and 
selectivity compared to their monomeric counter parts and hence, design of such ligands 
have gained popularity in medicinal chemists.  In general, a heterobivalent ligand is a 
designed single molecule that combines two different selective monovalent ligands of 
two different targets, suitably modified with an attached spacer (linker) (Figure 6.1).   
 
5.3.1 Selection of pharmacophores  
The ideal pharmacophore should be highly selective and potent for the targeted 





attachment point with a linker, feasibility of chemical modification and the tolerance of 
chemical modification to biological activity. The ligand should be low to medium in 
molecular weight (300<MW<400),
164




Figure 5.8: Heterobivalent ligands targeting CB1 and OX1 heteromers. 
 
 
 To determine the best attachment points to the pharmacophores, good 
understanding of structure-activity relationships is necessary. For example, Zhang et al. 
reported bivalent ligand probes of cannabinoids (CB1) and orexin (OX1) receptor 
heteromers for the potential treatment of neurological disorders (Figure 5.8). To target 
both receptors, they chose the marketed drug SR141716 (5.1) as the CB1 antagonist to be 





modified without detrimental effects on affinity. On the other hand, as OX1 antagonist, 
they chose ACT-078573 (5.2) with limited information on SAR. Therefore, they first 
focused on detailed SAR studies of the tetrahydroisoquinoline scaffold of 5.2. From the 
SAR data, they identified compound 5.3 with phenoxy group at C7 and C4’ as the most 
suitable attachment point. Afterwards, they replaced the piperdine of 5.1 with a 
hydrophobic linker with a tertiary amine that was later condensed with a phenol analog of 
the OX1 receptor antagonist 5.3 to synthesize bivalent ligand 5.4.  
 Most commonly, "adapter" sites are made with carboxylic acid, 1º amine, phenol 
or alcohol functional groups, and the attachment to the spacer can be achieved by 
forming esters, amides, or ethers. In this thesis work, we incorporated the 1,2,3-triazole 
functional group via click reaction (1,3- dipolar Huisgen cycloaddition) with easily 
achieved modifications by inserting alkynes and azides to the ligands.  
 
5.3.2 Spacer length and conformational flexibility 
After the selection of the suitable ligands with tolerated modification sites, both 
the length and the composition of a spacer are key features for connecting the ligands and 
their respective receptors of the complex. The length of spacer may have a profound 
effect in terms of selectivity and potency towards the targeted receptors. A short linker 
cannot fully occupy the distance between co-expressed receptors and in that case, 
bivalent ligands are likely to bind with monomers. On the other hand, a very long spacer 
could occupy the free space of the ligand and in turn, cannot interact with the neighboring 





like a monovalent ligand. The optimal distance depends on the interaction of the 
heteromers, however, 15 - 25 atom spacers have been reported.  
 
 
Figure 5.9: MMG22: A heterobivalent ligand targeting μOR and mGluR5 heteromers in the spinal cord 
 
For example, the antinociceptive activity of the MMG series (reported by 
Portoghese and co-workers) was highly dependent on spacer length (Figure 5.9). They 
developed the heterobivalent ligand MMG22 (5.7c) that targeted μOR–mGluR5 
heteromers in the spinal cord. The motive to target μOR–mGluR5 heteromers was to 
suppress morphine induced tolerance and dependence and to enhance morphine 
antinociception. To target the μOR, they chose oxymorphone (5.5). From the literature 
reported SAR data, modification at the ketone moiety was tolerated and morphine like 





amine. They targeted the mGluR5 receptor by extending the phenoxy ether linkage of the 
potent mGluR5 -antagonist M-MPEP (6). In both cases, modification retained the activity 
of targeted receptor and they connected the phenoxy oxygen of 5.6 with the spacer 
through the amino group of 5.5 to facilitate the synthesis of the heterobivalent ligands 
5.7a – 5.7d (Figure 6.3). They observed that the activity of the heterobivalent ligands was 
highly dependent on the length of the spacer. With the 17 atom spacer (5.7a), the bivalent 
ligand was not tolerated whereas the bivalent ligands with 18 (5.7b) and 22 (5.7d) atom 
spacers had no tolerance but were less potent. Ultimately, the 20 atom spaced bivalent 
ligand (5.7c) was the most potent (ED50 = 9 fmol per mouse) without any signs of 
tolerance after 24 h of i.t. administration.
 2013PortoPNAS
 In addition, 5.7c exhibited lack of 
tolerance and possessed >10
6
 therapeutic ratio (ratio of administered dose to effective 
dose) compared to 5.5. These findings established 5.7c as a tool candidate for the 
treatment of anti-inflammatory pain without tolerance development.  
The other key factor in bivalent ligand design is the chemical composition of the 
spacer. Both structural rigidity and conformational flexibility have been reported to 
contribute to the ligand binding and potency. Typically, a hydrophobic spacer like a long 
alkyl chain is the choice because of its flexibility, readily availability, easy to bind with 
ligand without many chemical transformative steps and advantage of “one-atom” 
increments to determine the optimum distance between heteromers. But its application is 
usually limited to spacers with 10 – 12 atoms due to solubility issues. This issue can be 
addressed by linking an additional hydrophilic portion like a 2º or 3º amine or amide to 
aliphatic chains. Hydrophobic linkers may be important when the ligand interaction site 





extracellular binding site and in such cases, bivalent ligands could benefit from 
hydrophilic spacers like polyethylene glycols (PEGs) or polyamides. Although long chain 
PEGs are expensive and cannot provide the benefit of “one-atom” increments, PEGs can 
offer a great deal of solubility in aqueous media and are the best to maintain 
conformational flexibility in aqueous environment. Alternatively, higher rigidity can 
selectively increase interactions between the bivalent ligands and the receptors. In such 
cases, diynes, piperazine rings or aromatic rings are incorporated to gain rigidity via 
reducing number of rotatable bonds. 
Indeed, chemical composition and length of the spacer play a key role in binding 
of bivalent ligands and ultimately, potency. Design of such spacers can be tailored based 
on the nature of the ligand, binding interactions, and distance between both receptors.  
 














Project snapshot (Figure 5.10): 
 
Figure 5.10: Project snapshot: Tissue selective antagonism of PAR1 – PAR2 heteromers could be 
beneficial in the treatment of restenosis and breast cancer.  
 
 Based on reported literature data about the involvement of PAR – PAR2 
complexes in the progression of restenosis and cancer metastasis, we hypothesized that 
selective targeting of PAR1 – PAR2 complexes with heterobivalent ligands will permit 
tissue selectivity and context selectivity to bind at putative PAR1 – PAR2  heteromers to 
inhibit cancer cell metastasis and restenosis (Figure 5.10) while minimizing inhibition of 
normal PAR1 and PAR2 signaling. We planned to target PAR – PAR2 heteromers by 
making PAR1 – PAR2 bivalent antagonists. Targeting vascular GPCR heteromers, rather 
than those in the CNS, has rarely been performed. Thus, the development of PAR 
bivalent ligands could be an attractive strategy to selectively engage PAR1/2 complexes 









Design and development of bivalent ligands to investigate PAR1-PAR2 heteromers 
for the treatment of cancer metastasis 
 
 
6.1       Design and synthesis of PAR1 – PAR2 bivalent ligands 
  
 Based on published SAR data and the potential for diverse modifications, we 
elected to utilize the PAR1 antagonist RWJ-58259
32
 and trisubstituted piperdine analogue 
by Bayer pharmaceuticals as PAR1 scaffolds to be modified by attachment to an alkyne 
"adapter" for connection to a spacer for the bivalent ligands. We selected the 
imidazopyridazine scaffold reported by Vertex
37
 for use in the construction of PAR2 
antagonists which could have a free terminal carboxylic acid functionality for connection 
to the spacer. To connect the monovalent ligands, we selected commercially available 
PEG-based spacers with a variety of lengths. PEG-based spacers can improve aqueous 
solubility and can be flexible in extracellular environment compared to hydrophobic 
spacers.
 
They may provide extra "slack" and may pay less of an entropic penalty upon 
binding. Commercially available PEG linkers with dual functionalities, azide and free 
primary amine, were chosen to perform convenient copper-catalyzed alkyne/azide 
cycloadditions (CuAAC)
39






6.1.1 Design and synthesis of PAR1 antagonists 
 
Figure 6.1: Selected PAR1 orthosteric antagonists to construct PAR1 – PAR2 heterobivalent ligands 
  
 Several orthosteric PAR1 ligands have been reported in literature. Based on PAR1 
potency, synthetic feasibility, and SAR data, we elected to investigate the benzamidine 
6.1,
37, 40
 the peptidomimetic 6.2 (RWJ-58259),
38
 and the reported piperidine scaffold 
6.3
165, 166
 as starting points for our efforts to prepare bivalent ligands (Figure 6.1). The 
synthesis of scaffold 6.1 was undertaken by Dr. Chris Dockendorff and by me. The 
synthesis of 6.2 was performed by me with assistance from undergraduate Kaitlin 
Kentala and Dr. Mark Majewski. The synthesis of 6.3 was initiated by me and has since 
been studied extensively by Ricardo Rosas Jr., and therefore has not been included in this 
thesis.  
 
6.1.1.1 Design and synthesis of Schering-Plough benzimidine scaffold 
Benzimidine 6.1 was reported by researchers at Schering-Plough as a potent 
inhibitor of platelet aggregation induced by the PAR1 agonist haTRAP (IC50 of 33 nM). 
6.1
IC50 = 33 nM
PAR1 [3H]haTRAP binding assay
Reported by 
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Several molecules with modifications at the east side of the scaffold showed moderate 
potency. We hypothesized that could be an ideal attachment point for a linker and thus, 
we designed alkyne analogue 6.11 (Figure 6.2) via a convergent 5-step synthesis. 
 
 
Figure 6.2: Proposed alkyne analogue of 6.11 
 
 
Scheme 6.1: Synthesis of west side intermediate of 6.11 
  
 Friedel-Crafts acylation of commercially available phenol 6.4 was initially 





the 4-position of the phenol (6.5b), an unexpected rearrangement product 6.5a was 
observed with 100% conversion. Later, acylation of 6.4 to desired product 6.5b was 
achieved with acetic acid in the presence of trifluoroacetic anhydride as solvent. 
Bromination of acetophenone 6.5b was first performed in the presence of stoichiometric 
Br2 and a catalytic amount of p-toluene sulfonic acid (PTSA) in the aprotic solvent 
dichloromethane, causing a sluggish and low yielding reaction. However, performing the 
reaction in the protic solvent ethanol gave faster conversion to 6.5b, in 91% yield.  
 
 
Scheme 6.2: Synthesis of east side intermediate of 6.11 with alkyne tether 
 
 Commercially available 1,4-diol 6.7 was mono-alkylated to 6.8 using propargyl 
bromide in 33% yield (Scheme 6.2). Benzyl alcohol 6.8 was tosylated with poor yields. 
Therefore, Appel reaction conditions were utilized to convert benzyl alcohol 6.8 to the 
highly reactive benzyl bromide electrophile 6.9 in 79% yield.   
 Synthesis of 6.11 was first attempted by alkylation of commercially available 2-
amino benzimidazole with excess bromoketone 6.6 to give 6.10a in 43% yield, followed 
by alkylation with benzyl bromide 6.9. However, the following alkylation step (6.10a to 






Scheme 6.3: Attempted synthesis of 6.11 
 
 After the failure of route A, the synthesis of 6.11 was attempted in the reverse 
order. Benzyl bromide 6.9 was monoalkylated with excess 2-aminobenzimidazole to give 
intermediate 6.10b in 28% yield. An unsuccessful attempt was made to alkylate 6.10b 
with bromoketone 6.6 (Scheme 6.3, route B). Reactions for both routes A and B were 
screened with different bases (K2CO3 and DBU), additives (KI and TBAI), and solvents 
(acetone, dioxane, ethanol, acetonitrile, and toluene) to yield complex and unidentifiable 
mixtures, which we speculate may be due to the instability of the desired product under 
basic conditions in the presence of oxygen. Therefore, the work on the development of 












6.1.1.2 Design and synthesis of peptidomimetic scaffold RWJ-58259 
 
Figure 6.3: Proposed alkyne analogue of 6.2 (RWJ-58259) 
 
 RWJ-58259 (6.2) is a potent and selective antagonist of PAR1 with IC50 of 110 
nM in a platelet aggregation assay. RWJ-58259 was derived from extensive medicinal 
chemistry efforts to develop peptidomimetics based on the tethered ligand peptide for 
PAR1. Initially, an indole-based template was proposed from extensive computer 
modeling. After extensive SAR studies, an indazole analog (6.2) was synthesized which 
showed an improved in vivo cardiovascular safety profile. The SAR data suggested the 
requirement of indazole template along with urea and crucial phenyl ring that fitted into 
the spatial rearrangement of peptide SFLLRN-NH2. However, several modifications were 
reported at the benzyl group at the west side of 6.2, and also at the 1° amine residue. Due 
to the ease of chemical modifications at the 1° amine residue, we attempted to attach an 






Scheme 6.4: Synthesis of RWJ-58259 alkyne analogue 6.24 
 
 We synthesized RWJ-58259 with a slightly modified protocol from the literature 
reports. The commercially available amino acid 6.12 was sequentially coupled with acid 
and amine building blocks with standard coupling conditions using EDC and Fmoc-
removal conditions using piperdine, to yield intermediate dipeptide 6.16. According to 
the protocols reported by Zhang and Maryanoff, commercially available 6-nitro indole 
6.17 underwent nitrosation and rearrangement to give analytically pure 3-formyl indazole 
6.18 with 95% yield. 3-formyl indazole 6.18 was subjected to reductive amination to give 
pyrrolidine indazole 6.19 with 70% yield. Pyrrolidine indazole 6.19 was alkylated with 
benzyl bromide derivative to give nitro-indazole 6.20, along with an inseparable bis-





without success, so the mixture was carried forward in the synthesis. Nitro-indazole 6.20 
was reduced to amino-indazole 6.21 using several conditions, including SnCl2 and FeCl3 
as reducing agents. The reported protocol using catalytic FeCl3 and stoichiometric 
hydrazine gave amino-indazole 6.21 with moderate yield but high purity after flash 
chromatography. The originally-reported synthesis of urea 6.22 from 4-
nitrophenylchlorformate was low yielding and unreproducible in our hands. We initially 
adopted the low yielding conditions using triphosgene and propylene oxide as acid 
scavenger, reported by Herranz. Finally, high purity urea 6.22 was reproducibly obtained 
in moderate yields via a slow addition of triphosgene to 6.21, followed by the addition of 
dipeptide 6.16 in the presence of DMAP as base (as reported by Caddick) and stirring the 
reaction initially at –5 °C for 30 min., and then gradually warming to room temperature. 
Boc removal of urea 6.22 was performed using HCl in dioxane to give RWJ-58259 as 
HCl salt 6.23a or as format salt 6.23b after purifying with semi-preparative HPLC. We 
attempted the conversion of 1° amine to 2° amine, urea, or amide using several 
conditions to attach alkyne with failure. Finally, coupling of the 1° amine of 6.23a with 
commercially available 4-pentynoic acid provided our first alkyne-linked PAR1 











6.1.2 Design and synthesis of PAR2 antagonists 
 
Figure 6.4: Literature reported PAR2 antagonists 
  
 Unlike PAR1, antagonism at PAR2 was not very well studied at the starting point 
of this project.  Fairlie, et al. reported non-peptidic PAR2 antagonist GB83 (6.25), 
however with structural limitations and unpredictability of scaffolds to behave as partial 
agonist to antagonists.  The other reported scaffolds either suffered from low potency or 
showed agonistic activity at higher concentrations and thus, no follow up studies were 
performed (6.26, 6.27 – Figure 6.4).  
 






 Meanwhile, Vertex published a patent containing PAR2 antagonists with 
nanomolar potencies. After careful consideration, we found that the imidazopyridazine 
scaffold of PAR2 antagonists could be modified at the pyridazine position and pyrazine 
position without adverse effects on potency. We selected analogues 6.28 and 6.29 from 
the patent to use in our synthesis of heterobivalent ligands.   
 
6.1.3 Synthesis of heterobivalent ligands 
 
Scheme 6.5: Synthesis of bivalent ligands 
 
 The carboxylic acid of PAR2 antagonist 6.28, prepared in our lab by Dr. Mark 
Majewski, was efficiently peptide coupled with commercially available varying lengths 
of azido-amino PEG linkers using PyBOP and HOBt to give amides 6.30a-d. The azides 
of 6.30a-d were subjected to CuAAC with the PAR1 ligand alkyne 31 to provide bivalent 





of the ligands (6.31a, 6.31c-d, 6.33a-d) were synthesized and characterized by Dr. Mark 
Majewski.  
 
6.1.4 Synthesis of monovalent controls with PEG spacers 
 
 
Figure 6.6: PAR1 control ligand 6.34 and PAR2 control ligands 6.34 and 6.36 
 
 
 All control ligands, composed of PAR1 or PAR2 antagonists with attached PEG 
spacers, were synthesized with a similar strategy of CuAAc and peptide coupling using 









6.1.5 Design of modified bivalent ligand with hydrophobic spacer 
 
  
Figure 6.7. A: X-ray structure of modified PAR2 with bound allosteric ligand AZ3451 (green) and docked 
ligand 6.28 (pink) 
 
 During the course of our study, Marshall and colleagues reported an x-ray 
structure of modified PAR2 with two different ligands, including the inhibitor AZ3451 
which binds at an allosteric site.
167
 We hypothesized that AZ3451 and the Vertex PAR2 
antagonist 6.28 may share a similar hydrophobic binding site based on structural 
similarities. We found that 6.28 docks into the lipophilic pocket of PAR2 with a similar 
pose as AZ3451, with both molecules possessing a heterocyclic nitrogen capable of 
accepting a hydrogen bond from Tyr210 (Figure 6.7). The position of this binding site 
within the cell membrane suggests that the hydrophilic PEG spacer may be 
counterproductive and could explain the greatly decreased potency at PAR2 of our PEG-







Figure 6.8: Novel bivalent ligand 6.38 and control compound 6.37 possessing a PEG-aminoalkylamide 
spacer 
 
 We addressed this potential issue by designing bivalent ligand 6.38 with a 
modified spacer. We hypothesized that incorporation of an additional hydrophobic 
section such as a terminal aminoalkylamide adjacent to 6.28 could lead to a higher 
affinity for the cell membrane above the putative PAR2 binding site, and could facilitate 
binding to PAR1 – PAR2 heteromers (Figure 6.8). Both bivalent ligand 6.38 and control 
6.37 were synthesized and characterized by Ricardo Rosas, Jr.  
 
6.2 Bioassay results and discussion 
The ligands were tested in our intracellular calcium mobilization assay (iCa
2+
) 
using the transformed human endothelial cell line EA.hy926, and this assay was also 
suitable for studying the signaling of the breast cancer cell line MDA-MB-231, which 





confluence over 41 – 44 h, then loaded with the fluorescent calcium binding dye Fluo-
4/AM, according to our reported protocol.
79
 Addition of the antagonists, followed by the 
relevant PAR peptide agonists TFLLRN-NH2 (PAR1), SLIGKV-NH2 (PAR2), or 
SFLLRN-NH2 (PAR1/2), permitted the measurement of inhibition of Gαq-driven 
signaling from both PAR1 and PAR2. 
 






Figure 6.9: Inhibition of TFLLRN-NH2 (5 µM) PAR1-mediated iCa
2+  mobilization by monovalent 
PAR1 ligand RWJ-58259 30a, RWJ-58259 alkyne analogue 31, and spacer-linked control 6.34 in 
EA.hy926 endothelial cells (A) and in MDA-MB-231 cancer cells (B). 
 
We first tested the activity of monovalent ligands in iCa
2+
 assay in both EA.hy926 
cells and MDA-MB-231 cells. In EA.hy926 cells (Figure 6.9A), PAR1-selective 
antagonists were tested in the presence of TFLLRN-NH2 (5 µM). RWJ-58259 (30a) was 
active with an IC50 of 0.02 µM. The alkyne analogue of RWJ-58259 (31) was 15-fold less 





connected to a PEG linker (6.34) was 5-fold less potent, but the activity was still tolerated 
considerably IC50 of 0.097 µM. Similar results were observed in MDA-MB-231 cells 
(Figure 6.9B), but all 3 ligands were more potent with IC50 of 0.005 µM for 30a, 0.010 
µM for 31, and 0.013 µM for 6.34.  
 









Figure 6.10: Inhibition of SLIGKV-NH2 (5 µM) PAR2-mediated iCa
2+ mobilization by monovalent 
PAR2 ligand 6.28 and spacer-linked control 6.35 in EA.hy926 endothelial cells (A) and in MDA-
MB-231 cancer cells (B); monovalent PAR2 ligand 6.29 and spacer-linked control 6.36 in EA.hy926 






Next, we tested the activity of the PAR2 ligands in the iCa
2+ assay in both 
EA.hy926 cells and MDA-MB-231 cells. In EA.hy926 cells, the PAR2-selective 
antagonists and spacer-linked controls were tested in the presence of SLIGKV-NH2 (5 
µM). The PAR2 antagonist 6.28 was active with an IC50 of 0.1 µM (Figure 6.13A). 
However, replacing the free carboxylic acid of 6.28 with an amide tethered to a PEG 
linker (6.35) was 70-fold less potent (IC50 = 7.0 µM, Figure 6.13A). The PAR2 
antagonist 6.29 was less potent than 6.28 with an IC50 of 0.58 µM (Figure 6.13C), 
whereas the spacer-linked control 6.36 showed an IC50 of 2.4 µM (Figure 6.13C). Full 
inhibition of SLIGKV-NH2 was not achieved with either of the controls 6.35 or 6.36. A 
similar pattern was observed in MDA-MB-231 cells. PAR2 control ligand 6.35 retained 
the activity with IC50 of 0.86 µM (Figure 6.13B), and was 2-fold less potent, and less 
efficacious than 6.28 with IC50 of 0.48 µM (Figure 6.13B). 6.29 was active with IC50 of 
0.42 µM (Figure 6.13D), but the IC50 of 6.36 could not be estimated due to the lack of 
full inhibition (Figure 6.13D). These results indicated that modifications to PAR2 ligand 
were not well tolerated. It may be because 6.28 and 6.29 bind at a hydrophobic site on 





















Figure 6.11: Inhibition of TFLLRN-NH2 (5 µM) PAR1-mediated iCa
2+ mobilization (A); SLIGKV-NH2 (5 
µM) PAR2-mediated iCa2+ mobilization (B); Inhibition of SFLLRN-NH2 (3.16 µM) PAR1/2-mediated 
iCa2+ mobilization by bivalent ligands 6.31a–d (C), and individual and co-dosed monovalent control 
compounds (6.34 + 6.35) in EA.hy926 endothelial cells (D). 
 
After testing the PAR1 and PAR2 monovalent ligands and spacer-linked controls, 
we proceeded to measure the activities of our bivalent ligands from the shortest ligand 
6.31a to the longest ligand 6.31d in the iCa
2+
 assay. All four ligands 6.31a-d were 
reasonably potent in the TFLLRN-NH2 (5 µM) PAR1-mediated iCa
2+





the range of 0.03 – 0.18 µM (Figure 6.11A), with the longest bivalent ligand 6.31d as the 
most efficacious compound showing full inhibition at higher concentrations. 
Unfortunately, 6.31a-d showed weak antagonism in the SLIGKV-NH2 (5 µM)-PAR2 
mediated iCa
2+
 assay (Figure 6.11B). Weak antagonism of 6.31a-d at PAR2 may be due 
to higher affinity towards PAR1 and/or higher density of PAR1 in EA.hy926 cells 
causing the ligands to bind only monomeric PAR1 receptor. Next, we analyzed 6.31a-d 
in the SFLLRN-NH2 mediated (PAR1 and PAR2-driven) iCa
2+
 assay at 3.16 µM 
concentration (Figure 6.11C). We selected SFLLRN-NH2 because of its activity for both 
PAR1 and PAR2 receptors. Amongst 6.31a-d, only 6.31d showed significant potency 
with an IC50 of 0.15 µM, with partial inhibition. We next compared the activity of the 
bivalent ligands with the individual and co-dosed monovalent spacer-linked controls 6.34 
and 6.35 in the SFLLRN-NH2-mediated iCa
2+
 assay (Figure 6.11D). The individual 
ligand 6.34 was potent with an IC50 of 0.074 µM, but 6.35 showed no activity. However, 
co-dosed 6.34 and 6.35 showed a similar profile to the bivalent ligand 6.31d, with an IC50 
of 0.32 µM. These results suggested that inhibition of SFLLRN-NH2-mediated iCa
2+
 




















Figure 6.12: Inhibition of TFLLRN-NH2 (5 µM) PAR1-mediated iCa
2+  mobilization (A); SLIGKV-
NH2 (5 µM) PAR2-mediated iCa
2+  mobilization (B); Inhibition of SFLLRN-NH2 (3.16 µM) PAR1/2-
mediated iCa2+ mobilization by bivalent ligands 6.33a–d (C), and Individual and co-dosed 
monovalent control compounds (6.34 + 6.36) in EA.hy926 endothelial cells (D). 
 
Next, we measured the pharmacology the of next set of bivalent ligands, from the 
shortest ligand 6.33a to the long ligand 6.33c in iCa
2+
 assay. Unlike the first set 6.31a-d, 
all three ligands 6.33a-c were less potent in the TFLLRN-NH2 (5 µM) PAR1-mediated 
iCa
2+
 assay, with IC50s in the range of 3.3 – 6.2 µM (Figure 6.12A), with the long 
bivalent ligand 6.33c as the most efficacious compound showing full inhibition at higher 
concentrations. Similar to the previous results, 6.33a-c showed weak antagonism in the 
SLIGKV-NH2 (5 µM) PAR2-mediated iCa
2+





NH2 (3.16 µM) PAR1/2-mediated iCa
2+
 assay (Figure 6.12C). The behavior of individual 
and co-dosed monovalent spacer-linked controls 6.34 and 6.36 in the SFLLRN-NH2-
mediated iCa
2+
 assay (Figure 6.12D) was similar to the first set of ligands. The individual 
ligand 6.34 was potent with IC50 of 0.074 µM but 6.36 showed no activity. Whereas, co-
dosed 6.34 and 6.36 showed considerable inhibition, supporting the hypothesis of largely 
PAR1 driven iCa
2+
 mobilization with the agonist SFLLRN-NH2. 
 
 
Figure 6.13: Inhibition of TFLLRN-NH2 (5 µM) PAR1-mediated, SLIGKV-NH2 (5 µM) PAR2-mediated, 
and SFLLRN-NH2 (3.16 µM) PAR1/2-mediated iCa
2+ mobilization of 6.31d in MDA-MB-231 breast 
cancer cells. 
 
 From 6.31a-d and 6.33a-c, only 6.31d showed promising results in Ea.hy926 
cells. Therefore, 6.31d was studied in the breast cancer cell line MDA-MB-231 with all 
three agonists (Figure 6.13). It was most effective at the inhibition of TFLLLRN-NH2-
driven calcium mobilization, with an IC50 of 0.14 µM and excellent efficacy. The IC50 for 





inhibition of SLIGKV-NH2 by 6.31d was less efficient, with an IC50 estimated at 3.5 µM, 














Figure 6.14. Inhibition of TFLLRN-NH2 (5 µM) PAR1-mediated iCa
2+





µM) PAR2-mediated iCa2+ mobilization, SFLLRN-NH2 (3.16 µM) PAR1/2-mediated iCa
2+ mobilization by 
bivalent ligand 6.38 in EA.hy926 endothelial cells (A) and in MDA-MB-231 cells (B); Inhibition of 
SLIGKV-NH2 (5 µM) PAR2-mediated iCa
2+ mobilization by monovalent control 6.37 in EA.hy926 
endothelial cells (C) and MDA-MB-231 cancer cells (D); Inhibition of SFLLRN-NH2 (3.16 µM) PAR1/2-
mediated iCa
2+
 mobilization by co-dosed control 6.34 and 6.37 in EA.hy926 endothelial cells (E) and 
MDA-MB-231 cancer cells (F). 
 
Finally, the bivalent ligand 6.38 (possessing a more hydrophobic spacer) and 
control with hydrophobic spacer 6.37 were tested for possible improved activity at PAR2 
in both Ea.hy926 and MDA-MB-231 cell lines (Figure 6.14). Unfortunately, attachment 
of the more hydrophobic spacer had adverse effects on both PAR1 and PAR2 inhibition. 
 
6.3 Conclusion 
We designed and synthesized the first heterobivalent ligands targeting putative 
PAR1 – PAR2 complexes. To our knowledge, this is the first example of PAR1 – PAR2 
bivalent ligands reported in literature on the vascular receptors. We analyzed their 
behavior in endothelial Ea.hy926 cells and in breast cancer MDA-MB-231 cells. We first 
tested monovalent ligands and then controls having monovalent ligands coupled to PEG 
spacers in iCa
2+
 flux assays in both cell lines. The decrease in potency was observed with 
controls for PAR1 and significantly for PAR2 receptor. From the current set of bivalent 
ligands, 6.31d showed a similar potency to two co-dosed monovalent controls in the 
presence of the PAR1/2 agonist SFLLRN-NH2. 6.31d showed inhibition of TFLLRN-
NH2-mediated signaling (PAR1 agonist), but was poorly active against SLIGKV-NH2 
medicated signaling (PAR2 agonist). These resultas suggested that modification of the 
PAR2 pharmacophore in the current set of bivalent ligands might cause a loss of affinity 





heteromers in Ea.hy926 endothelial cells and MDA-MB-231 cancer cells and their 
selective inhibition with our bivalent ligands. Performing binding assays with the range 
of picomolar to micromolar concentrations may provide evidence of binding to 
heteromers, such as biphasic concentration curves which would indicate selective binding 
to heteromers. We plan to synthesize labeled ligands to perform binding assays. In 
addition, PAR-driven cell migration assays (e.g. scratch assay) are underway to explore 
the effects of bivalent ligands relevent to metastasis. In summary, the use of PAR1 – 
PAR2 bivalent antagonists is a novel approach to target the pathological signaling of 
PARs while retaining their productive signaling. This approach is promising for the 















Project summary and future work 
 
 
7.1 PAR1 monovalent ligands 
 
Figure 7.1: “Hit molecules” from PAR1 mediated iCa2+ screening at 10 µM concentration of parmodulins 
in the presence of 5 µM TFLLRN-NH2 agonist  
 
We designed and synthesized ~100 parmodulin analogues focusing on detailed 
exploration of the western region of the 1,3-diaminobenzene scaffold. We screened them 
in a Gαq mediated iCa
2+
 flux assay for PAR1 in endothelial cells. From this screen, we 
selected 6 “hit” molecules (Figure 7.1) that will be further characterized in this and other 
assays. We will perform experiments to demonstrate selectivity of these analogues for 
PAR1 and negative allosteric modulation at PAR1 with the iCa
2+
 flux assay in an 





mediated RhoA activation assay in endothelial cells to demonstrate signaling bias. In this 
assay using agarose beads conjugated to GST-Rhotekin-Rho binding domain to 
precipitate and quantify GTP-bound RhoA,
168
 in the lab of Dr. Robert Flaumenhaft at 
Beth Israel Deaconess Medical Center and in β-arrestin assay in the lab of Dr. Bryan 
Roth at University of North Carolina at Chapel Hill.  
We hypothesize that modifications to ML161 should not affect cytoprotective 
effects and the SAR profile of parmodulins should be consistent with Gαq mediated iCa
2+
 
flux assay.  To test the hypothesis, we are currently developing a FXa mediated 
cytoprotection assay in the lab of Dr. Hartmut Weiler at Blood research Institute. We 
have planned to screen all parmodulins in this assay.  
Promising molecules will also be profiled for drug-like properties. These 
molecules will tested in the lab of Dr Alexander Arnold at University of Wisconsin – 
Milwaukee for water solubility, plasma stability, plasma protein binding, microsomal 
stability, and membrane permeability. Depending on data, the promising analogues will 
be reinvestigated with additional SAR studies or could go additional PK and selectivity 












7.2 Heterobivalent PAR ligands 
We designed and synthesized first generation of heterobivalent ligands targeting 
putative PAR1 – PAR2 complexes. We analyzed their behavior in functional iCa
2+
 flux 
assay in endothelial EA.hy 926 cells and in breast cancer MDA-MB-231 cells, although 
we didn’t find evidences to binding to PARs heteromer. Therefore, we have planned to 
adopt TR-FRET based approach to demonstrate first the existence of PAR1 – PAR2 
complexes (figure 7.2). 
 
 
Figure 7.2.  FRET-paired ligands for PAR heteromer detection  
 
We have planned to tether PAR1 and PAR2 antagonist with PEG linker (having 
terminal azide and amine) via alkyne – azide cycloaddition, and the resultant terminal 
amines will be acylated with commercially available N-hydroxysuccinimide (NHS) esters 





and AlexaFluor-647. Lumi-4-Tb at PAR1 will be excited at 345 nm (that emits light at 
550 nm). If PAR2 is nearby (< 100 A) then FRET will odducr at AlexaFluor-647 at 
PAR2 that emits at 665 nm and FRET ratio will be calculated. The long-lasting 
fluorescence emission from lanthanide cryptates permits time-resolved FRET (TR-FRET) 
to minimize background signals and provide optimal signal/noise.  
Next, we will develop competitive binding assay for PARs. Competitive binding 
assay for PAR1 has been reported only for platelets. Whereas our PAR2 anatgonist binds 
at an allosteric site of PAR2, that means we may not have competitive binding at PAR2. 
Therefore, we will use lanthanied tagged PAR1 and PAR2 ligands to perfom competitive 
binding assay against PAR1 and PAR2 agonists. The dye-labeled ligands will be 
confirmed for their ability to selectively inhibit iCa
2+ 
mediated by PAR1 or PAR2 
agonists, then they will be tested for their ability to bind to the endothelial and breast 
cancer cells. From this assay, supposed biphasic binding dose-response curves will be 
obtained that will support bivalent ligand binding to the putative PAR1 – PAR2 complex. 
After demonstrating the existence of PAR1 – PAR2 complexes and bivalent 
ligand binding, we will measure the migration and invasion of metastatic cancer cells 
using our bivalent ligand. The scratch wound assay in MDA-MB-231 cells is under 
development stage. MDA-MB-231 cells are grown in 96-well plates, “scratched” with an 
automated scratch tool to remove cells and create a defined gap, and imaged to measure 
the relative rates at which each cell line migrates with or without antagonists.  
After the assay development and analyzing the first generation of bivalent ligands, 
we will study the SAR of bivalent ligands with different spacers, and different 





Pharmaceuticals is under progress. This piperidine scaffold will require fewer synthetic 
steps and offer more flexibility for attaching various adapters to connect PEG spacers. 
We discussed earlier about an allosteric binding site for PAR2 antagonists. we will 
replace the current allosteric PAR2 antagonist with literature reported orthosteric PAR2 
antagonist. Additionally, both PAR1 and PAR2 pharmacophores will be linked with a 
variety of alternative spacers with variable with variable flexibility and length. to profile 













8.1 General information on Assays 
 Water for solutions was deionized and filtered through charcoal (Milli-Q by 
Millipore) to a resistance of 18 MΩ. TFLLRN-NH2 (PAR1 agonist) was obtained from 
AnaSpec (cat# AS-62937) or was synthesized (as the TFA salt) by Trudy Holyst, Blood 
Research Institute Protein Chemistry Core. SFLLRN-NH2 (TFA salt) (PAR1/2 agonist) 
was obtained from Bachem (cat# H-2936.0005) or was synthesized (as the TFA salt) by 
Trudy Holyst, Blood Research Institute Protein Chemistry Core. SLIGKV-NH2 (TFA 
salt) (PAR2 agonist) was obtained from Bachem (cat# H-5042.0025) or AnaSpec (cat# 
AS-60217-1). AYPGFK-NH2 (TFA salt) (PAR4 agonist) was obtained from AnaSpec 
(cat# AS-60218-1). Atopaxar (E5555 HBr) was obtained from Axon Medchem (cat# 
2030). Vorapaxar (SCH 530348) was obtained from Axon Medchem (cat# 1755). Q94 
(HCl) was obtained from Axon Medchem (cat# 2055). 
Adherent Ea.hy926 cells (ATCC CRL-2922) and MDA_MB-231were used for 
assays. The cells were cultured using the suggested protocol from the manufacturer 
(ATCC), except that 150 cm
2
 tissue culture flasks were used, and DMEM complete 
media was prepared as described below. Cells were frozen in 40% fetal bovine serum 





passages 2 and 11. All manipulations prior to the assays were performed in a sterile 
laminar flow cell culture hood. 
Cell counting was performed with an automated cell counter (Countess, 
Invitrogen) using Invitrogen cell counting chamber slides and trypan blue stain. All 
assays were run in 96-well plates (Corning Costar #3603, polystyrene black wall, clear 
bottom). Unless otherwise noted, media exchanges with 96-well plates were performed 
using an automated liquid handler (Beckmann-Coulter, Biomek 3000) with 220 µL 
pipette tips.  Cells were imaged with an Evos Fl inverted microscope.  All assays were 
run on a multimode plate reader (Perkin Elmer EnSpire). Data was exported to Microsoft 
Excel for nominal processing, then analyzed with GraphPad Prism (versions 5 or 6). 
 
8.2 Preparation of stock solutions 
Complete cell media (for Ea.hy926 cells). 
  Dulbecco’s Modified Eagle Medium (DMEM) with 4.5 g/L glucose (500 mL) 
was supplemented with 200 mM L-glutamine (10 mL, 4 mM final conc.), 100 mM 
sodium pyruvate (2.5 mL, 1 mM final conc.), 7.5% (w/v) sodium bicarbonate (5.0 mL, 
0.75 g/L final conc.), 100X penicillin and streptomycin (Corning #30-002-CI, 2.0 mL) 









Complete cell media (for MDA-MB-231 cells). 
 Dulbecco’s Modified Eagle Medium (DMEM) with 4.5 g/L glucose (500 mL) 
was supplemented with 200 mM L-glutamine (5 mL, 2 mM final conc.), 1M HEPES 
buffer (5 mL, 10 mM final conc.), 100X penicillin and streptomycin (Corning #30-002-
CI, 2.0 mL) and heat inactivated FBS (50 mL). The prepared media was stored in a 
refrigerator (5 °C) until needed. 
 
Probenecid solution (250 mM, aqueous).  
 Probenecid (Alfa Aesar, catalog # B20010-88, 36 mg) was added to a 1 mL 
microcentrifuge tube and dissolved in 0.6 M NaOH (500 μL). NaOH (0.6 M) was 
prepared by dissolving NaOH (480 mg) in H2O (20 mL). This solution was made the day 
of the experiment and was sufficient for up to 50 mL of buffer (for 2 96-well plates). 
 
HBSS–HEPES wash buffer.  
 HEPES (1.19 g) was added to a 500 mL bottle of Ca/Mg/phenol red-free HBSS to 
make a 10 mM solution in HEPES. MgCl2 (1 M solution, 500 μL) and CaCl2 (1 M 
solution, 500 μL) were added and the solution was stored in the refrigerator. Before use, 
the desired amount (46 mL total per 96 well plate) was warmed to room temperature and 
added to a 50 mL centrifuge tube, then supplemented with 250 mM probenecid solution 
(1:100, i.e. 46 mL of buffer needs 460 μL of probenecid solution) to give a 2.5 mM 






10% Pluronic F-127 in DMSO.  
 Pluronic F-127 (Sigma Aldrich, 20 mg) was added to a 1 mL microcentrifuge tube 
and dissolved with DMSO (200 μL), to make a 10% w/v solution.  This solution was 
stored at room temperature. 
 
Fluo-4/AM loading buffer.  
 Fluo-4/AM (Invitrogen via Fisher, catalogue # F23917, 50 μg) was dissolved in 
DMSO (24 μL), then 6 μL of the solution (light-sensitive) was transferred to a 200 μL 
microcentrifuge tube and mixed with 6 μL of 10% pluronic F-127 in DMSO (sufficient 
for 1 96-well plate). The remainder of the Fluo-4/AM solution was stored in the freezer at 
–30 ºC. The solution was then transferred to a foil-covered 14 mL centrifuge tube already 
containing HBSS–HEPES wash buffer (6 mL) and vortexed for 5 seconds. 50 μL of this 
prepared dye solution (2 μM) can be added to each well of a 96-well plate containing 
adherent cells. 
 
Preparation of agonist/antagonist solutions.  
 Prior to the assay, stock solutions of PAR1 and PAR2 agonists were prepared by 
dissolving the agonists in 100% H2O (sterile, deionized) to give stock solutions (10 mM, 
5 mM, or 1 mM depending on agonist). These were aliquoted into sterile microcentrifuge 
tubes and stored in a –30 ºC freezer, and thawed before use. Stock solutions of 





give stock solutions (31.6 mM, 10 mM, or 1 mM depending on antagonist used) that were 
stored in the freezer at –30 ºC, and thawed in a desiccator before use. 
Agonist solutions: Prepared as 10 mM stock solutions in 100% water (sterile, deionized). 
Diluted solutions were then prepared with water to give half log concentrations. 
Antagonist solutions: Vehicle (diluent) was prepared by mixing 1:9 DMSO:HBSS-
HEPES wash buffer. An aliquot from the antagonist stock solution (in 100% DMSO) was 
then diluted 10x with vehicle to give a 10% DMSO solution, then subsequent dilutions 
were made with vehicle to give a consistent concentration of DMSO (1%). 
 
8.3 Protocol for calcium mobilization assay with adherent endothelial cells 
Cell Preparations (Aseptic Conditions).  
 Unless otherwise noted, EA.hy926 cells were plated at 25,000 cells per well in 
100 μL, which corresponds to 250,000 cells/mL and MDA-MB-231 cells were plated at 
15,000 cells per well in 100 μL, which corresponds to 150,000 cells/mL. Complete cell 
media (25 mL per plate) was transferred to a 50 mL centrifuge tube and warmed to 37 °C 
in a water bath. A vial of frozen EA.hy926 cells (ATCC CRL-2922) or MDA-MB-231 
cells was taken from liquid N2 storage and warmed to 37 °C in a water bath for 5 min. 
Complete cell media (1 mL) was added dropwise to the vial and the contents were mixed 
and transferred to a 14 mL centrifuge tube. The cells were centrifuged at 130 g for 3 min 
and the supernatant was removed via aspiration with a Pasteur pipet. The cells were re-
suspended in complete cell media (2 mL) and the suspension was mixed thoroughly with 





tube. A small fraction of this suspension (25 μL) was mixed with 25 μL of trypan blue 
solution and a cell count was taken. Based on the cell count, an appropriate volume of 
complete cell media was added to the 2 mL of cell suspension to assure that each well of 
the 96-well plate would have 25,000 cells. The suspension was gently mixed, and the 
contents of the tube were slowly poured into a sterile disposable pipetting reservoir. This 
suspension containing the cells was then added (column by column, 100 μL per well) to a 
96-well plate (Corning Costar #3603, black wall, clear bottom) with a multichannel 
pipette. The plate was gently rocked back and forth to get even coverage of cells and the 
plate was incubated at 37 °C (5% CO2) for 40–48 h. 
 
Loading of Fluo-4/AM dye.  
 The 96-well plate was removed from the incubator after 40–48 h and then 
checked with an EVOS Fl microscope and optionally imaged (20X magnification) to 
confirm that cells were >80% confluent and viable. Note: All media exchanges were 
performed with the Biomek 3000, unless otherwise noted. The complete cell media was 
removed and HBSS–HEPES wash buffer (100 μL) was added to each well. The plate was 
left to sit at room temperature for 5 min. to allow the probenecid to be absorbed, then the 
media was removed. Fluo-4/AM solution (50 μL per well) was added (in the dark), and 
the plate was incubated at 37 °C (5% CO2) for 40–50 min. The dye solution was removed 
from each well and the wells were washed with HBSS–HEPES wash buffer (50 μL/well) 
twice. HBSS–HEPES wash buffer (200 μL/well) was added to each well and the plate 
was imaged with the EVOS Fl microscope (20X magnification, GFP setting) to verify 






Running the assay. 
Basic plate reader info and settings: 
a. Instrument: Perkin Elmer EnSpire plate reader 
b. Temperature: 37°C 
c. Excitation wavelength: 485 nm 
d. Emission wavelength: 525 nm 
e. Measurement height: 7.8 mm (optimized) 
f. Number of flashes: 100 
g. Number of repeats: 250, every 5 sec. Experiment was halted after the emission 
signal starts to decrease from the maximum. 
 Vehicle or antagonists (2 μL) were added (single or multichannel pipette) to each 
well, and the plate was incubated in the plate reader for 15 min at 37 °C.  Response to 
agonists was measured 2 columns at a time, since this plate reader scanned wells 
individually, but plate readers that measure wells concurrently could optionally support 
assays with all agonists added concurrently, for higher throughput. Upon starting the 
assay, the basal level of the 2 columns was measured (20 scans) prior to the addition of 
the agonist. The agonist (2 μL) was then added (over 10 seconds with a multichannel 
pipette or over 90–120 seconds with a single channel pipette), and the wells were 








Data analysis.  
 Concentration-response curves were obtained by measuring the maximal increase 
in emission intensity (Δ Relative Fluorescence Units, RFU) from basal levels (average of 
20 scans prior to agonist addition), then dividing by the average basal levels to give Δ 
RFU/basal. From this data, % stimulation was obtained by normalizing Δ RFU/basal for 
each column of the plate with a well from the same column where vehicle had been 
added instead of antagonist solution. The Δ RFU/basal value from the vehicle well was 
considered to be 100% stimulation for each column. This normalization was necessary 
due to increasing background signal over time, presumably due to dye efflux. Data (% 
stimulation versus log concentration) was then plotted for 3 or more repetitions and 
analyzed using GraphPad Prism (versions 5 or 6). All concentration-response curves were 
fitted using 4-variable non-linear regression, showing the standard error of the mean 
(SEM) for each concentration. 
 
8.4 Reversibility Assay Protocol 
Preparation of Plate for Assay.  
 Cell preparations (under aseptic conditions), loading of probenecid and Fluo-4 
dye, the washing/removal of dye, and the replacement with HBSS-HEPES buffer solution 








Wash Procedure.  
 Vehicle or antagonist (2 μL) was added to the wells of interest (already containing 
200 µL of HBSS-HEPES wash buffer) and the plate was incubated in the plate reader for 
20–30 min. The wash buffer was carefully removed from the wells with a multichannel 
pipette, replaced with fresh HBSS-HEPES wash buffer (200 µL) and incubated in the 
plate reader for 10 min. at 37 °C. Wash buffer was carefully removed from the wells 
again with a multichannel pipette and replaced with fresh HBSS-HEPES wash buffer 
(200 µL). The plate was incubated again in the plate reader for 10 min., and then the 
assay was performed according to the regular protocol above. Note that the washing steps 
can alternatively be performed with the automated liquid handler. 
 
8.5 Instructions for Screening 
General notes. 
a. Vehicle: Water  
b. Agonist TFLLRN-NH2 concentration was set to 5 µM. 
c. This map was designed for n = 4 of parmodulins. 
d. Parmodulins were designated according to ELN entry. 
e. For 1 mM dilution of PMs and addition of agonist solution, multichannel 
pipette was used.  







Preparation of Vehicle and solutions. 
 Vehicle was 100% Water to prepare 1 mM PMs solution. All other solutions like 
HBSS-HEPES wash buffer, probenecid solution, and Fluo-4 dye solution were prepared 
as described above.  
 
Preparation of 10 µM solution of PMs: 
a. 0.2 – 0.4 mg of PMs were dissolved in 100% DMSO to make stock concentration 
31.6 mM. 
b. 3.2 µL of stock solution (31.6 mM) was diluted with 96.8 µL of vehicle to prepare 
1 mM, 100 µL solution.  
c. 4 µL of 1 mM solution was diluted with 196 µL of vehicle to prepare 0.02 mM, 
200 µL solution.  
d. 100 µL of 0.02 mM solution was diluted with 100 µL of wash buffer to prepare 
0.01 mM, 200 µL solution. 100 µL of 0.01 mM PMs solution was added to assay 
plate using automated liquid handler. 
e. Concentration of DMSO: 
(
3.2 µ𝐿, 31.6 𝑚𝑀 𝑠𝑡𝑜𝑐𝑘
100µ𝐿 𝑣𝑒ℎ𝑖𝑐𝑙𝑒
) ∗ (
4 µ𝐿, 1 𝑚𝑀 
200 µ𝐿 𝑤𝑎𝑠ℎ 𝑏𝑢𝑓𝑓𝑒𝑟
) ∗ (
100 µ𝐿, 0.02 𝑚𝑀
200 µ𝐿 𝑤𝑎𝑠ℎ 𝑏𝑢𝑓𝑓𝑒𝑟
) ∗ 100%
=  0.032% 𝑓𝑖𝑛𝑎𝑙 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 𝑜𝑓 𝐷𝑀𝑆𝑂 𝑖𝑛 𝑡ℎ𝑒 𝑎𝑠𝑠𝑎𝑦 
 
Preparation of 1 µM solution of Vorapaxar. 
 






b. 1 µL of stock solution (10 mM) was diluted with 99 µL of vehicle to prepare 0.1 
mM, 100 µL solution.  
c. 4 µL of 0.1 mM solution was diluted with 196 µL of vehicle to prepare 0.002 
mM, 200 µL solution.  
d. 100 µL of 0.002 mM solution was diluted with 100 µL of wash buffer to prepare 
0.001 mM, 200 µL solution. 100 µL of 0.001 mM PMs solution was added to 
assay plate using automated liquid handler. 
e. Concentration of DMSO: 
(
1 µ𝐿, 10 𝑚𝑀 𝑠𝑡𝑜𝑐𝑘
100µ𝐿 𝑣𝑒ℎ𝑖𝑐𝑙𝑒
) ∗ (
4 µ𝐿, 0.1 𝑚𝑀 
200 µ𝐿 𝑤𝑎𝑠ℎ 𝑏𝑢𝑓𝑓𝑒𝑟
) ∗ (
100 µ𝐿, 0.002 𝑚𝑀
200 µ𝐿 𝑤𝑎𝑠ℎ 𝑏𝑢𝑓𝑓𝑒𝑟
) ∗ 100%
=  0.01% 𝑓𝑖𝑛𝑎𝑙 𝑐𝑜𝑐𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 𝑖𝑛𝑡𝑜 𝑡ℎ𝑒 𝑎𝑠𝑠𝑎𝑦 
 
Preparation of 5 µM solution of agonist. 
  0.2 mg of TFLLRN-NH2 in was dissolved into 524.3 µL of water to make stock 
concentration of 0.5 mM. 
 
Running the assay. 
Basic plate reader info and settings: 
h. Instrument: Perkin Elmer EnSpire plate reader 
i. Temperature: 37°C 
j. Excitation wavelength: 485 nm 
k. Emission wavelength: 525 nm 





m. Number of flashes: 100 
n. Number of repeats: 50, every 5 sec. Experiment was halted after the emission 
signal starts to decrease from the maximum. 
 Vehicle or antagonists (0.01 mM, 100 μL) were added to each well (according to 
the plate map, Table 7.1) using automated liquid handler, and the plate was incubated in 
the plate reader for 5 min at 37 °C.  Response to agonists was measured 2 columns at a 
time, since this plate reader scanned wells individually, but plate readers that measure 
wells concurrently could optionally support assays with all agonists added concurrently, 
for higher throughput. Upon starting the assay, the basal level of the 2 columns was 
measured (20 scans) prior to the addition of the agonist. The agonist (2 μL) was then 
added (over 30 seconds with a multichannel pipette), and the wells were analyzed with 






Table 7.1 Assay map for screening: 
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8.6 P-Selectin Expression Assay.169  
 Blood from healthy donors who had not ingested aspirin in the 2 weeks prior to 
donation was collected by veinpuncture into 0.4% sodium citrate. Citrate-anticoagulated 
blood was centrifuged at 200g for 20 minutes to prepare platelet-rich plasma. Washed 
platelets were subsequently prepared from platelet-rich plasma by centrifugation at 
1,000g in the presence of 0.15 µM PGE1. For analysis of P-selectin expression, 20 μL 
washed platelets (0.5-1 x 108/mL) were incubated with the indicated agonists. Platelet 
activation was measured by P-selectin surface expression using PE-antihuman P-selectin 
(BD) and flow cytometry.1 Results are expressed as percent inhibition of P-selectin 
surface expression.  
 
8.7 General comments on synthetic procedures 
 All reagents and solvents, including anhydrous solvents, were purchased from 
commercial vendors and used as received. Deionized water was purified by charcoal 
filtration and used for reaction workups and in reactions with water. NMR spectra were 
recorded on Varian 300 MHz or 400 MHz spectrometers as indicated. Proton and carbon 
chemical shifts are reported in parts per million (ppm; δ) relative to tetramethylsilane (
1
H 
δ 0), or CDCl3 (
13
C δ 77.16), (CD3)2CO (
1
H δ 2.05, 
13
C δ 29.84), d6-DMSO (
1
H δ 2.50, 
13




C δ 49.00). NMR data are reported as follows: 
chemical shifts, multiplicity (obs = obscured, app = apparent, br = broad, s = singlet, d = 
doublet, t = triplet, q = quartet, m = multiplet, comp = complex overlapping signals); 





collected at 25 °C. Filtration was performed by vacuum using VWR Grade 413 filter 
paper, unless otherwise noted. Flash chromatography was performed using Biotage 
SNAP cartridges filled with 40-60 µm silica gel on Biotage Isolera automated 
chromatography systems with photodiode array UV detectors. Analytical thin layer 
chromatography (TLC) was performed on Agela Technologies 0.25 mm glass plates with 
0.25 mm silica gel. Visualization was accomplished with UV light (254 nm) and KMnO4 
stain, unless otherwise noted. Chemical names were generated and select chemical 
properties were calculated using either ChemAxon Marvin suite 
(https://www.chemaxon.com) or ChemDraw Professional 15.1. NMR data were 
processed using either MestreNova or ACD/NMR Processor Academic Edition 
(http://www.acdlabs.com) using the JOC report format. High-resolution mass spectra 
(HRMS) were obtained either at the University of Wisconsin-Milwaukee Mass 
Spectrometry Laboratory with a Shimadzu LCMS-IT-TOF with ESI and APCI ionization 
or  from the University of Cincinnati with an Agilent 6540 Accurate-Mass with Q-TOF 
LC/MS. 
 
LC-MS Characterization Methods 
 Tandem liquid chromatography/mass spectrometry (LC-MS) was performed on a 
Shimadzu LCMS-2020 with autosampler, photodiode array detector, and single-
quadrupole MS with ESI and APCI dual ionization using a Peak Scientific nitrogen 
generator. 
Method A 





Column temperature: 40 °C 
Sample Injection: 1–5 µL of sample in MeCN or MeOH 
Chromatographic monitoring: UV absorbance at 210 or 254 nm 
Mobile Phase: Solvent A: H2O w/ 0.1% formic acid; Solvent B: MeCN w/ 0.1% formic 
acid 
Flow Rate: 1.0 mL/min 
Gradient:  0 to 0.5 min: 25% MeCN  
   0.5 min to 5 min: 25% to 95% MeCN  
   5 min to 7.3 min: 95% MeCN  
   7.3 min to 7.5 min: 95% to 25% MeCN 
Method B 
Column: Phenomenex Gemini C18 (100 x 4.6 mm, 3 µm particle size, 110 Å pore size) 
Column temperature: 40 °C 
Sample Injection: 1–5 µL of sample in MeCN or MeOH 
Chromatographic monitoring: UV absorbance at 210 or 254 nm 
Mobile Phase: Solvent A: H2O w/ 0.1% formic acid; Solvent B: MeCN w/ 0.1% formic 
acid 
Flow Rate: 1.0 mL/min 
Gradient:  0 to 0.5 min: 25% MeCN  
   0.5 min to 5 min: 25% to 95% MeCN  
   5 min to 7.3 min: 95% MeCN  







Column: Phenomenex Gemini C18 (100 x 4.6 mm, 3 µm particle size, 110 Å pore size) 
Column temperature: 40 °C 
Sample Injection: 1–5 µL of sample in MeCN or MeOH 
Chromatographic monitoring: UV absorbance at 210 or 254 nm 
Mobile Phase: Solvent A: H2O w/ 0.1% formic acid; Solvent B: MeCN w/ 0.1% formic 
acid 
Flow Rate: 1.0 mL/min 
Gradient:  0 to 0.5 min: 25% MeCN  
   0.5 min to 5 min: 25% to 95% MeCN  
   5 min to 7.3 min: 95% MeCN  
7.3 min to 7.5 min: 95% to 25% MeCN 
 
Preparative HPLC Purification Methods 
 Preparative liquid chromatography was performed on a Shimadzu LC-20AP 
preparative HPLC with autosampler, dual wavelength detector, and fraction collector. 
 
Method A 
Column: Phenomenex Gemini C18 Semi Preparative Column (250 x 10 mm, 5 µm 
particle size, 110 Å pore size) 
Mobile Phase: Solvent A: H2O w/ 0.1% formic acid; Solvent B: MeOH w/ 0.1% formic 
acid 





Sample Injection: 0.1–1.9 mL (2 mL sample loop) of sample in DMSO 
Flow Rate: 6.0 mL/min  
Gradient:  0 to 1.5 min: 25% MeOH 
   1.5 min to 8 min: 25% to 95% MeOH 
   8 min to 10.5 min: 95% MeOH 
Method B 
Column: Phenomenex Gemini C18 Semi Preparative Column (250 x 10 mm, 5 µm 
particle size, 110 Å pore size) 
Mobile Phase: Solvent A: H2O w/ 0.1% formic acid; Solvent B: MeCN w/ 0.1% formic 
acid 
Peak collection: measured by UV absorbance at 210 or 254 nm 
Sample Injection: 0.1–1.9 mL (2 mL sample loop) of sample in DMSO 
Flow Rate: 6.0 mL/min  
Gradient:  0 to 1.5 min: 25% MeCN 
   1.5 min to 8 min: 25% to 95% MeCN 
   8 min to 10.5 min: 95% MeCN 
 
8.8 Experimental protocol for Chapter 4 
Method A: Peptide Coupling using EDC 
 To a round bottom flask with stir bar under nitrogen were added the appropriate 
carboxylic acid and anhydrous DCM/DMF (85:15; 0.2-0.6 M). The amine HCl salt to be 





and the reaction was stirred under nitrogen.  The reaction was diluted with DCM (75 
mL), washed with saturated NaHCO3, 1M HCl (30 mL), brine, dried over Na2SO4, 
filtered, and concentrated under reduced pressure to give crude product. 
 
Method B: Conversion to the Acid Chloride for Subsequent Acylation 
 To an oven-dried round bottom flask with stir bar under nitrogen were added the 
carboxylic acid, dry DCM, and 3Å molecular sieves. Oxalyl chloride (1.2 eq.) and a 
catalytic amount of DMF (1–2 mol %) were added and the reaction was stirred while 
attached to a bubbler (to monitor production of CO2) at 20 °C for 2–3 h. The amine HCl 
salt (1 eq.) in DCM and DIPEA (2 eq.) were added and the reaction was stirred under 
nitrogen for 3–6 h. The reaction was diluted with EtOAc and washed with half-saturated 
aqueous NaHCO3, 1M HCl (30 mL), brine, dried over Na2SO4, filtered, and concentrated 
under reduced pressure to give crude material.  
 
Method C: Acylation 
 To an oven-dried round bottom flask with stir bar and under nitrogen were added 
the acid chloride, dry DCM, and 3Å molecular sieves. The amine HCl salt (1 eq.) in 
DCM and DIPEA (2 eq.) were added and the reaction was stirred under nitrogen for 3–6 
h. The reaction was diluted with EtOAc and washed with half-saturated aq. NaHCO3, 1M 
HCl (30 mL), brine, dried over Na2SO4, filtered, and concentrated under reduced pressure 






Method D: Peptide Coupling using HATU 
 To a round bottom flask with stir bar under nitrogen was added the carboxylic 
acid and anhydrous DCM. The amine (1.2 eq.), HATU (1.2 eq.), and DIPEA (1.2 eq.) 
were added and the reaction was stirred under nitrogen. The reaction was diluted with 
DCM (75 mL) and washed with saturated NaHCO3, 1M HCl (30 mL), brine, dried over 
Na2SO4, filtered, and concentrated under reduced pressure to give crude material. 
 
Method E: Boc removal 
 To an 8 mL scintillation vial with stir bar and under nitrogen was added the boc-
protected amine, dry DCM, and a large excess of TFA. The reaction was allowed to stir 
at 20°C for 1–2 h. The reaction mixture was concentrated under reduced pressure (passed 
through a base trap) to give crude material that was suspended in EtOAc and washed with 
half-saturated aq. NaHCO3, and brine. The reaction was dried over Na2SO4, filtered, and 
concentrated under reduced pressure to give crude material that was carried onto the next 











8.9 Experimental procedures for the selected Parmodulins (specifically central 

















N-(3-aminophenyl)-2-bromobenzamide hydrochloride (4.3). To a round bottom flask 
with stir bar was added a solution of SnCl2•2H2O (6.15 g, 0.03 mol) in conc. HCl (5 mL).  
To this solution was added a solution of 2-bromo-N-(3-nitrophenyl)benzamide (4.2, 1.75 
g, 0.01 mol) in ethanol (50 mL), and the resulting suspension was stirred at 55 °C for 2 h.  
A sample aliquot was taken from the reaction, made basic with 2M aq. NaOH, filtered 
and the filtrate was concentrated under reduced pressure, dissolved in a minimal amount 
of HPLC grade MeCN, and analyzed with LCMS to confirm reaction completion. The 
reaction was cooled to 20 °C, made basic with 2 M aq. NaOH (until pH 9), then filtered. 
The filtrate was concentrated under reduced pressure to half volume and then extracted 
with DCM (150 mL). The organic layer was washed with brine, dried over Na2SO4, 
filtered, and concentrated under reduced pressure to give crude product. The crude 
material was dissolved in DCM and added to 0.9 M HCl in ether (20 mL), and stirred for 
5 min. at 20 °C to form a precipitate. The precipitate was filtered, washed with DCM, 
collected, and dried to give aniline HCl salt 4.3
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N-(3-aminophenyl)butanamide hydrochloride (4.28). A solution of nitroarene 4.27 
(5.95 g, 28.7 mmol) in MeOH (85 mL) was flushed with nitrogen for 5 min. To a 10 mL 
scintillation vial under nitrogen was suspended 10% Pd/C (0.95 g, 0.88 mmol) in 
MeOH/H2O (4:1) and the resultant suspension was added to the solution of 4. A balloon 





for 2 min. The reaction was left to stir under a full balloon of H2 for 16 h, after which an 
aliquot was taken from the reaction, filtered through Celite and cotton, and concentrated 
under reduced pressure. The aliquot was dissolved in a minimal amount of HPLC grade 
MeCN, and analyzed with LCMS to confirm reaction completion. The reaction was 
filtered through a funnel packed with Celite. The filter cake was washed with MeOH and 
the filtrate was concentrated under reduced pressure, to give crude material that was 
dissolved in DCM and added to 0.9 M HCl in ether (40 mL). The reaction was stirred for 
5 min. at 20 °C to give a precipitate that was filtered and washed with excess DCM. The 





2-Azido-N-(3-butyramidophenyl)benzamide (4.31).  
 Part 1: Diazotization. To a round bottom flask with stir bar was added 2-
aminobenzoic acid 4.29 (1.50 g, 10.9 mmol) and deionized H2O (100 mL). The reaction 
was cooled to 0 °C and conc. aq. HCl (5 mL) was added dropwise over 5 min. A solution 
of NaNO2 (0.75 g, (11 mmol) in H2O (1 mL) was added, and the reaction was stirred for 
10 min. at 2 °C. A solution of NaOAc (0.63 g, 11 mmol) in H2O (1 mL) and a solution of 





stirred for 30 min at 2 °C. A sample aliquot was taken from the reaction, diluted with 
TBME, extracted and the organic phase was separated,  concentrated under reduced 
pressure, dissolved in a minimal amount of HPLC grade MeCN, and analyzed with 
LCMS to confirm reaction completion. The reaction was extracted with TBME (100 mL) 
and the organic layer was washed with brine, dried over Na2SO4, filtered, and 
concentrated under reduced pressure to give 2-azidobenzoic acid 25 (1.5 g) as a yellow 
solid in 85% yield. TLC: mobile phase: ethyl acetate/hexanes/formic acid (25/25/1), Rf = 
0.4; 1H NMR (300 MHz, CDCl3) δ = 8.19 - 8.14 (m, 1 H), 7.67 - 7.59 (m, 1 H), 7.29 (dd, 
J = 2.0, 7.3 Hz, 2 H).  
 Part 2: Acylation. Crude azide analogue 4.31 was synthesized by acylation of 
aniline•HCl salt 4.28 with 2-azidobenzoic acid 4.30 according to general method B. The 
crude material was dissolved in a minimal amount of DCM, loaded onto a 25 g column, 
and purified with flash chromatography (EtOAc/hexanes, 0–80%) to give 4.31 (160 mg, 
80%) as a colorless oil. TLC: mobile phase: ethyl acetate/hexanes (50:50), Rf: 0.6; 
LC/MS tR = 5.01 min (characterization method A); m/z = 323.80 (M + H+) 368.00 (M + 
formate); 1H NMR (400 MHz, CDCl3) δ = 9.36 (br. s., 1 H), 8.26 - 8.19 (m, 1 H), 7.98 
(br. s., 1 H), 7.61 - 7.50 (m, 1 H), 7.41 (d, J = 7.6 Hz, 2 H), 7.36 - 7.23 (m, 5 H), 2.33 (t, J 
= 7.4 Hz, 2 H), 1.76 (sxt, J = 7.4 Hz, 2 H), 0.99 (t, J = 7.3 Hz, 3 H); 13C NMR (101 
MHz, CDCl3) δ = 162.7, 138.6, 138.4, 136.9, 132.1, 129.6, 125.4, 118.4, 115.6, 111.6, 









6-nitro-2-propyl-1H-benzimidazole (4.11). To an oven dried 50 mL round bottomed 
flask with stir bar and under N2 was added was added 4-nitrobenzene-1,2-diamine 4.10 
(0.29 g, 1.87 mmol), POCl3 (3 mL) and butyric acid (0.2 mL, 2.2 mmol). The flask was 
attached to a reflux condenser, sealed with a septum, and placed under positive pressure 
of N2, then the reaction was refluxed at 105 °C (oil bath temp.) for 3 h. A sample aliquot 
was taken from the reaction, made basic with 2N NH4OH solution, extracted with EtOAc 
and concentrated under reduced pressure, dissolved in a minimal amount of HPLC grade 
MeOH, and analyzed with LC-MS to confirm reaction completion.  The reaction was 
slowly cooled to room temperature, and then to 10 °C in an ice water bath. The reaction 
was made basic with dropwise addition of 2N NH4OH solution over 10 min. to pH 9. 
After that, the reaction was extracted with EtOAc (30 mL x 2), washed with brine, dried 
over Na2SO4, filtered and concentrated under reduced pressure to give the crude nitro-















































2-propyl-1H-benzimidazol-6-amine (4.12). To a 25 mL round bottom flask with stir bar 
and under N2 was added nitro-benzimidazole 4.11 (54.0 mg, 0.24 mmol) and MeOH (4 
mL). The flask was flushed well with nitrogen. Then, 10% Pd/C (5.4 mg, 0.0048 mmol, 2 
mol%, pre-wetted with 0.5 mL of H2O) was added to the reaction. 
The flask was sealed with rubber septum; the reaction was evacuated and back-filled with 
hydrogen 3-4 times from a large hydrogen gas balloon inserted via needle, while stirring 
vigorously. The reaction was stirred under a hydrogen balloon for 1 h, after which time 
the reaction was passed through a funnel packed with cotton and Celite. The filter cake 
was washed with MeOH, and the combined filtrate was concentrated under reduced 
pressure to give the crude aniline 4.12 (50.0 mg) as a brown solid, which was used in the 





2-bromo-N-(2-propyl-1H-benzimidazol-6-yl)benzamide (4.13). Benzimidazole 4.13 
was synthesized from acylation of aniline 4.12 (50.0 mg, 0.29 mmol) and 2-
bromobenzoyl chloride (37 µL, 0.29 mmol) according to general method C. The crude 
material was wet loaded using DCM onto a 10 g silica gel column and purified by flash 

















44%). LC-MS tR = 4.47 min (Characterization Method A); m/z = 348.70 (M + H); 1H 
NMR (400 MHz ,DMSO-d6) δ = 8.11 - 7.89 (m, 1 H), 7.70 (dd, J = 0.8, 8.0 Hz, 1 H), 
7.54 (dd, J = 1.7, 5.8 Hz, 1 H), 7.51 - 7.34 (m, 3 H), 7.30 - 7.18 (m, 1 H), 2.80 - 2.67 (m, 
2 H), 1.76 (sxt, J = 7.4 Hz, 2 H), 0.92 (t, J = 7.4 Hz, 3 H); 13C NMR (75 MHz ,DMSO-






6-nitro-1H-indazole (4.15). To a 250 mL round bottom flask with stir bar was added 2-
methyl-5-nitro-aniline 4.14 (1.01 g, 6.64 mmol) and glacial acetic acid (150 mL). The 
reaction was cooled to 0 °C (ice bath temp.) and then a pre-cooled solution of NaNO2 
(490 mg, 7.102 mmol) in 2.5 mL of water was added dropwise at 0⁰C via a separatory 
funnel over 5 min., then the reaction was warmed to room temperature and stirred for 3 
days. The reaction was concentrated under reduced pressure (with base trap attached to 
rotary evaporator), to give crude material that was suspended in EtOAc (50 mL), passed 
through a silica plug, and concentrated again under reduced pressure. The crude was wet 
















































loaded in minimal DCM onto a 100 g silica gel column and purified by flash 
chromatography (0-100% EtOAc:hexanes) to yield nitro-indazole 4.15 (940 mg, 87%). 
1H NMR (300 MHz, DMSO-d6) d = 8.44 (s, 4 H), 8.31 (s, 1 H), 8.03 - 7.97 (m, 1 H), 
7.95 - 7.89 (m, 1 H). 
 
 
1-butyl-6-nitro-1H-indazole (4.16) and 2-butyl-6-nitro-2H-indazole (4.17). To an 
oven dried 15 mL round bottom flask with stir bar was added nitro-indazole 4.15 (0.10 g, 
0.61 mmol), 3A⁰ molecular sieves (0.5 g), dry DMF (3 mL) and freshly powdered K2CO3 
(0.17 g, 1.23 mmol). The reaction was stirred vigorously at room temperature for 1.5 h, 
after which time 1-bromobutane (66 µL, 0.61 mmol) was added. The flask was sealed 
with a rubber septum and the reaction was heated to 60 °C (oil bath temp.) for 25 h. A 
sample aliquot was taken from the reaction, diluted with water, extracted with EtOAc, 
concentrated under reduced pressure, re-dissolved in HPLC grade MeOH, and analyzed 
by LC-MS to confirm reaction completion. The reaction was then cooled to room 
temperature, diluted with water (30 mL) and extracted with 30:10 EtOAc:MTBE (30 mL 
x 2). The combined organics were washed with brine, dried over Na2SO4, filtered and 
concentrated under reduced pressure to give a yellow crude that was wet loaded with 
minimal DCM onto a 10 g silica gel column and purified by flash chromatography 
(EtOAc:hexanes, 0 – 60%) to yield 37% (75 mg) of 4.16 and 37% (75 mg) of 4.17. 













13C NMR, and only 1H NMR was taken for isomer 4.17. Characterization of 4.16: 
1
H 
NMR (400 MHz ,CDCl3) δ = 8.36 (m, 1 H), 8.08 (d, J = 1.0 Hz, 1 H), 7.96 (dd, J = 1.9, 
8.9 Hz, 1 H), 7.79 (dd, J = 0.6, 8.9 Hz, 1 H), 4.44 (t, J = 7.1 Hz, 2 H), 1.96 - 1.87 (m, 2 
H), 1.32 (sxt, J = 7.5, 15.1 Hz, 2 H), 0.92 (t, J = 7.4 Hz, 3 H). 
13
C NMR (101MHz, 
CDCl3) δ = 146.3, 138.1, 133.1, 126.9, 121.8, 115.2, 105.8, 49.3, 31.9, 20.0, 13.6. 
 
 
2-butyl-2H-indazol-6-amine (4.18A). To a 25 mL round bottom flask with stir bar was 
added nitro-indazole 4.17 (70 mg, 0.32 mmol), the flask was sealed with septum under  
N2 and MeOH (6 mL). The flask was flushed well with nitrogen. Then, 10% Pd/C (34 
mg, 0.032 mmol, 10 mol%, pre-wetted with 1 mL of H2O) was added to the reaction. The 
flask was sealed with a septum and evacuated and back-filled with hydrogen 4 times from 
a large hydrogen gas balloon inserted via needle, while stirring vigorously. The reaction 
was stirred under the hydrogen balloon for 4 h, after which time, the reaction was passed 
through a funnel packed with cotton and Celite. The filter cake was washed with MeOH, 
and the filtrate was concentrated to give brown colored crude aniline 4.18A (50.0 mg). 
Aniline 20 was wet loaded with minimal DCM onto a 10 g silica gel column and purified 
by flash chromatography (EtOAc:hexanes, 10 – 100%) to give 4.18A (40 mg, 60%) with 










1-butyl-1H-indazol-6-amine (4.19B). Aniline 4.19B(40 mg, 66%) was synthesized from 
nitro-indazole 4.17 using same protocol for 4.19.  
 
 
2-bromo-N-(2-butyl-2H-indazol-6-yl)benzamide (4.19A). Amide 4.19A was 
synthesized by coupling of aniline 4.18A (25 mg, 0.13 mmol) with 2-bromobenzoyl 
chloride (19 µL, 0.15 mmol) according to general method C. The crude material was wet 
loaded with minimal DCM onto a 10 g silica gel column and purified by flash 
chromatography (EtOAc:hexanes, 0–60%) to give 4.19A as a colorless oil (40 mg, 49%). 
1H NMR (300 MHz ,DMSO-d6) δ = 10.46 (s, 1 H), 8.29 (s, 1 H), 8.15 (s, 1 H), 7.71 (d, J 
= 7.2 Hz, 1 H), 7.63 (d, J = 8.9 Hz, 1 H), 7.59 - 7.53 (m, 1 H), 7.52 - 7.37 (m, 2 H), 7.20 
(dd, J = 1.5, 9.0 Hz, 1 H), 4.36 (t, J = 6.9 Hz, 2 H), 1.93 - 1.79 (m, 2 H), 1.29 - 1.14 (m, 2 
H), 0.87 (t, J = 7.1 Hz, 3 H). 13C NMR (75 MHz, DMSO-d6) δ = 166.6, 148.7, 140.0, 




















2-bromo-N-(1-butyl-1H-indazol-6-yl)benzamide (4.19B). Amide 4.19B was 
synthesized by coupling of aniline 4.18B (25 mg, 0.13 mmol) with 2-bromobenzoyl 
chloride (19 µL, 0.14 mmol) according to general method C. The crude material was wet 
loaded with minimal DCM onto a 10 g silica gel column and purified by flash 
chromatography (MeOH:DCM, 0–10%) to give 4.19B as a white solid (40 mg, 81%). 1H 
NMR (400 MHz ,CD3CO) δ = 9.77 (br s, 1 H), 8.41 (br s, 1 H), 7.95 (apparent d, J = 1.0 
Hz, 1 H), 7.75 - 7.65 (m, 2 H), 7.60 (dd, J = 1.7, 7.5 Hz, 1 H), 7.47 (dt, J = 1.1, 7.5 Hz, 1 
H), 7.42 - 7.36 (m, 1 H), 7.33 (dd, J = 1.7, 8.7 Hz, 1 H), 4.39 (t, J = 7.0 Hz, 2 H), 1.94 - 
1.85 (m, 2 H), 1.33 (sxt, J = 7.5 Hz, 2 H), 0.93 (t, J = 7.4 Hz, 3 H). 13C NMR (101 MHz 
,CD3CO) δ = 166.0, 139.8, 139.3, 137.4, 133.0, 132.3, 131.2, 129.0, 127.6, 121.2, 120.9, 















N-(2-hydroxy-5-nitrophenyl)butanamide (4.21). To an oven dried 50 mL round bottom 
flask with stir bar was added 2-amino-4-nitro-phenol (0.75 g, 4.8 mmol) and dry THF (10 
mL). The flask was sealed with septum and flushed well with N2. The reaction was 
cooled to 5 °C, and pyridine (0.47 mL, 5.8 mmol) was added followed by dropwise 
addition of butanoyl chloride (0.6 mL, 5.3 mmol) via 1 mL syringe over 5 min. The 
reaction was warmed to room temperature, the flask was connected to a reflux condenser, 
and the reaction was refluxed for 68 h under a positive pressure of N2. A sample aliquot 
was taken from the reaction, washed with 1 M HCl, extracted with EtOAc, concentrated 
































































confirm reaction completion. The reaction was cooled to room temperature, diluted with 
EtOAc (50 mL), washed with 1 M aqueous HCl (50 mL x 2) and brine, then dried over 
Na2SO4, filtered, and concentrated under reduced pressure to give a brown colored crude. 
The crude was wet loaded with minimal DCM onto a 10 g silica gel column and purified 
by flash chromatography (EtOAc:hexanes, 0 – 60%) to yield amide 4.21 (0.79 g, 72%). 
1H NMR (300 MHz , CD3CO) δ = 9.10 (br. s., 1 H), 8.85 (d, J = 2.7 Hz, 1 H), 7.92 (dd, J 
= 2.8, 8.9 Hz, 1 H), 7.06 (d, J = 8.9 Hz, 1 H), 2.54 (t, J = 7.3 Hz, 2 H), 1.74 (sxt, J = 7.4 
Hz, 2 H), 0.98 (t, J = 7.4 Hz, 14 H). 13C NMR (75 MHz, CD3CO) δ = 173.3, 153.4, 
140.7, 127.5, 120.8, 116.8, 116.3, 38.5, 18.9, 13.3 
 
 
2-(butanoylamino)-4-nitrophenyl trifluoromethanesulfonate (4.22). To an oven dried 
250 mL round bottom flask with stir bar was added sodium hydride (60%, 0.18 g, 4.6 
mmol), the flask was sealed with septum, flushed under N2 and dry MeCN (20 mL). The 
reaction was cooled to 5 °C, and a suspension of phenol 4.21 (0.75 g, 3.34 mmol) in dry 
MeCN (70 mL) was added slowly. After 30 min., triflic anhydride (0.67 mL, 4.01 mmol) 
was added dropwise over 2 min. using a 1 mL syringe. The reaction was stirred for 6 h at 
5 °C, and then warmed to room temperature and stirred for another 16 h. The reaction 
was quenched with water (20 mL), and solvent volume was reduced under pressure. The 
reaction was diluted with water (30 mL) and extracted with EtOAc (2 x 30 mL). The 










dried over Na2SO4, filtered, and concentrated under reduced pressure. The crude was wet 
loaded with minimal DCM onto a 100 g silica gel column and purified by flash 
chromatography (EtOAc:hexanes, 0 – 80%) to yield of triflate 4.22 as a yellow solid 
(0.55 g, 46%). 1H NMR (300 MHz, CDCl3) δ =  8.04 (dd, J = 2.8, 9.1 Hz, 1 H), 7.72 (s, 1 
H), 7.49 (d, J = 9.1 Hz, 1 H), 2.47 (t, J = 7.4 Hz, 2 H), 1.88 - 1.71 (m, 2 H), 1.03 (t, J = 
7.4 Hz, 3 H).  
 
 
N-[5-nitro-2-(pent-1-yn-1-yl)phenyl]butanamide (4.23). To an oven dried 250 mL 
round bottom flask with stir bar and under N2 was added triflate 4.22 (0.51 g, 1.43 mmol) 
and dry  MeCN (10 mL). The flask was sealed under N2. Pd(PPh3)4 (165 mg, 0.143 
mmol), tetrabutylammonium;iodide (793.14 mg, 2.147 mmol) and iodocopper (90 mg, 
0.47 mmol) were added, respectively. The flask was immediately sealed with rubber 
septum and flushed well with N2 over 2 min, and then TEA (2 mL) and pent-1-yne (0.1 g, 
1.43 mmol), were added respectively. The reaction was stirred at room temperature for 2 
h. A sample aliquot was taken from the reaction, quenched with half saturated NH4Cl 
solution, extracted with EtOAc, cocncntrated, dissolved in HPLC MeOH grade, and 
analyzed to LC-MS to confirm reaction completion. The reaction was quenched with half 
saturated NH4Cl solution (25 mL) and then extracted with EtOAc (2 X 30 mL). The 









concentrated under reduced pressure. The crude was wet loaded with minimal DCM to 25 
g silica gel column and purified by flash chromatography (EtOAc:Hexane, 0 – 80%) to 
yield 70% (0.28 g) of alkyne 4.24 as an yellow solid. 1H NMR (300 MHz, CDCl3) δ = 
9.29 - 9.22 (m, 1 H), 8.03 (br. s., 1 H), 7.85 - 7.76 (m, 1 H), 7.47 - 7.39 (m, 1 H), 2.56 - 
2.46 (m, 2 H), 2.46 - 2.35 (m, 2 H), 1.83 - 1.61 (m, 4 H), 1.11 - 0.95 (m, 6 H).  
 
 
6-nitro-2-propyl-1H-indole (4.24). To an oven dried 20 mL scintillation vial with stir 
bar and under N2 was added alkyne 4.23 (0.28 g, 1.01 mmol), t-BuOK (0.15 g, 1.38 
mmol) and NMP (2.3 mL). The vial was flushed well with N2 and the reaction was heated 
at 70 °C for 24 h. The reaction was cooled to room temperature, added 1 equivalent of t-
BuOK (0.15 g, 1.38 mmol) and the reaction was heated again at 70 °C for 5 h. The 
reaction was then cooled again to room temperature, quenched with water (10 mL), and 
stirred for 10 min. The reaction was diluted with water (30 mL), extracted with EtOAc 
(50 mL), washed with brine, dried over Na2SO4, filtered, and concentrated. The crude 
was wet loaded with minimal DCM to a 25 g silica gel column and purified by flash 
chromatography (EtOAc:hexanea, 0 – 80%) to yield nitroindole 4.24 (0.082 g, 40%) as a 
yellow solid. 1H NMR (300 MHz, CDCl3) δ =  9.04 (br s, 1 H), 8.35 (s, 1 H), 7.99 (dd, J 
= 1.9, 8.8 Hz, 1 H), 7.51 (d, J = 8.8 Hz, 1 H), 6.35 (s, 1 H), 2.80 (t, J = 7.5 Hz, 2 H), 1.79 











2-propyl-1H-indol-6-amine (4.25). To a 50 mL round bottom flask with stir bar and 
under N2 was added nitroindole 4.24 (82 mg, 0.37 mmol) and MeOH (3 mL). The flask 
was flushed well with nitrogen. Then, 10% Pd/C (5.4 mg, 0.0048 mmol, 2 mol%, pre-
wetted with 1 mL of H2O) was added to the reaction. The flask was sealed with a septum 
and evacuated and back-filled with hydrogen 4 times from a hydrogen gas balloon 
inserted via needle, while stirring vigorously. The reaction was stirred under a hydrogen 
balloon for 3 h. The mixture was filtered through a funnel packed with cotton and Celite 
and washed with MeOH, and the filtrate was concentrated to give brown colored crude 




2-bromo-N-(2-propyl-1H-indol-6-yl)benzamide (4.26). Analogue 4.26 was synthesized 
by coupling of aniline 4.25 (70 mg, 0.4 mmol) with 2-bromobenzoyl chloride (52 µL, 0.4 
mmol) according to general method C. The crude material was wet loaded with minimal 
DCM onto a 10 g silica gel column and purified by flash chromatography 
(EtOAc:hexanes, 0 – 80%) to give 4.26 as a pale yellow solid (20 mg, 20%). 1H NMR 















H), 7.45 - 7.41 (m, 1 H), 7.41 - 7.35 (m, 1 H), 7.33 - 7.26 (m, 1 H), 6.87 (dd, J = 1.9, 8.3 
Hz, 1 H), 6.18 - 6.13 (m, 1 H), 2.58 (t, J = 7.6 Hz, 2 H), 1.63 (sxt, J = 7.4 Hz, 2 H), 0.90 
(t, J = 7.5 Hz, 3 H);  13C NMR (101 MHz ,CD3CO) δ = 165.7, 140.5, 140.1, 136.7, 







8.10 Characterisation data for the selected Parmodulins (specifically central 
































































































































































































































































































































































































































































dicarbamate (6.13). To a round bottom flask with stir bar under nitrogen was added 





(0.15 mL, 1.4 mmol), HOBt (229 mg, 1.50 mmol), and EDC•HCl (433 mg, 2.26 mmol) 
were added and the reaction was stirred under nitrogen for 2 h. A sample aliquot was 
taken from the reaction, concentrated under reduced pressure, dissolved in a minimal 
amount of HPLC grade MeCN, and analyzed with LCMS to confirm reaction completion. 
The reaction was diluted with DCM (75 mL) and washed with saturated NaHCO3 (30 
mL), 1M HCl (30 mL), brine, dried over MgSO4, filtered, and concentrated under 
reduced pressure to give 6.13 (588 mg) as a white solid in 98% yield. mp = 154–156 °C; 
LC/MS tR = 6.09 min (Characterization Method A); m/z = 530.05 (M + H+); 1H NMR 
(300 MHz, CDCl3) δ = 7.76 (d, J = 7.6 Hz, 2 H), 7.61 - 7.49 (overlapping signals, 3 H), 
7.43 - 7.22 (m, 9 H), 5.96 (d, J = 6.7 Hz, 1 H), 5.11 (br. m., 1 H), 4.50 - 4.13 (overlapping 
m, 6 H), 3.48 - 3.32 (br. s., 1 H), 3.04 - 2.90 (br. m., 1 H), 1.97 - 1.71 (overlapping 
signals, 2 H), 1.45 - 1.37 (m, 9 H); 13C NMR (75 MHz, CDCl3) δ = 171.2, 157.2, 156.3, 
143.9, 141.5, 138.0, 128.8, 127.9, 127.8, 127.6, 127.3, 125.3, 120.2, 80.1, 67.2, 52.2, 










 Part 1: Fmoc removal. Dicarbamate 6.13 (550 mg, 1.03 mmol) was added to a 
round bottom flask with stir bar and sealed under nitrogen, then MeCN (25 mL), DCM 
(10 mL), and piperidine (0.220 mL, 2.22 mmol) were added. The reaction was stirred for 
2 h. A sample aliquot was taken from the reaction, concentrated under reduced pressure, 
dissolved in a minimal amount of HPLC grade MeCN, and analyzed with LCMS to 
confirm reaction completion. The reaction was concentrated under reduced pressure and 
then re-dissolved in (CHCl3/EtOAc, 1:1, 75 mL), washed with H2O (2 x 20 mL) and 
brine (20 mL). The organic phase was dried over MgSO4, filtered, and concentrated 
under reduced pressure to give crude material (496 mg) as a white solid that was carried 
onto the next reaction without further purification.  
 Part 2: Coupling. To a round bottom flask with stir bar already containing crude 
material from Part 1 (496 mg crude material, max. yield is 319 mg) was added anhydrous 
MeCN (30 mL) and anhydrous DCM (15 mL). (S)-2-((((9H-Fluoren-9-
yl)methoxy)carbonyl)amino)-3-(3,4-difluorophenyl)propanoic acid (300 mg, 0.709 
mmol), HOBt (191 mg, 1.41 mmol), and EDC•HCl (272 mg, 1.41 mmol) were added, 
and the resulting white suspension was stirred for 2 h. A sample aliquot was taken from 
the reaction, concentrated under reduced pressure, dissolved in a minimal amount of 
HPLC grade MeCN, and analyzed with LCMS to confirm reaction completion. The 
reaction was concentrated under reduced pressure, re-suspended in EtOAc (100 mL), and 
washed with H2O (20 mL), 0.5 M HCl (20 mL), saturated NaHCO3 (20 mL), and brine. 
The organic phase was dried over MgSO4, filtered, and concentrated under reduced 
pressure to give crude material (yellow oil) that was dry loaded using silica onto a 5 g 





give 3 (368 mg, 49%) as a white solid over 6.15 steps. m.p. = 183–185 °C; LC/MS tR = 
6.43 min (Characterization Method A); m/z = 713.15 (M + H+), m/z = 757.35 (formic 
acid adduct);  1H NMR (300 MHz, DMSO-d6) δ = 8.43 (dd, J = 5.0, 5.9 Hz, 1 H), 8.22 
(d, J = 7.9 Hz, 1 H), 7.86 (d, J = 7.6 Hz, 2 H), 7.68 - 7.53 (m, 2 H), 7.52 - 7.43 (br. s., 1 
H), 7.43 - 7.07 (m, 11 H), 6.74 (br. s., 1 H), 4.28 (br. d, J = 5.6 Hz, 4 H), 4.15 (br. s, 3 H), 
3.05 - 2.85 (overlapping br. s, 3 H), 2.73 (app. t, J = 12.0 Hz, 1 H), 1.86 - 1.73 (m, 1 H), 
1.73 – 1.58 (m, 1H), 1.34 (s, 9 H); 13C NMR (75 MHz, DMSO-d6) δ = 171.8, 171.7, 
156.4, 156.1, 150.8 (dd, J = 45.2, 13 Hz), 147.6 (dd, J = 45.8, 12.1 Hz), 144.4, 144.3, 
141.35, 141.33, 139.8, 136.6, 128.9, 128.2, 127.7, 127.6, 127.4, 126.7, 125.9, 120.7, 




4-oxobutyl)carbamate (6.16). Carbamate 6.15 (250 mg, 0.351 mmol) was added to a 
round bottom flask with stir bar and sealed under nitrogen, then anhydrous MeCN (30 
mL) and piperidine (2 mL) were added and the reaction was stirred for 90 min. A sample 
aliquot was taken from the reaction, concentrated under reduced pressure, dissolved in a 





completion. The reaction was concentrated under reduced pressure to give crude material 
(light yellow solid) that was triturated with 75/25 hexanes/ether. The material was then 
dry loaded using silica onto a 10 g silica gel column and purified with flash 
chromatography (IPA/DCM, 0 to 20%) to give 6.16 (86 mg) as a white solid in 50% 
yield. mp = 216–219 °C; LC/MS tR = 3.15 min (Characterization Method A); m/z = 
491.35 (M + H+), m/z = 489.30 (M - H+), 535.30 (formic acid adduct); 1H NMR (300 
MHz, CDCl3) δ = 8.06 (d, J = 7.9 Hz, 1 H), 7.72 (br. t, J = 5.0 Hz, 1 H), 7.37 - 7.20 (m, 5 
H), 7.14 - 6.95 (m, 2 H), 6.94 - 6.83 (br. m, 1 H), 5.37 (app. t. J = 5.3, 6.2 Hz, 1 H), 4.56 - 
4.47 (m, 1 H), 4.47 - 4.35 (m, 2 H), 3.53 - 3.42 (m, 1 H), 3.39 - 3.25 (br. m, 1 H), 3.09 
(dd, J = 3.8, 9.7 Hz, 1 H), 3.02 - 2.89 (br. m, 1 H), 2.66 (dd, J = 4.7, 9.1 Hz, 1 H), 2.00 - 
1.85 (br. m, 1 H), 1.84 - 1.67 (br. m, 1 H), 1.54 (br. m., 2 H), 1.43 (s, 9 H); 13C NMR (75 
MHz, CDCl3) δ = 174.4, 171.2, 156.9, 151.6 (dd, J = 53.5, 12.7 Hz), 148.4 (dd, J = 52.1, 
12.4 Hz), 138.1, 134.8 (dd, J = 5.3, 3.9 Hz), 128.8, 127.9 (partially obs.) 127.8, 127.6, 




6-Nitro-1H-indazole-3-carbaldehyde (6.18). To a 500 mL round bottomed flask with 
stir bar was added NaNO2 (6.38 g, 92.5 mmol) and H2O (150 mL). 6-Nitro-1H-indole 





mixture was stirred vigorously until evenly suspended (over 5 min.). To this bright 
yellow suspension was added 6 M HCl (14 mL) via addition funnel over 30 min. at 20 
°C, and the resultant suspension was stirred for 90 min. A sample aliquot was taken from 
the reaction, filtered, and the precipitate was dissolved in a minimal amount of HPLC 
grade MeCN. Analysis with LCMS confirmed reaction completion. The product was 
vacuum filtered and the precipitate was washed with additional H2O (50 mL). The 
precipitate was dried to give 6.18 (1.37 g) as an orange solid in 77% yield. m.p.: changed 
color from orange to brown between 120 and 160 °C, decomposed after 200 °C; LC/MS 
tR = 2.40 min (Characterization Method A); m/z = 190.05 (M - H+); 1H NMR (400 
MHz, DMSO-d6) δ = 10.22 (s, 1 H), 8.57 (d, J = 1.5 Hz, 1 H), 8.29 (dd, J = 0.5, 8.9 Hz, 1 
H), 8.13 (dd, J = 2.0, 8.9 Hz, 1 H); 13C NMR (100 MHz, DMSO-d6) δ = 187.7, 146.9, 
124.0, 122.4, 118.7, 108.6. 
 
 
6-Nitro-3-(pyrrolidin-1-ylmethyl)-1H-indazole (6.19). Aldehyde 6.18 (1.3 g, 6.80 
mmol) was added to a round bottom flask with stir bar and sealed under nitrogen. A pre-
mixed solution of anhydrous DCE:DMF:AcOH (300:30:0.3 mL), and pyrrolidine (2.8 
mL, 34.01 mmol) was then added. The resulting yellow suspension became a reddish 
brown solution immediately after the addition of pyrrolidine, and the reaction was stirred 





at 5 min. intervals, and the resultant suspension was stirred at 20°C for 4 h. A sample 
aliquot was taken from the reaction, diluted with DCM, and washed with half saturated 
Na2CO3.  The organic layer was separated, concentrated under reduced pressure, 
dissolved in a minimal amount of HPLC grade MeCN, and analyzed with LCMS to 
confirm reaction completion. The reaction was diluted with DCM (100 mL), washed with 
aqueous NaHCO3 solution (100 mL), brine, dried over Na2SO4, vacuum filtered, and 
concentrated under reduced pressure to give 2.2 g of dark brown solid. The crude 
material was dissolved in minimal DCM and loaded onto a 50 g SiO2 column and 
purified by flash chromatography (1N NH3 in MeOH/DCM, 0–18%) to give 6.19 (1.09 
g) as an orange brown shiny solid in 65% yield. mp = 37–40°C; LC/MS tR = 0.91 min 
(Characterization Method A); m/z = 247.05 (M + H+);  m/z= 245.15 (M - H+); 1H NMR 
(400 MHz , CD3OD) δ = 8.44 (d, J = 1.5 Hz, 1 H), 8.05 (d, J = 8.8 Hz, 1 H), 7.99 (dd, J = 
2.0, 7.0 Hz, 1 H), 4.16 (s, 2 H), 2.78 - 2.71 (m, 4 H), 1.84 (spt, J = 3.3 Hz, 4 H); 13C 




1-(2,6-Dichlorobenzyl)-6-nitro-3-(pyrrolidin-1-ylmethyl)-1H-indazole (6.20). Amine 
6.19 (1.06 g, 4.30 mmol) and 2-(bromomethyl)-1,3-dichlorobenzene (1.03 g, 4.30 mmol) 





THF (50 mL) was added, followed by Cs2CO3 (1.4 g, 4.30 mmol) added in 3 portions (1 
portion every 5 min.), and the flask was flushed with nitrogen. The resultant orange 
solution was stirred for 16 h at 20 °C. A sample aliquot was taken from the reaction, 
diluted with EtOAc, and washed with H2O. The organic phase was separated, 
concentrated under reduced pressure, dissolved in CDCl3 and analyzed with NMR to 
confirm reaction completion. The reaction was diluted with EtOAc (200 mL), washed 
with H2O (200 mL) and brine, dried over Na2SO4, vacuum filtered, and concentrated 
under reduced pressure. The brown crude (1.5 g) was dissolved in minimal DCM and 
loaded onto a 50 g column and purified with flash chromatography (MeOH/DCM, 0-
18%) to give 6.20 (1.33 g) as an orange brown shiny solid (containing ~10% 
dibenzylated side-product) in 76% yield. 8 was carried forward to the next step without 
additional purification. LC/MS tR = 3.15 min (Characterization Method A); m/z = 404.80 
(M + H
+
); for dibenzylated impurity LC/MS tR = 3.63 min (Characterization Method A); 





1-(2,6-Dichlorobenzyl)-3-(pyrrolidin-1-ylmethyl)-1H-indazol-6-amine (6.21). To an 
oven dried pressure tube with stir bar was added indazole 6.20 (18 mg, 0.044 mmol) and 
MeOH (5 mL). FeCl3•6H2O (25 mol%, 2.6 mg), hydrazine monohydrate solution (65% 





tube was capped tightly, and the reaction was stirred at 100 °C for 2 h. A sample aliquot 
was taken from the reaction, concentrated under reduced pressure, dissolved in a minimal 
amount of HPLC grade MeCN, and analyzed with LCMS to confirm reaction 
completion. The reaction was filtered, the charcoal and filtered solids were washed with 
MeOH (10 mL), and the filtrate was concentrated under reduced pressure to give crude 
material that was dry loaded using silica onto a 5 g silica column and purified with flash 
chromatography (0 to 20% MeOH/DCM) to give 6.21 (11.5 mg) as a white solid in 69% 





NMR (300 MHz, CDCl3) δ = 7.57 (d, J = 8.5 Hz, 1 H), 7.37 (d, J = 8.2 Hz, 2 H), 7.31 - 
7.20 (s, 1 H), 6.63 (d, J = 8.8 Hz, 1 H), 6.58 (s, 1 H), 5.63 (s, 2 H), 4.29 (s, 2 H), 3.96 (br. 
s., 2 H), 3.13 (br. s., 4 H), 1.84 (br. s., 4 H); 
13
C NMR (75 MHz, CDCl3) δ = 146.5, 142.5, 






 Part 1: Coupling reaction. Aniline 6.21 (40 mg, 0.11 mmol) was added to an 





mL) was added. The solution was cooled in a NaCl/H2O bath (–5 °C) for 15 min., and 
then both DMAP (34.6 mg, 0.282 mmol) and triphosgene (12 mg, 0.04 mmol) were 
added consecutively. Immediately the reaction became a light orange suspension. The 
reaction was stirred at –5°C for 8 min., and then amine 6.16 (35 mg, 0.071 mmol) was 
added and the reaction was stirred at –5°C for 1 h, then for an additional 1 h while 
warming to room temperature. A sample aliquot was taken from the reaction, 
concentrated under reduced pressure, dissolved in a minimal amount of HPLC grade 
MeCN, and analyzed with LCMS to confirm reaction completion.  The reaction was 
concentrated under reduced pressure to give crude material 6.22 that could be either 
carried onto the next reaction without purification, or triturated with DCM/hexanes (1:1) 
to provide purer material. 
 Part 2: Boc removal. The round bottom flask already containing either the crude 
or triturated material 6.22 was cooled in a NaCl/H2O bath for 10 min (–5°C), and then 
HCl in dioxane (4 M, 3 mL) was slowly added. The reaction immediately became a 
heterogeneous dark red mixture and was stirred for 40 min. at –5° C. A sample aliquot 
was taken from the reaction, concentrated under reduced pressure, dissolved in a minimal 
amount of HPLC grade MeCN, and analyzed with LCMS to confirm reaction 
completion.  The reaction was concentrated under reduced pressure to give a red-orange 
solid that was free-based with 0.075 N NH3 in MeOH and concentrated under reduced 
pressure.  The crude product was dissolved in a minimal amount of DCM, loaded onto a 
10 g normal phase silica column, and purified with flash chromatography (0–18% (0.75 
N NH3 in MeOH)/DCM,) to give amine 6.23 (free base) as a light pink oily solid. The 





lyophilizing overnight to give bis HCl salt as a light pink solid. LCMS Data tR = 
(Characterization Method A); m/z = 396.65 [(M/2) + H
+
], 835.30 (M - H
+
, formic acid 
adduct); 
1
H NMR (400 MHz, CD3OD, free base) δ =  7.98 (s, 1 H), 7.75 (d, J = 8.7 Hz, 1 
H), 7.45 - 7.38 (m, 2 H), 7.37 - 7.05 (m, 10 H), 5.56 (br. s., 2 H), 4.64 (s, 2 H), 4.60 - 
4.48 (m, 2 H), 4.40 (d, J = 4.5 Hz, 2 H), 3.57 - 3.45 (m, 2 H), 3.29 - 3.12 (m, 3 H), 3.12 - 
2.93 (m, 3 H), 2.35 - 2.20 (m, 1 H), 2.15 - 1.85 (m, 5 H); 
13
C NMR (75 MHz, CD3OD, 
free base) δ =  173.3, 171.0, 156.2, 141.7, 139.0, 138.2, 136.6, 135.1, 134.3, 131.4, 
130.3, 128.3, 128.1, 126.9, 126.7, 125.6, 119.7, 118.3, 118.1, 117.8, 117.0, 116.7, 115.2, 
97.4, 55.6, 53.5, 51.0, 48.8, 42.6, 36.8, 36.6, 29.5, 22.6. Alternatively, the crude product 
could be dissolved in DMSO and purified in batches with preparative HPLC (method A). 
Pooled fractions were concentrated under reduced pressure in lukewarm water (to remove 
MeCN) and lyophilized overnight to give 6.23b (36.3 mg) as a light pink oil in 58% yield 















 Note: If using 6.23b, it is necessary to convert this compound to the bis HCl salt 
(6.23a) prior to performing this EDC coupling reaction as it has been seen that the 
formate salt will give a mixture of products. To a 5 mL scintillation vial with stir bar was 
added 6.23b (5.5 mg, 6.4 μmol).  The vial was purged with N2 for 5 min and then dry 
dioxane (0.5 mL) and 4 M HCl in dioxane (0.3 mL, 172 eq.) was added. The reaction was 
stirred for 5 min, concentrated under reduced pressure, and then lyophilized to give the 
bis HCl salt (6.23a). The vial containing 6.23a was purged with nitrogen and then 
dissolved in dry DMF (0.5 mL). 4-Pentynoic acid (1 mg, 10 µmol), HOBt (1.2 mg, 8.9 
µmol), EDC•HCl (3 mg, 12 µmol), and DIPEA (9.6 μL, 55 µmol) were added 
consecutively and the reaction was stirred for 5 h under N2. A sample aliquot was taken 
from the reaction, concentrated under reduced pressure, dissolved in a minimal amount of 





reaction was diluted with EtOAc (5 mL) and washed with saturated NaHCO3 (5 mL) and 
brine (5 mL).  The organic layer was dried over MgSO4, filtered, and concentrated under 
reduced pressure to give crude material that was dissolved in DMSO and purified with 
preparative HPLC (method A) to give 6.24 (2.4 mg) as a colorless oily residue in 43%. 
1
H NMR (600 MHz, CD3OD) δ = 8.54 (br. s, 1 H, formate CHO), 7.94 (d, J = 1.2 Hz, 1 
H), 7.67 (d, J = 8.8 Hz, 1 H), 7.44 (s, 1 H), 7.42 (s, 1 H), 7.33 (dd, J = 1.2, 7.6 Hz, 1 H), 
7.28 - 7.11 (m, 7 H), 7.09 - 7.05 (br. m, 1 H), 6.99 (dd, J = 1.8, 7.0 Hz, 1 H), 5.61 (dd, J = 
14.1, 2.3 Hz, 2 H), 4.55 (dd, J = 2.9, 5.3 Hz, 1 H), 4.44 - 4.41 (m, 1 H), 4.39 (s, 2 H), 
4.37 - 4.34 (br. m, 2 H), 3.58 (dd, J = 4.7, 6.5 Hz, 1 H), 3.51 (dd, J = 4.7, 6.5 Hz, 1 H), 
3.20 - 3.13 (m, 2 H), 3.12 - 3.04 (br. s, 3 H), 2.99 (dd, J = 5.9, 8.2 Hz, 1 H), 2.41 - 2.37 
(m, 2 H), 2.34 - 2.29 (m, 2 H), 2.21 - 2.20 (m, 1 H), 2.07 - 1.98 (m, 2 H), 1.93 - 1.86 (m, 
4 H). LC/MS tR = 3.46 min (Characterization Method A); m/z = 871.15 (M + H
+
), m/z = 
915.30 (M - H
+
, formic acid adduct). HRMS (ESI-TOF) calcd. for C45H47Cl2F2N8O4 (M + 
H
+














 To a 5 mL vial with stir bar was added 6.24 (1.7 mg, 2.0 µmol) and 6.30c (2.0 mg, 2.2 
µmol).  In a second 5 mL vial was added sodium ascorbate (1.2 mg, 6.1 µmol), TBTA (1.0 mg, 
1.9 µmol), and CuSO4 (50 mol%, 49 µL of a 0.02 M solution in H2O).  This suspension was 
diluted with DMSO (0.2 mL) and nitrogen gas was bubbled through the resulting solution for 1 
min.  This solution was then added to the first vial, the reaction was further diluted with DMSO 
(0.2 mL), N2 gas was bubbled through the reaction for 10 seconds, and the reaction was stirred 
under N2 for 1 h.  A sample aliquot was taken from the reaction, diluted with a minimal amount 
of HPLC grade MeOH, and analyzed with LCMS to confirm reaction completion.   The reaction 





fractions were pooled together, concentrated under reduced pressure in room temperature H2O (to 
remove MeOH), and lyophilized overnight to give 6.31c (2.9 mg) as a white solid in 83% yield. 
LC/MS tR = 3.85 min (Characterization Method B); m/z = 895.05 [(M + H
+)/2], 1785.00 (M - H
+
), 
1831.90 (formic acid adduct); HRMS (ESI-TOF) calcd. for C89H112N17O15F3Cl2 (M – H
+
) 
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